0000105770-20-000057.txt : 20201023 0000105770-20-000057.hdr.sgml : 20201023 20201023160357 ACCESSION NUMBER: 0000105770-20-000057 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201023 DATE AS OF CHANGE: 20201023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 201257791 BUSINESS ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 530 HERMAN O. WEST DRIVE CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 10-Q 1 wst-20200930.htm 10-Q wst-20200930
0000105770--12-312020Q3false00001057702020-01-012020-09-30xbrli:shares00001057702020-10-19iso4217:USD00001057702020-07-012020-09-3000001057702019-07-012019-09-3000001057702019-01-012019-09-30iso4217:USDxbrli:shares00001057702020-09-3000001057702019-12-3100001057702018-12-3100001057702019-09-3000001057702019-04-012019-04-3000001057702019-04-300000105770us-gaap:AccountingStandardsUpdate201613Member2020-01-01xbrli:pure0000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770wst:BiologicsCustomersMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:GenericsCustomersMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:GenericsCustomersMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:GenericsCustomersMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:GenericsCustomersMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:PharmaCustomersMember2020-07-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:PharmaCustomersMember2019-07-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:PharmaCustomersMember2020-01-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:PharmaCustomersMember2019-01-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberwst:ContractManufacturedCustomersMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2020-07-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2019-07-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2020-01-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMemberwst:HighValueComponentsMember2019-01-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberwst:StandardPackagingMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770wst:DeliveryDevicesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770wst:ContractManufacturedProductsMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:AmericasMember2020-07-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:AmericasMember2019-07-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:AmericasMember2020-01-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:AmericasMember2019-01-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:EMEAMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:GeographicConcentrationRiskMembersrt:AsiaPacificMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-07-012019-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300000105770us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-09-300000105770srt:MinimumMember2020-01-012020-09-300000105770srt:MaximumMember2020-01-012020-09-300000105770wst:SmartDoseMember2013-06-300000105770wst:SmartDoseMember2020-09-3000001057702018-10-012018-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2018-12-310000105770wst:DaikyoSeikoLtdDaikyoMember2019-11-0100001057702019-11-012019-11-010000105770wst:TermLoanDue2024Member2020-09-300000105770wst:TermLoanDue2024Member2019-12-310000105770wst:SeniorNotesDue2022Member2020-09-300000105770wst:SeniorNotesDue2022Member2019-12-310000105770wst:SeniorBNotesDue2024Member2020-09-300000105770wst:SeniorBNotesDue2024Member2019-12-310000105770wst:SeniorCNotesDue2027Member2020-09-300000105770wst:SeniorCNotesDue2027Member2019-12-310000105770wst:Revolvingcreditfacilitydue2024Member2020-09-300000105770us-gaap:LetterOfCreditMemberwst:Revolvingcreditfacilitydue2024Member2020-09-30iso4217:SGD0000105770currency:SGDus-gaap:ForwardContractsMember2019-12-310000105770currency:SGDus-gaap:ForwardContractsMember2020-09-300000105770us-gaap:ForwardContractsMembercurrency:USD2020-09-300000105770us-gaap:ForwardContractsMembercurrency:USD2019-12-310000105770us-gaap:ForeignExchangeForwardMember2020-01-012020-09-300000105770us-gaap:ForeignExchangeForwardMembercurrency:USDus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMembercurrency:USDus-gaap:DesignatedAsHedgingInstrumentMember2020-09-30iso4217:EURiso4217:JPY0000105770us-gaap:ForeignExchangeForwardMembercurrency:JPYus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMembercurrency:JPYus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000105770us-gaap:ForeignExchangeForwardMembercurrency:SGDus-gaap:LongMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000105770us-gaap:ForeignExchangeForwardMemberus-gaap:ShortMembercurrency:SGDus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USDus-gaap:NetInvestmentHedgingMember2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:JPY2019-12-310000105770us-gaap:CrossCurrencyInterestRateContractMembercurrency:USD2019-12-31utr:bbl0000105770us-gaap:OptionMember2017-11-012020-09-300000105770us-gaap:OptionMember2020-01-012020-09-30iso4217:USDwst:bbl0000105770us-gaap:OptionMember2020-09-300000105770us-gaap:ForeignCurrencyGainLossMember2020-07-012020-09-300000105770us-gaap:ForeignCurrencyGainLossMember2019-07-012019-09-300000105770us-gaap:ForeignCurrencyGainLossMember2020-01-012020-09-300000105770us-gaap:ForeignCurrencyGainLossMember2019-01-012019-09-300000105770us-gaap:FairValueHedgingMember2020-07-012020-09-300000105770us-gaap:FairValueHedgingMember2020-01-012020-09-300000105770us-gaap:FairValueHedgingMember2019-07-012019-09-300000105770us-gaap:FairValueHedgingMember2019-01-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMember2020-07-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMember2019-07-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2020-07-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2019-07-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000105770us-gaap:TreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300000105770us-gaap:TreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2019-07-012019-09-300000105770us-gaap:CashFlowHedgingMember2020-07-012020-09-300000105770us-gaap:CashFlowHedgingMember2019-07-012019-09-300000105770wst:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2020-07-012020-09-300000105770wst:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2019-07-012019-09-300000105770us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMember2020-07-012020-09-300000105770us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMember2019-07-012019-09-300000105770us-gaap:NetInvestmentHedgingMember2020-07-012020-09-300000105770us-gaap:NetInvestmentHedgingMember2019-07-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMember2020-01-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-gaap:ForeignCurrencyGainLossMember2019-01-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2020-01-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberwst:NetSalesMember2019-01-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-300000105770us-gaap:TreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-300000105770us-gaap:TreasuryLockMemberus-gaap:InterestExpenseMemberus-gaap:CashFlowHedgingMember2019-01-012019-09-300000105770us-gaap:CashFlowHedgingMember2020-01-012020-09-300000105770us-gaap:CashFlowHedgingMember2019-01-012019-09-300000105770wst:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2020-01-012020-09-300000105770wst:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignCurrencyGainLossMember2019-01-012019-09-300000105770us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMember2020-01-012020-09-300000105770us-gaap:NetInvestmentHedgingMemberus-gaap:CurrencySwapMemberus-gaap:ForeignCurrencyGainLossMember2019-01-012019-09-300000105770us-gaap:NetInvestmentHedgingMember2020-01-012020-09-300000105770us-gaap:NetInvestmentHedgingMember2019-01-012019-09-300000105770wst:NetSalesMember2020-07-012020-09-300000105770wst:NetSalesMember2019-07-012019-09-300000105770wst:NetSalesMember2020-01-012020-09-300000105770wst:NetSalesMember2019-01-012019-09-300000105770us-gaap:CostOfSalesMember2020-07-012020-09-300000105770us-gaap:CostOfSalesMember2019-07-012019-09-300000105770us-gaap:CostOfSalesMember2020-01-012020-09-300000105770us-gaap:CostOfSalesMember2019-01-012019-09-300000105770us-gaap:InterestExpenseMember2020-07-012020-09-300000105770us-gaap:InterestExpenseMember2019-07-012019-09-300000105770us-gaap:InterestExpenseMember2020-01-012020-09-300000105770us-gaap:InterestExpenseMember2019-01-012019-09-300000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2020-07-012020-09-300000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2019-07-012019-09-300000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2020-01-012020-09-300000105770us-gaap:CostOfSalesMemberus-gaap:NondesignatedMemberus-gaap:CommodityOptionMember2019-01-012019-09-300000105770us-gaap:NondesignatedMember2020-07-012020-09-300000105770us-gaap:NondesignatedMember2019-07-012019-09-300000105770us-gaap:NondesignatedMember2020-01-012020-09-300000105770us-gaap:NondesignatedMember2019-01-012019-09-300000105770us-gaap:FairValueInputsLevel1Member2020-09-300000105770us-gaap:FairValueInputsLevel2Member2020-09-300000105770us-gaap:FairValueInputsLevel3Member2020-09-300000105770us-gaap:CommodityMember2020-09-300000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel1Member2020-09-300000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel2Member2020-09-300000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel3Member2020-09-300000105770us-gaap:CurrencySwapMember2020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2020-09-300000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2020-09-300000105770us-gaap:ForeignExchangeContractMember2020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2020-09-300000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2020-09-300000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2020-09-300000105770us-gaap:FairValueInputsLevel1Member2019-12-310000105770us-gaap:FairValueInputsLevel2Member2019-12-310000105770us-gaap:FairValueInputsLevel3Member2019-12-310000105770us-gaap:CommodityMember2019-12-310000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel1Member2019-12-310000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770us-gaap:CommodityMemberus-gaap:FairValueInputsLevel3Member2019-12-310000105770us-gaap:CurrencySwapMember2019-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel1Member2019-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel2Member2019-12-310000105770us-gaap:CurrencySwapMemberus-gaap:FairValueInputsLevel3Member2019-12-310000105770us-gaap:ForeignExchangeContractMember2019-12-310000105770us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel1Member2019-12-310000105770us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeContractMember2019-12-310000105770us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMember2019-12-310000105770wst:SalesProjectionsMembersrt:MinimumMember2020-09-300000105770srt:MaximumMemberwst:SalesProjectionsMember2020-09-300000105770wst:SalesProjectionsMembersrt:WeightedAverageMember2020-09-300000105770wst:ProbabilitiesOfSuccessfulFDAApprovalMembersrt:MinimumMember2020-09-300000105770srt:MaximumMemberwst:ProbabilitiesOfSuccessfulFDAApprovalMember2020-09-300000105770srt:MinimumMemberwst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember2020-09-300000105770srt:MaximumMemberwst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember2020-09-300000105770us-gaap:MeasurementInputDiscountRateMember2020-09-3000001057702019-01-012019-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000105770us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000105770us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000105770us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:ForeignExchangeContractMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:TreasuryLockMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000105770us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000105770us-gaap:CommonStockMember2019-12-310000105770us-gaap:AdditionalPaidInCapitalMember2019-12-310000105770us-gaap:TreasuryStockMember2019-12-310000105770us-gaap:RetainedEarningsMember2019-12-310000105770us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000105770srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310000105770us-gaap:RetainedEarningsMember2020-01-012020-03-3100001057702020-01-012020-03-310000105770us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310000105770us-gaap:TreasuryStockMember2020-01-012020-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000105770us-gaap:CommonStockMember2020-03-310000105770us-gaap:AdditionalPaidInCapitalMember2020-03-310000105770us-gaap:TreasuryStockMember2020-03-310000105770us-gaap:RetainedEarningsMember2020-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100001057702020-03-310000105770us-gaap:RetainedEarningsMember2020-04-012020-06-3000001057702020-04-012020-06-300000105770us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000105770us-gaap:TreasuryStockMember2020-04-012020-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000105770us-gaap:CommonStockMember2020-06-300000105770us-gaap:AdditionalPaidInCapitalMember2020-06-300000105770us-gaap:TreasuryStockMember2020-06-300000105770us-gaap:RetainedEarningsMember2020-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000001057702020-06-300000105770us-gaap:RetainedEarningsMember2020-07-012020-09-300000105770us-gaap:CommonStockMember2020-07-012020-09-300000105770us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000105770us-gaap:TreasuryStockMember2020-07-012020-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000105770us-gaap:CommonStockMember2020-09-300000105770us-gaap:AdditionalPaidInCapitalMember2020-09-300000105770us-gaap:TreasuryStockMember2020-09-300000105770us-gaap:RetainedEarningsMember2020-09-300000105770us-gaap:CommonStockMember2018-12-310000105770us-gaap:AdditionalPaidInCapitalMember2018-12-310000105770us-gaap:TreasuryStockMember2018-12-310000105770us-gaap:RetainedEarningsMember2018-12-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000105770us-gaap:RetainedEarningsMember2019-01-012019-03-3100001057702019-01-012019-03-310000105770us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310000105770us-gaap:TreasuryStockMember2019-01-012019-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310000105770us-gaap:CommonStockMember2019-03-310000105770us-gaap:AdditionalPaidInCapitalMember2019-03-310000105770us-gaap:TreasuryStockMember2019-03-310000105770us-gaap:RetainedEarningsMember2019-03-310000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-3100001057702019-03-310000105770us-gaap:RetainedEarningsMember2019-04-012019-06-3000001057702019-04-012019-06-300000105770us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300000105770us-gaap:TreasuryStockMember2019-04-012019-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300000105770us-gaap:CommonStockMember2019-06-300000105770us-gaap:AdditionalPaidInCapitalMember2019-06-300000105770us-gaap:TreasuryStockMember2019-06-300000105770us-gaap:RetainedEarningsMember2019-06-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-3000001057702019-06-300000105770us-gaap:RetainedEarningsMember2019-07-012019-09-300000105770us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000105770us-gaap:TreasuryStockMember2019-07-012019-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000105770us-gaap:CommonStockMember2019-09-300000105770us-gaap:AdditionalPaidInCapitalMember2019-09-300000105770us-gaap:TreasuryStockMember2019-09-300000105770us-gaap:RetainedEarningsMember2019-09-300000105770us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000105770us-gaap:PerformanceSharesMember2020-01-012020-09-300000105770us-gaap:PerformanceSharesMember2020-09-300000105770us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2019-07-012019-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-07-012019-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-07-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-07-012019-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2020-07-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2019-07-012019-09-300000105770country:US2020-07-012020-09-300000105770country:US2019-07-012019-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-07-012019-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-07-012019-09-300000105770us-gaap:ForeignPlanMember2020-07-012020-09-300000105770us-gaap:ForeignPlanMember2019-07-012019-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2020-01-012020-09-300000105770us-gaap:PensionPlansDefinedBenefitMembercountry:US2019-01-012019-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2020-01-012020-09-300000105770us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembercountry:US2019-01-012019-09-300000105770country:US2020-01-012020-09-300000105770country:US2019-01-012019-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000105770us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-01-012019-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000105770us-gaap:ForeignPlanMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-09-300000105770us-gaap:ForeignPlanMember2020-01-012020-09-300000105770us-gaap:ForeignPlanMember2019-01-012019-09-300000105770wst:A2020RestructuringPlanMember2020-07-012020-07-310000105770wst:A2020RestructuringPlanMembersrt:MinimumMember2020-07-310000105770srt:MaximumMemberwst:A2020RestructuringPlanMember2020-07-310000105770wst:A2020RestructuringPlanMember2020-07-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2019-12-310000105770wst:A2020RestructuringPlanMember2019-12-310000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2019-01-012019-09-300000105770wst:A2020RestructuringPlanMember2019-01-012019-09-300000105770wst:A2020RestructuringPlanMemberus-gaap:EmployeeSeveranceMember2020-09-300000105770wst:A2020RestructuringPlanMember2020-09-300000105770wst:A2018RestructuringPlanMember2018-02-012018-02-280000105770wst:A2018RestructuringPlanMember2018-02-280000105770wst:A2018RestructuringPlanMember2020-09-300000105770wst:A2018RestructuringPlanMember2019-07-012019-09-300000105770wst:A2018RestructuringPlanMember2019-01-012019-09-300000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2019-12-310000105770wst:A2018RestructuringPlanMember2019-12-310000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2020-01-012020-09-300000105770wst:A2018RestructuringPlanMember2020-01-012020-09-300000105770us-gaap:EmployeeSeveranceMemberwst:A2018RestructuringPlanMember2020-09-300000105770wst:SmartDoseMember2020-07-012020-09-300000105770wst:SmartDoseMember2019-07-012019-09-300000105770wst:SmartDoseMember2020-01-012020-09-300000105770wst:SmartDoseMember2019-01-012019-09-30wst:segment0000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2020-07-012020-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2019-07-012019-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2020-01-012020-09-300000105770us-gaap:OperatingSegmentsMemberwst:PackagingSystemsMember2019-01-012019-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2020-07-012020-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2019-07-012019-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2020-01-012020-09-300000105770us-gaap:OperatingSegmentsMemberwst:DeliverySystemsMember2019-01-012019-09-300000105770us-gaap:IntersegmentEliminationMember2020-07-012020-09-300000105770us-gaap:IntersegmentEliminationMember2019-07-012019-09-300000105770us-gaap:IntersegmentEliminationMember2020-01-012020-09-300000105770us-gaap:IntersegmentEliminationMember2019-01-012019-09-300000105770us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000105770us-gaap:CorporateNonSegmentMember2019-07-012019-09-300000105770us-gaap:CorporateNonSegmentMember2020-01-012020-09-300000105770us-gaap:CorporateNonSegmentMember2019-01-012019-09-300000105770us-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300000105770us-gaap:MaterialReconcilingItemsMember2019-07-012019-09-300000105770us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-300000105770us-gaap:MaterialReconcilingItemsMember2019-01-012019-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to

Commission File Number 1-8036

WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania23-1210010
 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification Number)
530 Herman O. West Drive, Exton, PA
19341-0645
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.25 per shareWSTNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.          Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).                      Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑ Accelerated filer☐
Non-accelerated filer
☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                      ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☑
As of October 19, 2020, there were 73,927,188 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS

  Page
 
ITEM 1. 
 
 
 
 
 
ITEM 2.
ITEM 3.
ITEM 4.
   
 
ITEM 1.
ITEM 1A.
ITEM 2.
ITEM 6.
   
   

2
PART I. FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)


 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2020201920202019
Net sales$548.0 $456.1 $1,566.7 $1,369.3 
Cost of goods and services sold353.4 308.3 1,010.0 916.8 
Gross profit194.6 147.8 556.7 452.5 
Research and development12.5 9.3 34.0 28.7 
Selling, general and administrative expenses76.2 64.8 225.7 203.7 
Other expense (income) (Note 15)6.7 6.4 6.2 1.6 
Operating profit99.2 67.3 290.8 218.5 
Interest expense2.1 2.1 6.1 6.4 
Interest income(0.2)(1.0)(1.2)(2.5)
Other nonoperating (income) expense(0.4)1.3 (0.3)0.2 
Income before income taxes97.7 64.9 286.2 214.4 
Income tax expense21.1 10.9 52.1 42.5 
Equity in net income of affiliated companies(5.7)(2.3)(13.7)(5.9)
Net income$82.3 $56.3 $247.8 $177.8 
Net income per share:   
Basic$1.11 $0.76 $3.35 $2.40 
Diluted$1.09 $0.75 $3.28 $2.36 
Weighted average shares outstanding:    
Basic73.9 74.0 73.9 73.9 
Diluted75.8 75.5 75.6 75.3 

See accompanying notes to condensed consolidated financial statements.
3
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)

 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2020201920202019
Net income$82.3 $56.3 $247.8 $177.8 
Other comprehensive income (loss), net of tax:   
Foreign currency translation adjustments29.4 (23.8)(4.9)(20.1)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.1, $0.7, $1.2, and $0.7, respectively
(0.2)2.4 (4.0)2.2 
Net (loss) gain on derivatives, net of tax of $0.2, $1.5, $0.4 and $0.7, respectively
(0.9)3.2 (1.0)1.7 
Other comprehensive income (loss), net of tax28.3 (18.2)(9.9)(16.2)
Comprehensive income$110.6 $38.1 $237.9 $161.6 

See accompanying notes to condensed consolidated financial statements.
4
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions, except per share data)
 September 30,
2020		December 31,
2019
ASSETS  
Current assets:  
Cash and cash equivalents$519.4 $439.1 
Accounts receivable, net373.0 319.3 
Inventories294.9 235.7 
Other current assets51.0 64.6 
Total current assets1,238.3 1,058.7 
Property, plant and equipment1,939.1 1,820.1 
Less: accumulated depreciation and amortization1,055.7 980.8 
Property, plant and equipment, net883.4 839.3 
Operating lease right-of-use assets67.5 70.1 
Investments in affiliated companies209.6 192.7 
Goodwill109.3 107.8 
Intangible assets, net30.6 29.8 
Deferred income taxes22.3 14.0 
Pension and other postretirement benefits— 4.3 
Other noncurrent assets21.8 24.7 
Total Assets$2,582.8 $2,341.4 
LIABILITIES AND EQUITY  
Current liabilities:  
Notes payable and other current debt$2.3 $2.3 
Accounts payable180.3 156.8 
Pension and other postretirement benefits2.2 2.2 
Accrued salaries, wages and benefits96.1 73.0 
Income taxes payable30.2 6.4 
Operating lease liabilities9.9 9.6 
Other current liabilities126.7 91.3 
Total current liabilities447.7 341.6 
Long-term debt253.4 255.0 
Deferred income taxes4.5 15.5 
Pension and other postretirement benefits51.6 52.5 
Operating lease liabilities59.9 62.4 
Other long-term liabilities46.8 41.2 
Total Liabilities863.9 768.2 
Commitments and contingencies (Note 17)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding
— — 
Common stock, par value $0.25 per share; 200.0 million and 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 73.9 million and 74.1 million
18.8 18.8 
Capital in excess of par value268.2 272.7 
Retained earnings1,773.4 1,549.4 
Accumulated other comprehensive loss(159.5)(149.6)
Treasury stock, at cost (1.4 million and 1.2 million shares)
(182.0)(118.1)
Total Equity1,718.9 1,573.2 
Total Liabilities and Equity$2,582.8 $2,341.4 
See accompanying notes to condensed consolidated financial statements.
5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
West Pharmaceutical Services, Inc. and Subsidiaries
(in millions)
 Nine Months Ended
September 30,
 20202019
Cash flows from operating activities:  
Net income$247.8 $177.8 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation77.3 74.6 
Amortization3.3 2.5 
Stock-based compensation27.6 18.8 
Non-cash restructuring charges— 1.6 
Pension settlement charge3.4 2.7 
Contingent consideration payments in excess of acquisition-date liability(0.7)(0.3)
Other non-cash items, net(9.5)(0.6)
Changes in assets and liabilities
(25.4)(16.3)
Net cash provided by operating activities323.8 260.8 
Cash flows from investing activities:  
Capital expenditures(116.7)(88.8)
Acquisition of business— (18.9)
Purchase of intangibles(3.8)— 
Other, net(1.4)0.3 
Net cash used in investing activities(121.9)(107.4)
Cash flows from financing activities:  
Borrowings under revolving credit agreements— 28.0 
Repayments under revolving credit agreements— (28.0)
Repayments of long-term debt(1.7)— 
Debt issuance costs— (0.9)
Dividend payments(35.5)(33.3)
Proceeds from stock-based compensation awards19.7 25.5 
Employee stock purchase plan contributions4.6 4.0 
Shares purchased under share repurchase programs(115.5)(83.1)
Net cash used in financing activities(128.4)(87.8)
Effect of exchange rates on cash6.8 (7.0)
Net increase (decrease) in cash and cash equivalents80.3 58.6 
Cash, including cash equivalents at beginning of period439.1 337.4 
Cash, including cash equivalents at end of period$519.4 $396.0 

See accompanying notes to condensed consolidated financial statements.
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1:  Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2020, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders.

In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date.

Note 2:  New Accounting Standards

Recently Adopted Standards

In April 2019, the Financial Accounting Standards Board (“FASB”) issued guidance which clarifies and improves areas related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020.
7
The adoption did not have a material impact on our financial statements. Please refer to Note 10, Fair Value Measurements, for additional details.

In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under the previous guidance, an entity reflected credit losses on financial assets measured on an amortized cost basis only when it was probable that losses had incurred, generally considering only past events and current conditions when determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a modified retrospective basis, to the accounts receivable and contract asset balances as of January 1, 2020. Under the current expected credit loss model, we have adopted a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. The effect of the adoption on the financial statement line items of accounts receivable and contract assets was not material as of January 1, 2020. As a result of our adoption, we recorded a cumulative-effect adjustment of $0.1 million within retained earnings in our condensed consolidated balance sheet as of January 1, 2020, to reflect the incremental estimated lifetime expected credit losses on the accounts receivable balance as of January 1, 2020. We have not presented the amortized cost basis within each credit quality indicator by year of origination as all of our accounts receivable are due within one year or less.

Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance.

In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740 and by clarifying and amending existing ASC Topic 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

Note 3:  Revenue

Our revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.

8
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Biologics
32 %
26 %
29 %
25 %
Generics
 18 %
20 %
19 %
20 %
Pharma
27 %
30 %
28 %
31 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
High-Value Components
47 %
42 %
45 %
43 %
Standard Packaging
25 %
28 %
26 %
29 %
Delivery Devices
5 %
6 %
5 %
4 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Americas
49 %
48 %
49 %
48 %
Europe, Middle East, Africa
42 %
44 %
43 %
44 %
Asia Pacific
9 %
8 %
8 %
8 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2019$9.8 
Contract assets, September 30, 2020
16.2 
Change in contract assets - increase (decrease)$6.4 
Deferred income, December 31, 2019$(34.9)
Deferred income, September 30, 2020
(56.7)
Change in deferred income - decrease (increase)$(21.8)

The Company has entered into new capacity reservation agreements, receiving cash up-front to be able to meet customer demand, which caused an increase in the Contract Liability account balance. The Company expects revenue related to the capacity reservation agreements to be recognized over the next 1 to 2 years.

9
During the nine months ended September 30, 2020, $23.0 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2020, there was $5.0 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.1 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Supply Chain Financing

We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of September 30, 2020 and 2019, we derecognized accounts receivable of $8.9 million and $7.9 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our condensed consolidated income statements for the nine months ended September 30, 2020 and 2019 were not material.

Voluntary Recall

On January 24, 2019, we issued a voluntary recall of our Vial2Bag® product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold, reflecting our inventory balance for these devices at December 31, 2018. During three and nine months ended September 30, 2019, we recorded a provision of $0.9 million and $4.9 million, respectively, for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the product back on the market, and on October 21, 2020 we received market clearance from the Food and Drug Administration ("FDA") for our Vial2BagAdvanced™ 20mm Admixture Device.

Note 4:  Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2020201920202019
Net income$82.3 $56.3 $247.8 $177.8 
Weighted average common shares outstanding73.9 74.0 73.9 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.5 1.7 1.4 
Weighted average shares assuming dilution75.8 75.5 75.6 75.3 

During the three months ended September 30, 2020 and 2019, there were 0.0 million and 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.2 million and 0.3 million antidilutive shares outstanding during the nine months ended September 30, 2020 and 2019, respectively.

10
In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2020. During the nine months ended September 30, 2020, we purchased 761,500 shares of our common stock under the program at a cost of $115.5 million, or an average price of $151.65 per share.

Note 5:  Inventories

Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:

($ in millions)September 30,
2020		December 31,
2019
Raw materials$125.4 $100.9 
Work in process55.8 37.4 
Finished goods113.7 97.4 
 $294.9 $235.7 

Note 6:  Leases

A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Operating lease cost$3.1 $3.4 $9.3 $9.7 
Short-term lease cost0.3 0.1 0.6 0.5 
Variable lease cost1.2 0.8 2.8 2.3 
Total lease cost$4.6 $4.3 $12.7 $12.5 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.2 $3.2 $9.6 $9.4 
Right-of-use assets obtained in exchange for new operating lease liabilities$0.3 $0.3 $4.6 $8.4 

11
As of September 30, 2020 and December 31, 2019, the weighted average remaining lease term for operating leases was 11.2 years and 11.7 years, respectively.

As of September 30, 2020 and December 31, 2019, the weighted average discount rate was 3.74% and 3.76%, respectively.

Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20202019
2020 (remaining three months)$3.4 $12.1 
202111.8 10.4 
20229.7 8.6 
20238.7 7.8 
20248.2 7.3 
Thereafter42.6 41.8 
84.4 88.0 
Less: imputed lease interest(14.6)(16.0)
Total lease liabilities$69.8 $72.0 

Note 7:  Affiliated Companies

At September 30, 2020 and December 31, 2019, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $194.2 million and $179.3 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $15.4 million and $13.4 million at September 30, 2020 and December 31, 2019, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo Seiko, Ltd. (“Daikyo”), we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.

Our purchases from, and royalty payments made to, affiliates totaled $36.6 million and $97.0 million, respectively, for the three and nine months ended September 30, 2020, as compared to $33.0 million and $85.2 million, respectively, for the same period in 2019. As of September 30, 2020 and December 31, 2019, the payable balance due to affiliates was $28.5 million and $20.8 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.7 million and $7.7 million, respectively, for the three and nine months ended September 30, 2020, as compared to $2.2 million and $6.9 million, respectively, for the same periods in 2019. As of September 30, 2020 and December 31, 2019, the receivable balance due from affiliates was $1.7 million and $1.9 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2019 Annual Report for additional details.

12
Note 8:  Debt

The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2020.

($ in millions)September 30,
2020		December 31,
2019
Term Loan, due December 31, 2024 (1.10%)
$88.4 $90.0 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
256.4 258.0 
Less: unamortized debt issuance costs0.7 0.7 
Total debt255.7 257.3 
Less: current portion of long-term debt2.3 2.3 
Long-term debt, net$253.4 $255.0 

Please refer to Note 8, Debt, to the consolidated financial statements in our 2019 Annual Report for additional details regarding our debt agreements.

Credit Agreement - Credit Facility

At September 30, 2020, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.5 million, was $297.5 million.

Credit Agreement Amendment - Term Loan

At September 30, 2020, we had $88.4 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $86.1 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.

Note 9:  Derivative Financial Instruments

Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2020 and December 31, 2019, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.

13
In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2020, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD74.7 — 64.8 
Yen9,876.6 55.9 32.5 
SGD57.9 33.3 7.2 

In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2020, we purchased several series of call options for a total of 439,732 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.

As of September 30, 2020, we had outstanding contracts to purchase 137,035 barrels of crude oil from October 2020 to March 2022, at a weighted-average strike price of $60.47 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2020 and December 31, 2019.

14
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Loss (Gain) Recognized in Income for theAmount of Loss (Gain) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Fair Value Hedges:
Hedged item (intercompany loan)
$9.3 $(8.4)$25.1 $(14.1)Other expense (income)
Derivative designated as hedging instrument
$(9.3)$8.4 $(25.1)$14.1 Other expense (income)
Amount excluded from effectiveness testing
$(1.9)$4.3 $(5.9)$(5.0)Other expense (income)
Total$(1.9)$4.3 $(5.9)$(5.0)

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2020 and 2019 were $1.3 million, $5.0 million, and $2.2 million, $6.4 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of (Loss) Gain Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$(0.1)$(0.6)$(0.7)$2.9 Other expense (income)
Total$(0.1)$(0.6)$(0.7)$2.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$0.7 $0.2 $(0.3)Net sales
Foreign currency hedge contracts— 0.6 0.1 (0.2)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.5)$1.3 $0.4 $(0.4) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.7 $— $— Other expense (income)
Cross-currency swap(3.0)— — — Other expense (income)
Total$(3.0)$0.7 $— $—  

15
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$2.8 $3.9 $(3.3)$(3.3)Other expense (income)
Total$2.8 $3.9 $(3.3)$(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$— $1.0 $(0.3)$(0.7)Net sales
Foreign currency hedge contracts(0.3)1.1 (0.1)(0.5)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(0.3)$2.1 $(0.2)$(1.0) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.5 $— $— Other (income)
Cross-currency swap(2.0)— — — Other (income)
Total$(2.0)$0.5 $— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales$0.2 $(0.3)$(0.3)$(0.7)
Cost of goods and services sold0.1 (0.2)(0.1)(0.5)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)(0.7)2.9 (3.3)(3.3)


The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Loss Recognized in Income for theAmount of Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Commodity call options$0.1 $0.1 $0.3 $0.3 Cost of goods and services sold
Total$0.1 $0.1 $0.3 $0.3 

For the three and nine months ended September 30, 2020 and 2019, there was no material ineffectiveness related to our hedges.

16
Note 10:  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.2 $11.2 $— $— 
Foreign currency contracts1.1 — 1.1 — 
Commodity call options0.1 — 0.1 — 
 $12.4 $11.2 $1.2 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap4.0 — 4.0 — 
Foreign currency contracts13.7 — 13.7 — 
 $34.0 $12.8 $17.7 $3.5 

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2019		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.3 $11.3 $— $— 
Foreign currency contracts7.7 — 7.7 — 
Commodity call options0.1 — 0.1 — 
 $19.1 $11.3 $7.8 $— 
Liabilities:    
Contingent consideration$3.3 $— $— $3.3 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap1.4 — 1.4 — 
Foreign currency contracts0.3 — 0.3 — 
 $17.8 $12.8 $1.7 $3.3 

17
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives.

Level 3 Fair Value Measurements

The fair value of the contingent consideration liability related to the SmartDose technology platform (the “SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.

The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2018$1.7 
Increase in fair value recorded in earnings2.1 
Payments(0.5)
Balance, December 31, 20193.3 
Increase in fair value recorded in earnings0.9 
Payments(0.7)
Balance, September 30, 2020$3.5 

18
Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2020, the estimated fair value of long-term debt was $266.4 million compared to a carrying amount of $253.4 million. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million and the carrying amount was $255.0 million.

19
Note 11:  Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2020:

($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2019$(0.8)$0.4 $(40.3)$(108.9)$(149.6)
Other comprehensive income (loss) before reclassifications2.5 — (6.2)(4.9)(8.6)
Amounts reclassified out from accumulated other comprehensive income (loss)(3.5)— 2.2 — (1.3)
Other comprehensive income (loss), net of tax(1.0)— (4.0)(4.9)(9.9)
Balance, September 30, 2020$(1.8)$0.4 $(44.3)$(113.8)$(159.5)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:

($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2020201920202019
Gains (losses) on derivatives:
Foreign currency contracts$(0.3)$0.3 $0.3 $0.8 Net sales
Foreign currency contracts(0.1)0.3 0.3 0.8 Cost of goods and services sold
Foreign currency contracts1.1 (4.3)5.1 5.0 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax0.6 (3.8)5.4 6.3 
Tax benefit (expense)(0.3)1.3 (1.9)(2.0)
Net of tax$0.3 $(2.5)$3.5 $4.3 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.4 $0.4 (a)
Actuarial losses0.2 0.2 — 0.2 (a)
Settlements(1.1)(2.7)(3.4)(2.7)(a)
Total before tax(0.8)(2.4)(3.0)(2.1)
Tax benefit (expense)0.3 0.6 0.8 0.5 
Net of tax$(0.5)$(1.8)$(2.2)$(1.6)
Total reclassifications for the period, net of tax$(0.2)$(4.3)$1.3 $2.7 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
20
Note 12: Shareholders’ Equity

The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard (see Note 2)— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive income, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 

21
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201875.3 $18.8 $282.0 1.2 $(103.7)$1,353.4 $(154.2)$1,396.3 
Net income— — — — — 55.4 — 55.4 
Activity related to stock-based compensation— — (3.5)(0.2)14.2 — — 10.7 
Shares purchased under share repurchase program— — — 0.8 (83.1)— — (83.1)
Dividends declared ($0.15 per share)
— — — — — (10.6)— (10.6)
Other comprehensive income, net of tax— — — — — — 0.8 0.8 
Balance, March 31, 201975.3 $18.8 $278.5 1.8 $(172.6)$1,398.2 $(153.4)$1,369.5 
Net income— — — — — 66.1 — 66.1 
Activity related to stock-based compensation— — (5.1)(0.2)24.8 — — 19.7 
Dividends declared ($0.15 per share)
— — — — — (11.4)— (11.4)
Other comprehensive income, net of tax— — — — — — 1.2 1.2 
Balance, June 30, 201975.3 $18.8 $273.4 1.6 $(147.8)$1,452.9 $(152.2)$1,445.1 
Net income— — — — — 56.3 — 56.3 
Activity related to stock-based compensation— — (4.9)(0.3)21.2 — — 16.3 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — (18.2)(18.2)
Balance, September 30, 201975.3 $18.8 $268.5 1.3 $(126.6)$1,497.3 $(170.4)$1,487.6 

22
Note 13:  Stock-Based Compensation

The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2020, there were 2,756,301 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2020, we granted 230,580 stock options at a weighted average exercise price of $175.22 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $39.58 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.3%; expected life of 5.7 years based on prior experience; stock volatility of 22.3% based on historical data; and a dividend yield of 0.4%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2020, we granted 52,187 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $175.18 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2020, we granted 8,072 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $194.21 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.

Stock-based compensation expense was $10.0 million and $27.6 million for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, stock-based compensation expense was $5.4 million and $18.8 million, respectively.

23
Note 14:  Benefit Plans

The components of net periodic benefit cost for the three months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$0.4 $0.4 $— $— $0.4 $0.4 
Interest cost1.7 1.9 — 0.1 1.7 2.0 
Expected return on assets(2.8)(3.1)— — (2.8)(3.1)
Amortization of prior service credit0.1 0.1 (0.2)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.4 0.5 (0.6)(0.7)(0.2)(0.2)
Settlements1.1 2.7 — — 1.1 2.7 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$0.5 $2.0 $(0.8)$(0.8)$(0.3)$1.2 
International plans0.4 0.5 — — 0.4 0.5 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$1.0 $1.1 $— $— $1.0 $1.1 
Interest cost5.5 6.8 0.1 0.2 5.6 7.0 
Expected return on assets(8.8)(8.9)— — (8.8)(8.9)
Amortization of prior service credit0.1 0.1 (0.5)(0.5)(0.4)(0.4)
Recognized actuarial losses (gains)1.4 1.6 (1.4)(1.8)— (0.2)
Settlements3.4 2.7 — — 3.4 2.7 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$1.5 $1.9 $(1.8)$(2.1)$(0.3)$(0.2)
International plans1.1 1.5 — — 1.1 1.5 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 

During the three and nine months ended September 30, 2020, we recorded a $1.1 million and $3.4 million pension settlement charge, respectively, within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified and non-qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

24
Note 15:  Other Expense (Income)

Other expense (income) consists of:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Restructuring and related charges:
Severance and post-employment benefits$4.5 $0.6 $4.5 $2.2 
Asset-related charges— 0.1 — 0.1 
Other charges— 1.1 — 1.5 
Total restructuring and related charges4.5 1.8 4.5 3.8 
Argentina currency devaluation— 1.0 — 1.0 
Fixed asset impairments0.9 0.8 7.2 2.3 
Development and licensing income(0.2)(0.2)(0.6)(0.6)
Contingent consideration0.8 0.1 0.9 0.4 
Foreign exchange transaction losses (gains)1.0 5.1 (4.5)(3.5)
Other items(0.3)(2.2)(1.3)(1.8)
Total other expense (income)$6.7 $6.4 $6.2 $1.6 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $15 million to $17 million. Since its approval, we recorded a net pre-tax amount equal to $4.5 million in restructuring related charges associated with this plan. All charges recorded to date are severance related and recorded within other expense (income) in the condensed consolidated statements of income.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$— $— 
Charges4.5 4.5 
Cash payments— — 
Balance, September 30, 2020$4.5 $4.5 

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan was considered complete as of December 31, 2019.

During the three months ended September 30, 2019, we recorded $1.8 million in restructuring and related charges associated with this plan, consisting of $0.6 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.1 million for other non-cash charges.

25
During the nine months ended September 30, 2019, we recorded $3.8 million in restructuring and related charges associated with this plan, consisting of $2.2 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.5 million for other non-cash charges.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$1.4 $1.4 
Cash payments(1.2)(1.2)
Balance, September 30, 2020$0.2 $0.2 

On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. Our remaining restructuring obligations related to the 2016 restructuring plan are complete.

Other Items

During both the three and nine months ended September 30, 2020 and 2019, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information.

Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.

Note 16:  Income Taxes

The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.

The provision for income taxes was $21.1 million and $10.9 million for the three months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 21.6% and 16.8%, respectively. The provision for income taxes was $52.1 million and $42.5 million for the nine months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 18.2% and 19.8%, respectively.

Note 17:  Commitments and Contingencies

From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2019 Annual Report.

26
Note 18:  Segment Information

Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab and other services, to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker (“CODM”) evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

The following table presents information about our reportable segments, reconciled to consolidated totals:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales:    
Proprietary Products$421.5 $345.2 $1,194.5 $1,045.9 
Contract-Manufactured Products126.6 111.1 372.5 323.6 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.2)
Consolidated net sales$548.0 $456.1 $1,566.7 $1,369.3 
Operating profit (loss):   
Proprietary Products$107.5 $72.9 $312.9 $238.7 
Contract-Manufactured Products18.8 11.6 52.1 33.5 
Corporate(22.4)(14.4)(67.1)(48.9)
Other unallocated items(4.7)(2.8)(7.1)(4.8)
Total operating profit$99.2 $67.3 $290.8 $218.5 
Interest expense2.1 2.1 6.1 6.4 
Interest income(0.2)(1.0)(1.2)(2.5)
Other nonoperating (income) expense(0.4)1.3 (0.3)0.2 
Income before income taxes$97.7 $64.9 $286.2 $214.4 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

Other unallocated items during the three months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges and $0.2 million of amortization expense associated with an acquisition of an intangible asset. Other unallocated items during the nine months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges, $2.2 million in severance related costs, and $0.4 million of amortization expense associated with an acquisition of an intangible asset.

27
Other unallocated items during the three and nine months ended September 30, 2019 consisted of $1.8 million and $3.8 million, respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2019, other unallocated items included a charge of $1.0 million as a result of the continued devaluation of Argentina's currency.

Please refer to Note 15, Other Expense (Income), for further discussion of certain unallocated items referenced above.


ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

The following discussion is intended to further the reader’s understanding of the consolidated financial condition and results of operations of our Company. It should be read in conjunction with our condensed consolidated financial statements and accompanying notes elsewhere in this Quarterly Report on Form 10-Q (“Form 10-Q”) as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations and the consolidated financial statements and accompanying notes included in our 2019 Annual Report. Our historical financial statements may not be indicative of our future performance. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains a number of forward-looking statements, all of which are based on our current expectations and could be affected by the uncertainties and risks discussed in Part I, Item 1A of our 2019 Annual Report and in Part II, Item 1A of this Form 10-Q.

Throughout this section, references to “Notes” refer to the notes to our condensed consolidated financial statements (unaudited) in Part I, Item 1 of this Form 10-Q, unless otherwise indicated.

Non-U.S. GAAP Financial Measures

For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign currency exchange rates. Organic net sales exclude the impact from acquisitions and/or divestitures and translate the current-period reported sales of subsidiaries whose functional currency is other than USD at the applicable foreign exchange rates in effect during the comparable prior-year period. We may also refer to financial results excluding the effects of unallocated items. The re-measured results excluding effects from currency translation, the impact from acquisitions and/or divestitures, and the effects of unallocated items are not in conformity with U.S. GAAP and should not be used as a substitute for the comparable U.S. GAAP financial measures. The non-U.S. GAAP financial measures are incorporated into our discussion and analysis as management uses them in evaluating our results of operations and believes that this information provides users a valuable insight into our overall performance and financial position.

Our Operations

We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab and other services and integrated solutions. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and additional medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes excellence in manufacturing, scientific and technical expertise and management, and enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently. The Company was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923.

28
Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services and integrated solutions, primarily to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We also maintain partnerships to share technologies and market products with affiliates in Japan and Mexico.

Impact of COVID-19

West has been actively monitoring the COVID-19 situation and its impact globally. Our primary objectives have remained the same throughout the pandemic: to support the safety of our team members and their families and continue to support patients around the world. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. Our capital and financial resources, including overall liquidity, remain strong. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders. However, we cannot predict the impact of the progression of the COVID-19 pandemic on future results due to a variety of factors, including the continued good health of our employees, the ability of suppliers to continue to operate and deliver, the ability of West and its customers to maintain operations, continued access to transportation resources, the changing needs and priorities of customers, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. We will continue to closely monitor the COVID-19 pandemic in order to ensure the safety of our people and our ability to serve our customers and patients worldwide.

2020 Financial Performance Summary

Consolidated net sales increased by $91.9 million, or 20.1%, for the three months ended September 30, 2020, as compared to the same period in 2019. Excluding foreign currency translation effects, consolidated net sales for the three months ended September 30, 2020 increased by $83.2 million, or 18.2%, as compared to the same period in 2019. The increase in net sales was primarily driven by the performance of our Proprietary Products segment, which delivered 20.3% organic growth compared to the same period in 2019. Contributing to this increase in sales were volumes related to COVID-19 antiviral treatments and treatment of underlying COVID-19 symptoms.

Consolidated net sales increased by $197.4 million, or 14.4%, for the nine months ended September 30, 2020, as compared to the same period in 2019. Excluding foreign currency translation effects as well as incremental sales of $1.2 million from our 2019 acquisition of our South Korea distributor, consolidated net sales for the nine months ended September 30, 2020 increased by $206.9 million, or 15.1%, as compared to the same period in 2019. The increase in net sales was primarily driven by the performance of our Proprietary Products segment, which delivered 15.1% organic growth compared to the same period in 2019. Contributing to this increase in sales were volumes related to COVID-19 antiviral treatments and treatment of underlying COVID-19 symptoms.

29
Net income for the three months ended September 30, 2020 was $82.3 million, or $1.09 per diluted share, as compared to $56.3 million, or $0.75 per diluted share, for the same period in 2019. Net income improvement of $26.0 million was largely driven by the $34.6 million improvement in our operating profit from growth in our Proprietary Products segment. Additionally, our results include a tax benefit of $2.0 million, or $0.02 per diluted share, associated with stock-based compensation compared to a tax benefit of $4.0 million, or $0.05 per diluted share, associated with stock-based compensation for the three months ended September 30, 2019.

Net income for the nine months ended September 30, 2020 was $247.8 million, or $3.28 per diluted share, as compared to $177.8 million, or $2.36 per diluted share, for the same period in 2019. Net income improvement of $70.0 million was largely driven by the $74.2 million improvement in our operating profit from growth in our Proprietary Products segment. Additionally, our results include a tax benefit of $14.0 million, or $0.18 per diluted share, associated with stock-based compensation compared to a tax benefit of $13.2 million, or $0.17 per diluted share, associated with stock-based compensation for the nine months ended September 30, 2019.

RESULTS OF OPERATIONS

We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

Percentages in the following tables and throughout the Results of Operations section may reflect rounding adjustments.

Net Sales

The following table presents net sales, consolidated and by reportable segment, for the three months ended September 30, 2020 and 2019:

Three Months Ended
September 30,		Percentage Change
($ in millions)20202019As-ReportedOrganic
Proprietary Products$421.5 $345.2 22.1 %20.3 %
Contract-Manufactured Products126.6 111.1 14.0 %11.7 %
Intersegment sales elimination(0.1)(0.2)— — 
Consolidated net sales$548.0 $456.1 20.1 %18.2 %

Consolidated net sales increased by $91.9 million, or 20.1%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $8.7 million. Excluding foreign currency translation effects, consolidated net sales for the three months ended September 30, 2020 increased by $83.2 million, or 18.2%, as compared to the same period in 2019.

Proprietary Products – Proprietary Products net sales increased by $76.3 million, or 22.1%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $6.3 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2020 increased by $70.0 million, or 20.3%, as compared to the same period in 2019, primarily due to growth in our high-value product offerings, including our FluroTec®-coated components, Daikyo® and Novapure® film-components, Westar® components and Envision® components, which included approximately $32 million in COVID-19 related activity for antiviral treatments and treatment of underlying COVID-19 symptoms.
30

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $15.5 million, or 14.0%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $2.4 million. Excluding foreign currency translation effects, net sales for the three months ended September 30, 2020 increased by $13.0 million, or 11.7%, as compared to the same period in 2019, due to an increase in the sale of healthcare-related injection and diagnostic devices.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

The following table presents net sales, consolidated and by reportable segment, for the nine months ended September 30, 2020 and 2019:

Nine Months Ended
September 30,		Percentage Change
($ in millions)20202019As-ReportedOrganic
Proprietary Products$1,194.5 $1,045.9 14.2 %15.1 %
Contract-Manufactured Products372.5 323.6 15.1 %15.1 %
Intersegment sales elimination(0.3)(0.2)— — 
Consolidated net sales$1,566.7 $1,369.3 14.4 %15.1 %

Consolidated net sales increased by $197.4 million, or 14.4%, for the nine months ended September 30, 2020, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $10.7 million. Excluding foreign currency translation effects, as well as incremental sales of $1.2 million from our 2019 acquisition, consolidated net sales for the nine months ended September 30, 2020 increased by $206.9 million, or 15.1%, as compared to the same period in 2019.

Proprietary Products – Proprietary Products net sales increased by $148.6 million, or 14.2%, for the nine months ended September 30, 2020, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $10.7 million. Excluding foreign currency translation effects, as well as incremental sales of $1.2 million from our 2019 acquisition of our South Korea distributor, net sales for the nine months ended September 30, 2020 increased by $158.1 million, or 15.1%, as compared to the same period in 2019, primarily due to growth in our high-value product offerings, including our FluroTec-coated components, Westar® components, Daikyo® and Novapure® film-components, Daikyo Crystal Zenith® products and our self-injection delivery platforms, which included approximately $52 million in COVID-19 related activity for antiviral treatments and treatment of underlying COVID-19 symptoms.

Contract-Manufactured Products – Contract-Manufactured Products net sales increased by $48.9 million, or 15.1%, for the nine months ended September 30, 2020, as compared to the same period in 2019, due to an increase in the sale of healthcare-related injection and diagnostic devices, with no impact from foreign currency translation.

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.
31
Gross Profit

The following table presents gross profit and related gross profit margins, consolidated and by reportable segment:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Proprietary Products:  
Gross profit$171.9 $131.8 $492.8 $406.3 
Gross profit margin40.8 %38.2 %41.3 %38.8 %
Contract-Manufactured Products:   
Gross profit$22.7 $16.0 $63.9 $46.2 
Gross profit margin17.9 %14.4 %17.2 %14.3 %
Consolidated gross profit$194.6 $147.8 $556.7 $452.5 
Consolidated gross profit margin35.5 %32.4 %35.5 %33.0 %

Consolidated gross profit increased by $46.8 million, or 31.7%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $2.5 million for the three months ended September 30, 2020, as compared to the same period in 2019. Consolidated gross profit margin increased by 3.1 margin points for the three months ended September 30, 2020, as compared to the same period in 2019.

Consolidated gross profit margin increased by $104.2 million, or 23.0% for the nine months ended September 30, 2020, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $4.2 million for the nine months ended September 30, 2020, as compared to the same period in 2019. Consolidated gross profit margin increased by 2.5 margin points for the nine months ended September 30, 2020, as compared to the same period in 2019.

Proprietary Products - Proprietary Products gross profit increased by $40.1 million, or 30.4%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $2.1 million. Proprietary Products gross profit margin increased by 2.6 margin points for the three months ended September 30, 2020, as compared to the same periods in 2019, due to a favorable mix of products sold, sales price increases and production efficiencies, partially offset by increased overhead costs including compensation costs.

Proprietary Products gross profit increased by $86.5 million, or 21.3%, for the nine months ended September 30, 2020, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $4.2 million. Proprietary Products gross profit margin increased by 2.5 margin points for the nine months ended September 30, 2020, as compared to the same period in 2019, due to favorable mix of products sold, sales price increases and production efficiencies, partially offset by increased overhead costs including compensation costs and COVID-19 related expenses.

Contract-Manufactured Products - Contract-Manufactured Products gross profit increased by $6.7 million, or 41.9%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $0.4 million. Contract-Manufactured Products gross profit margin increased by 3.5 margin points for the three months ended September 30, 2020, as compared to the same period in 2019, due to a favorable mix of products sold and production efficiencies, partially offset by increased overhead costs including compensation costs.

32
Contract-Manufactured Products gross profit increased by $17.7 million, or 38.3%, for the nine months ended September 30, 2020, as compared to the same period in 2019, with no impact from foreign currency translation. Contract-Manufactured Products gross profit margin increased by 2.9 margin points for the nine months ended September 30, 2020, as compared to the same period in 2019, due to a favorable mix of products sold and production efficiencies, partially offset by increased overhead costs including compensation costs.

Research and Development (“R&D”) Costs

The following table presents R&D costs, consolidated and by reportable segment:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Proprietary Products$12.5 $9.3 $34.0 $28.7 
Contract-Manufactured Products— — — — 
Consolidated R&D costs$12.5 $9.3 $34.0 $28.7 

Consolidated R&D costs increased by $3.2 million, or 34.4%, and $5.3 million, or 18.5% for the three and nine months ended September 30, 2020, respectively, as compared to the same period in 2019. Efforts remain focused on the continued investment in self-injection systems development, fluid transfer admixture devices, elastomeric packaging components, and formulation development.

All of the R&D costs incurred during the three and nine months ended September 30, 2020 related to Proprietary Products.

Selling, General and Administrative (“SG&A”) Costs

The following table presents SG&A costs, consolidated and by reportable segment and corporate:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Proprietary Products$50.6 $46.3 $144.7 $142.3 
Contract-Manufactured Products3.7 4.1 11.4 12.5 
Corporate21.9 14.4 69.6 48.9 
Consolidated SG&A costs$76.2 $64.8 $225.7 $203.7 
SG&A as a % of net sales13.9 %14.2 %14.4 %14.9 %

Consolidated SG&A costs increased by $11.4 million, or 17.6%, for the three months ended September 30, 2020, respectively, as compared to the same period in 2019, due to an increase in compensation costs and an unfavorable foreign currency translation impact of $0.3 million.

Consolidated SG&A costs increased by $22.0 million, or 10.8%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019, due to an increase in compensation costs, partially offset by incremental cost incurred in 2019 associated with our voluntary recall and a favorable foreign currency translation impact of $1.3 million.
33

Proprietary Products - Proprietary Products SG&A costs increased by $4.3 million, or 9.3%, for the three months ended September 30, 2020, respectively, as compared to the same period in 2019. Proprietary Products SG&A costs increased primarily due to an increase in compensation costs and an unfavorable foreign currency translation impact of $0.3 million.

Proprietary Products SG&A costs increased by $2.4 million, or 1.7%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019. Proprietary Products SG&A costs increased primarily due to an increase in compensation costs, partially offset by incremental costs incurred in 2019 associated with our voluntary recall and a favorable foreign currency translation impact of $1.3 million.

Contract-Manufactured Products - Contract-Manufactured Products SG&A costs decreased by $0.4 million, or 9.8% for the three months ended September 30, 2020, as compared to the same period in 2019.

Contract-Manufactured Products SG&A costs decreased by $1.1 million, or 8.8% for the nine months ended September 30, 2020, as compared to the same period in 2019.

Corporate - Corporate SG&A costs increased by $7.5 million, or 52.1%, for the three months ended September 30, 2020, respectively, as compared to the same period in 2019, primarily due to an increase in compensation costs.

Corporate SG&A costs increased by $20.7 million, or 42.3%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019, primarily due to an increase in compensation costs.

Other Expense (Income)

The following table presents other expense and income items, consolidated and by reportable segment, corporate and unallocated items:

Expense (Income) Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Proprietary Products$1.3 $3.3 $1.2 $(3.4)
Contract-Manufactured Products0.2 0.3 0.4 0.2 
Corporate0.7 — 0.1 — 
Unallocated items4.5 2.8 4.5 4.8 
Consolidated other expense (income) $6.7 $6.4 $6.2 $1.6 

Other income and expense items, consisting of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, development and licensing income, contingent consideration, fixed asset impairments and miscellaneous income and charges, are generally recorded within segment results.

Consolidated other expense (income) changed by $0.3 million or 4.7% for the three months ended September 30, 2020, as compared to the same period in 2019, due to the factors described below. Consolidated other expense (income) changed by $4.6 million or 287.5% for the nine months ended September 30, 2020, as compared to the same period in 2019, due to the factors described below.

34
Proprietary Products - Proprietary Products other expense (income) changed by $2.0 million or 60.6% for the three months ended September 30, 2020, as compared to the same period in 2019, primarily due to a reduction in hedge settlement losses partially offset by an increase in the SmartDose contingent consideration charge.

Proprietary Products other expense (income) changed by $4.6 million or 135.3% for the nine months ended September 30, 2020, as compared to the same period in 2019, primarily due to an increase in the fixed asset impairments recorded and an increase in the SmartDose contingent consideration charge.

Contract-Manufactured Products - Contract-Manufactured Products other expense (income) changed by $0.1 million and $0.2 million for the three and nine months ended September 30, 2020, respectively, as compared to the same periods in 2019.

Corporate - Corporate other expense (income) changed by $0.7 million and $0.1 million for the three and nine months ended September 30, 2020, respectively, as compared to the same periods in 2019.

Unallocated items - During the three and nine months ended September 30, 2020, we recorded $4.5 million in restructuring and related charges. During the three and nine months ended September 30, 2019, we recorded $1.8 million and $3.8 million, respectively, in restructuring and related charges and a charge of $1.0 million as a result of the continued devaluation of Argentina's currency.

Operating Profit

The following table presents adjusted operating profit, consolidated and by reportable segment, corporate and unallocated items:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Proprietary Products$107.5 $72.9 $312.9 $238.7 
Contract-Manufactured Products18.8 11.6 52.1 33.5 
Corporate(22.4)(14.4)(67.1)(48.9)
Adjusted consolidated operating profit$103.9 $70.1 $297.9 $223.3 
Adjusted consolidated operating profit margin19.0 %15.4 %19.0 %16.3 %
Unallocated items(4.7)(2.8)(7.1)(4.8)
Consolidated operating profit$99.2 $67.3 $290.8 $218.5 
Consolidated operating profit margin18.1 %14.8 %18.6 %16.0 %

Consolidated operating profit increased by $31.9 million, or 47.4%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $2.1 million for the three months ended September 30, 2020, as compared to the same period in 2019.

Consolidated operating profit increased by $72.3 million, or 33.1%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $3.0 million for the nine months ended September 30, 2020, as compared to the same period in 2019.

Proprietary Products - Proprietary Products operating profit increased by $34.6 million, or 47.5%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $1.7 million, due to the factors described above.

Proprietary Products operating profit increased by $74.2 million, or 31.1%, for the nine months ended September 30, 2020, as compared to the same period in 2019, including an unfavorable foreign currency translation impact of $3.1 million, due to the factors described above.
35
Contract-Manufactured Products - Contract-Manufactured Products operating profit increased by $7.2 million, or 62.1%, for the three months ended September 30, 2020, as compared to the same period in 2019, including a favorable foreign currency translation impact of $0.4 million, due to the factors described above.

Contract-Manufactured Products operating profit increased by $18.6 million, or 55.5%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019, including a favorable foreign currency translation impact of $0.1 million, due to the factors described above.

Corporate- Corporate costs increased by $8.0 million, or 55.6%, for the three months ended September 30, 2020, as compared to the same period in 2019, due to the factors described above.

Corporate costs increased by $18.2 million, or 37.2%, for the nine months ended September 30, 2020, respectively, as compared to the same period in 2019, due to the factors described above.

Unallocated items –Other unallocated items during the three months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges and $0.2 million of amortization expense associated with an acquisition of an intangible asset. Other unallocated items during the nine months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges, $2.2 million in severance related costs, and $0.4 million of amortization expense associated with an acquisition of an intangible asset.

Other unallocated items during the three and nine months ended September 30, 2019 consisted of $1.8 million and $3.8 million, respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2019, other unallocated items included a charge of $1.0 million as a result of the continued devaluation of Argentina's currency.

Interest Expense, Net

The following table presents interest expense, net, by significant component:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Interest expense$2.4 $2.2 $7.1 $7.0 
Capitalized interest(0.3)(0.1)(1.0)(0.6)
Interest income(0.2)(1.0)(1.2)(2.5)
Interest expense, net$1.9 $1.1 $4.9 $3.9 
Interest expense, net, increased by $0.8 million, or 72.7%, for the three months ended September 30, 2020, respectively, as compared to the same periods in 2019, primarily due to a decrease in interest income during the three months ended September 30, 2020.

Interest expense, net, increased by $1.0 million, or 25.6%, for the nine months ended September 30, 2020, respectively, as compared to the same periods in 2019, primarily due to a decrease in interest income during the nine months ended September 30, 2020.

Other Nonoperating (Income) Expense

Other nonoperating (income) expense changed by $1.7 million or 130.8% for the three months ended September 30, 2020, as compared to the same period in 2019, primarily due to a decrease in pension settlement charges of $1.6 million. In the current year and prior year, we determined that normal-course lump-sum payments for our U.S. qualified and non-qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.
36
Other nonoperating (income) expense changed by $0.5 million or 250.0% for the nine months ended September 30, 2020, as compared to the same period in 2019, primarily due to a reduction in interest costs offset by an increase in pension settlement charges of $0.7 million. In the current and prior year, we determined that normal-course lump-sum payments for our U.S. qualified and non-qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.

Income Tax Expense
The provision for income taxes was $21.1 million and $10.9 million for the three months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 21.6% and 16.8%, respectively. The increase in the effective tax rate is primarily due to a decrease in stock-based compensation deductions for the three months ended September 30, 2020 as compared to the same period in 2019.

The provision for income taxes was $52.1 million and $42.5 million for the nine months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 18.2% and 19.8%, respectively. The decrease in the effective tax rate is primarily due to an increase in stock-based compensation deductions for the nine months ended September 30, 2020 as compared to the same period in 2019.

Equity in Net Income of Affiliated Companies
Equity in net income of affiliated companies represents the contribution to earnings from our 25% ownership interest in Daikyo, which increased to 49% during the fourth quarter of 2019, and our 49% ownership interest in five companies majority-owned by a long-time partner located in Mexico. Please refer to Note 7, Affiliated Companies, for further discussion. Equity in net income of affiliated companies increased by $3.4 million for the three months ended September 30, 2020, as compared to the same period in 2019, due to favorable operating results at Daikyo and the Mexico affiliates, partially offset by amortization expense related to our increase in ownership interest in Daikyo of $0.5 million.

Equity in net income of affiliated companies increased by $7.8 million for the nine months ended September 30, 2020, as compared to the same period in 2019, due to favorable operating results at Daikyo and the Mexico affiliates, partially offset by amortization expense related to our increase in ownership interest in Daikyo of $2.5 million.

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Cash Flows

The following table presents cash flow data for the nine months ended September 30:

($ in millions)20202019
Net cash provided by operating activities$323.8 $260.8 
Net cash used in investing activities$(121.9)$(107.4)
Net cash used in financing activities$(128.4)$(87.8)

37
Net Cash Provided by Operating Activities – Net cash provided by operating activities increased by $63.0 million for the nine months ended September 30, 2020, as compared to the same period in 2019, primarily due to improved operating results.

Net Cash Used in Investing Activities – Net cash used in investing activities increased by $14.5 million for the nine months ended September 30, 2020, as compared to the same period in 2019, due to an increase in capital expenditures in 2020, partially offset by the business acquisition of our South Korea distributor in 2019.

Net Cash Used in Financing Activities – Net cash used in financing activities increased by $40.6 million for the nine months ended September 30, 2020, as compared to the same period in 2019, primarily due to increases in purchases under our share repurchase programs.

Liquidity and Capital Resources

The table below presents selected liquidity and capital measures:

($ in millions)September 30,
2020		December 31,
2019
Cash and cash equivalents$519.4 $439.1 
Accounts receivable, net$373.0 $319.3 
Inventories$294.9 $235.7 
Accounts payable$180.3 $156.8 
Debt$255.7 $257.3 
Equity$1,718.9 $1,573.2 
Working capital$790.6 $717.1 

Cash and cash equivalents include all instruments that have maturities of ninety days or less when purchased. Working capital is defined as current assets less current liabilities.

Cash and cash equivalents – Our cash and cash equivalents balance at September 30, 2020 consisted of cash held in depository accounts with banks around the world and cash invested in high-quality, short-term investments. The cash and cash equivalents balance at September 30, 2020 included $166.5 million of cash held by subsidiaries within the U.S., and $352.9 million of cash held by subsidiaries outside of the U.S. During the nine months ended September 30, 2020, we purchased 761,500 shares of our common stock under our calendar-year 2020 share repurchase program at a cost of $115.5 million, or an average price of $151.65 per share.

Working capital – Working capital at September 30, 2020 increased by $73.5 million, or 10.2%, as compared to December 31, 2019, which includes an unfavorable foreign currency translation impact of $16.4 million. Excluding the impact of currency exchange rates, cash and cash equivalents, accounts receivable, inventories and total current liabilities increased by $73.5 million, $49.3 million, $55.3 million and $100.6 million, respectively. The increase in accounts receivable was due to increased sales activity. The increase in inventories that occurred in the period was to ensure we have sufficient inventory on hand to support the needs of our customers. The increase in total current liabilities was primarily due to an increase in accounts payable, salaries and wages payable, accrued expenses and income taxes payable.

Debt and credit facilities – The $1.6 million decrease in total debt at September 30, 2020, as compared to December 31, 2019, resulted from debt repayments under our Term Loan.

38
Our sources of liquidity include our Credit Facility. At September 30, 2020, we had no outstanding borrowings under the Credit Facility. At September 30, 2020, the borrowing capacity available under the Credit Facility, including outstanding letters of credit of $2.5 million, was $297.5 million. We do not expect any significant limitations on our ability to access this source of funds.

Pursuant to the financial covenants in our debt agreements, we are required to maintain established interest coverage ratios and not to exceed established leverage ratios. In addition, the agreements contain other customary covenants, none of which we consider restrictive to our operations. At September 30, 2020, we were in compliance with all of our debt covenants.

We believe that cash on hand and cash generated from operations, together with availability under our Credit Facility, will be adequate to address our foreseeable liquidity needs based on our current expectations of our business operations, capital expenditures and scheduled payments of debt obligations.

Commitments and Contractual Obligations

A table summarizing the amounts and estimated timing of future cash payments resulting from commitments and contractual obligations was provided in our 2019 Annual Report. During the three months ended September 30, 2020, there were no material changes outside of the ordinary course of business to our commitments and contractual obligations.

OFF-BALANCE SHEET ARRANGEMENTS

At September 30, 2020, we had no off-balance sheet financing arrangements other than unconditional purchase obligations incurred in the ordinary course of business and outstanding letters of credit related to various insurance programs, as noted in our 2019 Annual Report.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the Critical Accounting Policies and Estimates disclosed in Part II, Item 7 of our 2019 Annual Report.

NEW ACCOUNTING STANDARDS

For information on new accounting standards that were adopted, and those issued but not yet adopted, during the three months ended September 30, 2020, and the impact, if any, on our financial position or results of operations, see Note 2, New Accounting Standards.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Our disclosure and analysis in this Form 10-Q contains some forward-looking statements that are based on management’s beliefs and assumptions, current expectations, estimates and forecasts. We also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such statements provide our current expectations or forecasts of future events. They do not relate strictly to historical or current facts. We have attempted, wherever possible, to identify forward-looking statements by using words such as “plan,” “expect,” “believe,” “intend,” “will,” “estimate,” “continue” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future - including statements relating to sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results - are forward-looking statements.

39
Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that, if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements:
•sales demand and our ability to meet that demand;
•competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability;
•customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them;
•interruptions or weaknesses in our supply chain, including from reasons beyond our control such as extreme weather, longer-term climate changes, natural disasters, pandemic, war, accidental damage, or unauthorized access to our or our customers’ information and systems, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products;
•the timing, regulatory approval and commercial success of customer products that incorporate our products and systems;
•whether customers agree to incorporate our products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of our products, and the rate, timing and success of regulatory approval for the drug products that incorporate our components and systems;
•the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Crystal Zenith prefilled syringes;
•average profitability, or mix, of the products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings;
•maintaining or improving production efficiencies and overhead absorption;
•dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo;
•the loss of key personnel or highly-skilled employees;
•the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements;
•the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials;
•the cost and progress of development, regulatory approval and marketing of new products;
•our ability to obtain and maintain licenses in any jurisdiction in which we do business;
•the relative strength of USD in relation to other currencies, particularly the Euro, SGD, the Danish Krone, Yen, Colombian Peso, Brazilian Real, and the South Korean Won; and
40
•the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability.

This list sets forth many, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all of the factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For further discussion of these and other factors, see the risk factors disclosed in Part I, Item 1A of our 2019 Annual Report as well as Part II, section 1A of this quarterly report. Except as required by law or regulation, we do not intend to update any forward-looking statements.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk or the information provided in Part II, Item 7A of our 2019 Annual Report.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosure controls are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this quarterly report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Our disclosure controls include some, but not all, components of our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures
An evaluation was performed under the supervision and with the participation of our management, including our CEO and CFO, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our CEO and CFO have concluded that, as of September 30, 2020, our disclosure controls and procedures are effective.

Changes in Internal Controls
During the quarter ended September 30, 2020, there have been no changes to our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.  OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

None.

ITEM 1A.  RISK FACTORS

We are providing the disclosure below and supplementing the risk factors described in Part I, Item 1A of our 2019 Annual Report with the following risk factor. The additional risk factor identified should be read in conjunction with the risk factors described in the 2019 Annual Report and the information under the “Forward Looking Statements” in the 2019 Annual Report.
41
Our results of operations and financial condition may be adversely affected by the novel coronavirus (COVID-19) pandemic and other public health epidemics.

Our results of operations and financial condition may be adversely affected if the progression of the COVID-19 pandemic interferes with our ability, or that of our employees, contractors, suppliers, customers and other business partners, to carry out and deliver on business obligations.

COVID-19 may have an adverse effect on our operations, supply chains and distribution systems. Known potential impacts are illness in our workforce as well as a reduction in access to raw materials for production and access to transportation of product. There could be other unknown and unforeseeable impacts. These impacts may also increase our expenses, including costs associated with preventive and precautionary measures that we, companies with which we conduct business and governments are taking. Government measures include actions that restrict or prohibit travel, which in turn may impact our operations by limiting our employees’ ability to come to work, or the employees of companies upon which our supply chain depends. The impacts of the pandemic and the aforesaid measures taken by other companies and governments may cause us to experience significant and unpredictable reductions or increases in demand for certain of our products. This is especially possible in the event customers re-prioritize their needs due to the changing environment.

Despite our efforts to manage these COVID-19 related risks, their ultimate impact on the Company will be determined by factors beyond our knowledge or control, including the duration of COVID-19 and further actions taken to control its spread and mitigate its public health effects.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended September 30, 2020, there were no purchases of our common stock made by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act.

In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares repurchased and the timing of such transactions will depend on a variety of factors, including market conditions.
There were no shares purchased during the three months ended September 30, 2020. During the nine months ended September 30, 2020, we purchased 761,500 shares of our common stock under the program at a cost of $115.5 million, or an average price of $151.65 per share.

ITEM 6.  EXHIBITS


The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

42
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)




By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer



October 23, 2020
43
EXHIBIT INDEX

Exhibit NumberDescription
3.1
3.2
4.1
4.2
4.3
4.4 (1)
Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted.
10.10
31.1
31.2
32.1*
32.2*
101.INSThe instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
104Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.


(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.

* Furnished, not filed.
F-1
 EX-10.10 2 ex10102020amendedresta.htm EX-10.10 Document

EXHIBIT 10.10






image011.jpg





West Pharmaceutical Services, INC.


NON-QUALIFIED DEFERRED COMPENSATION PLAN
FOR DESIGNATED EMPLOYEES



(Amended and Restated Effective as of January 1, 2020, except as otherwise noted herein or required by applicable law)









Plan Document






image11.jpgTHE WEST PHARMACEUTICAL SERVICES, INC.
NON-QUALIFIED DEFERRED COMPENSATION
PLAN FOR DESIGNATED EMPLOYEES
(Amended and Restated Effective January 1, 2020)
West Pharmaceutical Services, Inc. (the “Company”) hereby adopts this West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan For Designated Employees (the “Plan”), as amended and restated effective January 1, 2020, except as otherwise noted herein, to permit eligible employees of the Company to defer receipt of a specified portion of their cash and equity-based compensation:
1.    Eligible Employees. Employees of the Company or participating subsidiaries (as designated by the Company’s Senior Vice President and Chief Human Resources Officer) are eligible to make the elections set forth in this Plan if they are: (a) employed in the United States by the Company or a designated subsidiary and are designated as a Senior Director or higher by the Company, (b) any employee who was eligible for and participated in the Plan by making elective deferrals hereunder on or prior to January 1, 2020, or (c) any other employee of the Company or its subsidiaries who is specially designated by the Compensation Committee as eligible to participate in the Plan (each an “Eligible Employee”). An Eligible Employee who at any time makes a valid deferral election under the Plan is a “Participant.”
2.    Deferrable Compensation. An Eligible Employee may separately elect, in the form and manner determined by the Committee, to defer cash or stock compensation as follows:
i.    any whole percentage of his or her annual aggregate base salary paid by the Company for services rendered exclusive of any additional allowances, payments or non-cash benefits (“Base Salary”);
ii.     any whole percentage of his or her annual bonus (“Bonus”) earned and payable under the Company’s Annual Incentive Plan (“Annual Incentive Plan”), or any successor plan thereto, whether payable in cash or stock issued under the 2004 Stock-Based Compensation Plan, the 2007 Omnibus Incentive Compensation Plan, the 2011 Omnibus Incentive Compensation Plan, the 2016 Omnibus Incentive Compensation Plan and/or any successor plan(s) (collectively, the “Omnibus Plans”) or;
iii.     effective June 1, 2007 and for periods that end on or before December 31, 2021, any whole number of shares of deferred stock (including Performance-Vesting Restricted Stock and Performance-Vesting Stock Units, as applicable) (“PV Stock”) awarded under the Company’s Long-Term Incentive Plan (the “LTIP”), the Omnibus Plans, and/or any successor plan(s) thereto, to the extent such PV Stock is earned under the applicable plan. For avoidance of doubt, PV Stock granted or vested for periods that end after January 1, 2022 are not eligible for deferral under the Plan.
iv.    any who percentage of his or her other compensation that is not otherwise described by the foregoing provisions, but only to the extent specifically designated by the Committee as eligible for deferral, and subject to all terms and conditions as the Committee may establish in order to defer any such other compensation (“Other Designated Compensation”).
1.    Elections to Defer.
(a)    Base Salary or Other Designated Compensation. An Eligible Employee who wants to defer payment of any portion of his or her Base Salary or Other Designated Compensation in any calendar year must notify the Compensation Committee or its delegate in writing on or before December 31 of the prior year (or such earlier time as may be permitted by Code Section 409A and as designated by the Committee), stating the amount of his or her Base Salary or Other Designated Compensation to be deferred. This election becomes irrevocable on December 31 of such prior year (or such earlier time as may be permitted by Code Section 409A and as designated by the Committee); provided, however, that the Committee may designate such other time and manner for deferral of Other Designated Compensation that is not inconsistent with the rules under Code Section 409A.


(b)    Bonus Elections.
(i)    For bonuses earned on or prior to December 31, 2019,
(A)    An Eligible Employee who wants to defer payment of any portion of his or her Bonus in any calendar year shall notify the Compensation Committee or its delegate in writing on or before June 30 of the year prior to the year the Bonus would otherwise be paid. The election must state the amount of a Participant’s Bonus which is to be deferred, and the election is irrevocable as of such June 30.
(B)    For Bonuses paid with respect to services rendered and performance achieved before January 1, 2019, a Participant who is designated by the Committee as an officer (“Officer”) and who has elected to defer any portion of his or her Bonus, shall be permitted at the time of his or her election to designate that a portion of such Bonus will be deemed to be invested in common stock of the Company (“Common Stock”) and ultimately distributable in Common Stock in accordance with Section 8(g)(ii). The portion of such Participant’s Bonus so designated will be referred to as “Deferred Bonus Stock.” The portion of the Participant’s Bonus deferred hereunder that is not so designated shall be referred to as the “Deferred Cash Bonus.” No Participants, including Officers, are eligible to designate any portion of such Participant’s Bonus as Deferred Bonus Stock with respect to Bonuses paid for services rendered or performance achieved on or after January 1, 2019.
(ii)    For bonuses earned on or after January 1, 2020, an Eligible Employee who wants to defer payment of any portion of his or her Bonus in any calendar year shall notify the Compensation Committee or its delegate in writing on or before December 31 of the year prior to the year the Bonus would otherwise be earned (not paid). The election must state the amount of a Participant’s Bonus which is to be deferred, and the election is irrevocable as of such December 31.
(c)    PV Stock. An Eligible Employee who wants to defer payment of any portion of his or her PV Stock earned in any calendar year prior to 2021 must notify the Compensation Committee or its delegate in writing on or before December 31 of the second year of any performance-based vesting period applicable to such PV Stock (or such earlier time as may be permitted by Code Section 409A and as designated by the Committee), stating the amount of his or her PV Stock which shall be deferred. PV Stock is not eligible for deferral on or after January 1, 2022.
(d)     Special Rules for pre-2020 New-Hires.
(i)     Base Salary. Notwithstanding Section 3(a) above, on or before December 31, 2019, a newly Eligible Employee who is hired by the Company during a calendar year, may elect to participate in the Plan by notifying the Compensation Committee or its delegate in writing within the first 30 days after commencing employment or becoming eligible, stating the amount of his or her Base Salary to be deferred. Such election shall be effective on the first day of the payroll period following the end of such 30-day period and shall apply only with respect to Base Salary earned after the effective date of such election. An election so made shall be irrevocable on the first day of the applicable payroll period. This special enrollment rule shall not apply to new hires or newly eligible employees who become eligible on or after January 1, 2020. Such newly-hired and newly-eligible employees shall be eligible to enroll during the normal annual enrollment period applicable to all continuing employees (typically during November-December).
a.     Bonuses and PV Stock. The special pre-2020 newly-hired or newly-eligible enrollment period contained in Section 3(d)(i) shall not apply to elections to defer Bonuses or PV Stock in the year a Participant is hired (or first becomes eligible to participate).
2


i.     Revocation for Unforeseeable Emergency or Disability. If a Participant has an Unforeseeable Emergency as described in Section 8(d) or incurs a Disability as defined in Section 409A, then such Participant may make a request in writing to the Compensation Committee or its delegate to suspend any elections to make any deferrals to the Plan during the year such Unforeseeable Emergency or Disability is incurred. Upon approval by the Compensation Committee or its delegate, such contributions shall cease immediately.
2.    Matching Contributions.
i.    Base Salary. For years prior to 2007, the Company will contribute to the Plan an amount equal to 50% of the first 6% of Base Salary that a Participant elects to defer on a pre-tax basis. Matching contributions under this Section 4(a) (“Pre-2007 Base Salary Matching Contributions”) shall not be made for deferrals of Base Salary in excess of 6% or any portion of a Bonus or PV Stock deferred by a Participant.
ii.    Deferred Incentive Shares. The Company shall make a matching contribution (“Deferred Incentive Shares”) equal to 25% of the aggregate fair market value of the Deferred Bonus Stock that a Participant elects to defer. Fair market value shall be measured as of the date such Deferred Bonus Stock would otherwise be paid to such Participant. For the avoidance of doubt, (i) only Officers shall be eligible to elect to defer Deferred Bonus Stock and any related Deferred Incentive Shares matching contribution on and after January 1, 2016, and (ii) no Participants shall be eligible to earn any additional Deferred Incentive Shares (other than through crediting of Dividend Equivalents for previously Deferred Bonus Stock) for services rendered or performance achieved on or after January 1, 2019.
iii.    401(k) Plan True-up. Effective for calendar years beginning on or after January 1, 2007 and ending on December 31, 2018,
b.    With respect to any Participant who earns Base Salary in excess of Section 401(a)(17) of the Internal Revenue Code of 1986, as amended (the “Code”), except as provided in Sections 4(c)(ii), the Company will make matching contributions (“2007-18 Base Salary Matching Contributions”) equal to 100% of the Participant’s Base Salary deferred on a pre-tax basis and remaining to such Participant’s Account plus amounts deferred under the West Pharmaceutical Services, Inc. 401(k) Plan (the “401(k) Plan”) on a pre-tax basis only (not inclusive of after-tax or Roth 401(k) contributions), if applicable, up to 3% of such Participant’s total annual Base Salary and 50% of the Participant’s Base Salary deferred in excess of 3%, but no greater than 5%, of such Participant’s total annual Base Salary deferred. Such matching contributions shall be calculated without regard to Section 401(a)(17) of the Code. The total amount of matching contributions made for the Participant with respect to a calendar year (including a “true up” contributions) under the 401(k) Plan whether on pre-tax or after-tax contributions (or in accordance with Section 8 hereof), if any, shall be deducted from the 2007-18 Base Salary Matching Contributions made hereunder. 2007-18 Base Salary Matching Contributions under this Section 4(c) shall not be made for deferrals of Base Salary in excess of 5% of a Participant’s total annual Base Salary. Notwithstanding the foregoing, for purposes of this Section 4(c)(i), Base Salary shall mean Base Salary and Other Designated Compensation (to the extent so designated by the Committee in accordance with the Plan).
c.    Notwithstanding Section 4(c)(i), on or before December 31, 2018, a Participant may elect to opt out of being credited with any 2007-18 Base Salary Matching Contributions, and, such Participant will only be credited with matching contributions under the 401(k) Plan, if applicable.
d.     No contributions shall be made under this section with respect to contributions made to the 401(k) plan on or after January 1, 2019.
3


3.     Other Contributions.
i.    Effective October 1, 2014, the Company may credit any Eligible Employee’s account with a contribution of any amount determined in its discretion (“Discretionary Contributions”).
ii.    The Company shall enter into a written arrangement with the Eligible Employee (“Discretionary Contribution Agreement”) detailing the material terms of such Discretionary Contribution, including the vesting schedule, distribution options and investment options available. Any elections applicable to the distribution of such Discretionary Contributions shall comply with Section 409A of the Code and the other rules set forth in the Plan.
iii.     Effective for the year beginning January 1, 2017, with respect to any Eligible Employee who is first hired by the Company on or after January 1, 2017 or any Eligible Employee employed by Tech Group North America, Inc., Tech Group Grand Rapids, Inc., or West Pharmaceutical Services Delaware Acquisition, Inc. (the “Group”), in each case, who earns Base Salary and Other Designated Compensation for such year in excess of the limits in Section 401(a)(17) of the Code (“Excess Compensation”), the Company will make a non-elective contribution (“NEC”) equal to 1% of such Participant’s Excess Compensation for such year; and effective for the year beginning on January 1, 2018, with respect to any Eligible Employee who is first hired by the Company on or after January 1, 2017 or any Eligible Employee employed by the Group, in each case, who earns Excess Compensation for such year, the Company will make a NEC equal to 2% of such Participant’s Excess Compensation for such year. Effective for each year beginning on and after January 1, 2019, with respect to each Eligible Employee who earns Excess Compensation for such year, the Company will make a NEC equal to 3% of such Participant’s Excess Compensation for such year. Such NEC shall be calculated without regard to Section 401(a)(17) of the Code.
a.     Notwithstanding anything herein to the contrary, any NEC hereunder shall be allocated to such Eligible Employee only if such Eligible Employee was (a) employed by the Company or the applicable participating subsidiary on the last day of the year to which the NEC relates, (b) terminates employment due to death or a disability (as defined in the 401(k) Plan) during such year, (c) dies or becomes disabled while on qualified military service (as defined in the 401(k) Plan) during such year or (d) terminates employment during the year after attaining age 55 with 10 years of service.
b.     An Eligible Employee who has been allocated NEC amounts under an Account shall be considered a Participant with respect to any such NEC amounts.
4.    Investment of Deferred Compensation Accounts.
iv.    The Company shall establish separate bookkeeping accounts (each part of a Participant’s “Account”) as set forth in this Section 6. Such Accounts will be maintained on the books of the Company and will be used solely to calculate the amount payable to each Participant and shall not constitute separate funds of assets. Amounts will be credited to such Accounts as of the date such amounts would have been distributed or paid to a Participant but for an election to defer such amounts hereunder. If a Bonus or share of Deferred PV Stock is not earned under the Annual Incentive Plan or the LTIP, or any successor plan(s) thereto, as applicable, no amount shall be credited to a Participant’s Accounts.
v.     A Participant’s Base Salary and Other Designated Compensation deferred pursuant to Section 3(a) plus his or her Deferred Cash Bonus shall be allocated to his or her “Cash Deferral Account” as of the last day of the payroll period to which it relates.
vi.     Pre-2007 Base Salary Matching Contributions made pursuant to Section 4(a) on or before March 31, 2000 shall be allocated to a Participant’s “Participant-Directed Matching Contribution Account” as of the last day of the payroll period to which they relate.
4


vii.     Pre-2007 Base Salary Matching Contributions made pursuant to Section 4(a) on or after April 1, 2000 and all 2007-18 Base Salary Matching Contributions shall be allocated to a Participant’s “Stock-Invested Matching Contribution Account” as of the last day of the payroll period to which they relate or, with respect to 2007-18 Base Salary Matching Contributions, the date the amount of such 2007-18 Base Salary Matching Contributions is determined in the next following calendar year. Collectively, amounts credited to a Participant’s Stock-Invested Matching Contribution Account and his or her Participant-Directed Matching Contribution Account, shall be referred to as his or her “Matching Contribution Account.”
viii.     Deferred Bonus Stock, Deferred PV Stock, and Deferred Incentive Shares will be allocated to a separate “Deferred Stock Account” and subject to the rules of Section 8(g)(ii).
ix.    Discretionary Contributions shall generally be subject to the same rules applicable to a Participant’s Cash Deferral Account, unless specifically provided otherwise in the Participant’s Discretionary Contribution Agreement.
x.     NEC amounts shall be allocated to a separate “NEC Account,” as of the date the amount of such NEC is determined in the calendar year after the year to which such NEC relates, and such NEC Account shall generally be subject to the same rules applicable to a Cash Deferral Account, except to the extent provided with respect to vesting and distribution in Sections 7 and 8 hereof and except as otherwise provided by the Committee.

xi.    Investment of Cash Deferral Account and Participant-Directed Matching Contribution Account.
i.    Each Participant shall direct the deemed investment of his or her Cash Deferral Account and Participant-Directed Matching Contribution Account among the investment funds offered under the Plan (“Investment Funds”) by complying with administrative procedures established by the Compensation Committee. A Participant’s election shall specify the whole percentage of his or her Cash Deferral Account and Participant-Directed Matching Contribution Account deemed to be invested in an Investment Fund. A Participant’s election shall remain in effect until a new election is made. A Participant may change an election of Investment Funds or transfer existing amounts invested in his or her Account(s) among Investment Funds by complying with the administrative procedures established by the Compensation Committee. The Compensation Committee shall establish procedures to review the investment elections made by a Participant and shall retain the authority to override any investment election if it determines, in its sole discretion, that such an override is in the Company’s best interests. In addition, any discretionary investments in or divestments of amounts deemed invested in Company Stock shall be subject to the Company’s Securities Trading Policy.
ii.    Investment Funds. The Company shall make available to each Participant literature summarizing the investment characteristics of each Investment Fund.
iii.    Valuation of Participant Accounts. Any increase or decrease in the fair market value of an Investment Fund shall be computed and credited to or deducted from the Cash Deferral Account or Participant-Directed Matching Contribution Account, as applicable, of all Participants who are deemed to have invested in the Investment Fund in accordance with policies and procedures established by the Compensation Committee.
xii.    Investment of Stock-Invested Matching Contribution Account.
iv.    The Stock-Invested Matching Contribution Account of each Participant shall be deemed to be invested in Common Stock. Except as set forth herein, a Participant shall not be able to direct or invest amounts in his or her Stock-Invested Matching Contribution Account. Notwithstanding
5


the foregoing, effective January 1, 2008, a Participant who has been credited with three years of service, may direct the investment of his Stock-Invested Matching Contribution Account among the other Investment Funds offered under the Plan, and also may choose to re-invest any portion of their Stock-Invested Matching Contribution Account in Common Stock after previously investing it in the other available Investment Funds.
v.    Any increase or decrease in the fair market value of the common stock of the Company shall be computed and credited to or deducted from the Stock-Invested Matching Contribution Accounts of all of the Participants who are invested in the common stock of the Company in accordance with policies and procedures established by the Compensation Committee.
xiii.    Investment of Deferred Stock Account.
c.image11.jpg    The Deferred Stock Account of each Participant shall be deemed to be invested in Common Stock. A Participant shall not have the ability to direct or invest amounts in his or her Deferred Stock Account.
d.    Any increase or decrease in the fair market value of the common stock of the Company shall be computed and credited to or deducted from the Deferred Stock Accounts of all of the Participants who are invested in the common stock of the Company in accordance with policies and procedures established by the Compensation Committee.
xiv.    Indemnity. By electing to make contributions to this Plan, each Participant hereby recognizes and agrees that the Company and any other individual responsible for administering the Plan (including the Compensation Committee, its delegate or any trustee responsible for holding assets under the Plan) are in no way responsible for the investment performance of the Participant’s Accounts.
xv.    Dividends on Company Stock. Any dividends paid on that portion of a Participant’s Account that is deemed invested in Company Stock shall be treated as earnings hereunder, and, shall, in the manner determined by the Committee be credited to a Participant’s Account and remain deemed invested in Company Stock and shall be distributed in Company Stock. With respect to Deferred PV Stock, such amount shall be credited with dividends at the target level in a manner similar to that provided under the terms of the LTIP.
5.    Vesting.
i.    Cash Deferrals and 2007-18 Base Salary Matching Contributions. A Participant shall always be 100% vested in his or her Cash Deferral Account and 2007-18 Base Salary Matching Contributions made pursuant to Section 4(c).
ii.    Pre-2007 Base Salary Matching Contributions. A Participant shall be 40% vested in Pre-2007 Base Salary Matching Contributions made on his or her behalf under Section 4 after two years of employment with the Company or any of its subsidiaries (prior to such two-year period, no portion of the Pre-2007 Base Salary Matching Contributions shall be vested). A Participant’s vested interest in Pre-2007 Base Salary Matching Contributions will increase by 20% per year of employment, so that he or she is 100% vested after five years of employment with the Company or any of its subsidiaries. A “year of employment” will be credited to a Participant for each 12 month period, beginning on his or her date of hire by the Company or any of its subsidiaries (and each anniversary thereof), during which he or she is continuously employed by the Company or any of its subsidiaries, as determined in the Company’s sole discretion.
iii.    Bonus Stock and Deferred PV Stock. Any Bonus Stock deferred under Section 3(b) and any Deferred PV Stock deferred under Section 2(c) shall be immediately 100% vested.
iv.    Deferred Incentive Shares.
6


e.     Subject to Sections 7(d)(ii) through 7(d)(v), all Incentive Shares credited to a Participant’s Account will vest on the fourth anniversary of the date that the Bonus Stock with respect to which such Incentive Share relates (“Underlying Stock”) was granted to a Participant.
f.     If a Participant receives a distribution with respect to any share of Underlying Stock prior to the fourth anniversary of the grant date of the Underlying Stock, the Incentive Shares that relates to such Underlying Stock will be immediately forfeited by such Participant.
g.     If a participant sells, assigns, exchanges, pledges, hypothecates or otherwise encumbers any of the Underlying Stock, the Incentive Shares that relate to such Underlying Stock will be immediately forfeited by such Participant.
h.     If, as determined by the Committee in its sole and absolute discretion, a Participant terminates employment with the Company due to death, disability or retirement under a qualified pension plan maintained by the Company (collectively referred to as a “Qualified Termination”), then the following percentage of Incentive Shares shall vest and all unvested shares shall be immediately forfeited:
1.     25% if at least one but less than two years has elapsed since the grant date of the Underlying Stock.
2.    50% if at least two but less than three years has elapsed since the grant date of the Underlying Stock.
3.    75% if at least three but less than four years has elapsed since the grant date of the Underlying Stock.
i.     If, as determined by the Committee in its sole and absolute discretion, a Participant’s service with the Company terminates for any reason other than a Qualified Termination, all unvested Incentive Shares shall immediately be forfeited.
v.     Discretionary Contributions shall be 100% vested at the time contributed, unless provided otherwise in the Participant’s Discretionary Contribution Agreement.
vi.     An Eligible Employee shall be 100% vested in his or her NEC Account only after three years of employment with the Company or any of its subsidiaries (and, prior to the end of such three-year period, no interest in such NEC Account or any NEC amounts shall be vested). A “year of employment” will be credited in the manner described in Section 7(b).
vii.    Change in Control.
(i)    Notwithstanding anything in this Plan to the contrary, a Participant shall immediately be 100% vested in matching contributions made pursuant to Section 4 after a Change in Control, as defined below.
    (ii)    A “Change in Control” shall mean a change in control of a nature that would be required to be reported in response to Item 1 of the Current Report on Form 9-K as in effect on April 28,1998, pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Act”), provided that, without limitation, a Change in Control shall be deemed to have occurred if:
4.    any “Person” (as such term is used in sections 13(d) and 14(d) of the Act), other than:
7


(a)    the Company,
(b)    any Person who on the date hereof is a director or Participant of the Company, or
(c)    a trustee or fiduciary holding securities under an employee benefit plan of the Company,
5.    is or becomes the “beneficial owner,” (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s then outstanding securities; or
6.    during any period of two consecutive years during the term of this Plan, individuals who at the beginning of such period constitute the board of directors of the Company (the “Board”) cease for any reason to constitute at least a majority thereof, unless the election of each director who was not a director at the beginning of such period has been approved in advance by directors representing at least two-thirds of the directors then in office who were directors at the beginning of the period; or
7.    the shareholders of the Company approve:
(d)    a plan of complete liquidation of the Company; or
(e)    an agreement for the sale or disposition of all or substantially all of the Company’s assets; or
(f)     a merger, consolidation, or reorganization of the Company with or involving any other corporation, other than a merger, consolidation, or reorganization that would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity), at least fifty percent (50%) of the combined voting power of the voting securities of the Company (or the surviving entity, or an entity which as a result of such transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) outstanding immediately after such merger, consolidation, or reorganization.
6.    Distribution of Deferred Compensation.
viii.    Distributions of Certain Amounts Following Fifth Anniversary. For allocations to a Participant’s Cash Deferral Account and the vested portion of a Participant’s Deferred Stock Account only, during each calendar year, unless a Participant elects otherwise in accordance with Section 8(b), the amount contributed to each Account for each plan year plus any earnings and losses, shall be distributed on the first to occur of:
a.     The first normal payroll date on or after the January 15 that occurs following the fifth anniversary of the end of year such amounts would have been paid to the Participant absent his or her deferral hereunder; or,
b.    The first normal payroll date on or after the date which is six months following the Participant’s termination of employment.
ix.     Election to Receive Certain Amounts at a Different Time. Notwithstanding Section 8(a), a Participant may elect in writing and only to the extent described in this Section 8(b) to have amounts that would be distributed in accordance with Section 8(a) distributed at a different time.
8


c.     With respect to amounts described in Section 8(a) that were earned and vested on or before December 31, 2004 (“Grandfathered Amounts”), the election must be made in writing by December 31 of the year which is two years’ prior to the date the Grandfathered Amounts would otherwise be distributed under the Plan. A Participant may elect to receive his or her Grandfathered Amounts on either: (A) a subsequent date that is at least 24 months later than the date the amounts would otherwise be distributed hereunder, or (B) termination of employment. A Participant is permitted to make subsequent deferrals under this Section 8(b)(i) provided that such subsequent elections satisfy the requirements in the previous sentence. Notwithstanding any election under this Section 8(b), Grandfathered Amounts will be distributed by the end of the month following the Participant’s termination of employment if it occurs earlier.
d.    With respect to amounts described in Section 8(a) that were earned and vested on or after January 1, 2005 (“Non-Grandfathered Amounts”), the election must be made in writing by the later of (A) the date his or her election becomes irrevocable as described in Section 3, or (B) December 31, 2008. A Participant may elect to receive his or her Non-Grandfathered Amounts on either: (A) a subsequent date that is at least 24 months later than the date the amounts would otherwise be distributed hereunder, or (B) termination of employment. A Participant is not permitted to make subsequent deferrals under this Section 8(b)(ii). Notwithstanding any election under this Section 8(b)(ii), Non-Grandfathered Amounts will be distributed on the date that is six months following the Participant’s termination of employment if it occurs earlier.
x.     Distributions of Matching Contributions and NEC. Allocations of Grandfathered and Non-Grandfathered Amounts to a Participant’s Participant-Directed Matching Contribution Account and Stock-Invested Matching Contribution Account, and of any NEC amounts to a NEC Account, are distributable only following the termination of a Participant’s employment with the Company and all of its subsidiaries for any reason, including retirement or death. Distributions of Grandfathered Amounts shall be made by the end of the month following the month of the Participant’s termination of employment, and distributions of Non-Grandfathered Amounts, including NEC amounts, shall be made on the date that is six months following the Participant’s termination of employment.
xi.     Distributions in the Event of an Unforeseeable Emergency. Notwithstanding anything herein to the contrary, a Participant may elect to receive a distribution from his Cash Deferral Account and the vested portion of a Participant’s Deferred Stock Account in the event of an Unforeseeable Emergency. An Unforeseeable Emergency shall be defined in accordance with Section 409A(a)(2)(B)(ii) of the Code. The distributed amount may not exceed the amount necessary to eliminate the Unforeseeable Emergency plus pay any applicable taxes. To apply for an Unforeseeable Emergency distribution, a Participant must submit a written application to the Compensation Committee or its delegate indicating (A) the nature of the Unforeseeable Emergency, (B) the amount the Participant needs to alleviate the Unforeseeable Emergency, and (C) the Account from which a distribution, if approved, shall be made. The determination of whether an Unforeseeable Emergency exists shall be made in accordance with the claims procedures in Section 13. Amounts allocated to a Participant’s Participant-Directed Matching Contribution Account, Stock-Invested Matching Contribution Account and the unvested portion of a Participant’s Deferred Stock Account shall not be available for distribution under this Section 8(d).
xii.    Valuing Accounts for Distributions. The value of each of the Accounts of a Participant shall be determined as of the effective date of a distribution from the Plan (the “Valuation Date”). The value of the Accounts will be adjusted on the Valuation Date to reflect earnings, losses, dividends, stock splits, and previous withdrawals. The relevant portion of each of the Accounts, as applicable, shall then be distributed in accordance with this Section 8.
xiii.    Method of Distribution.
e.    Subject to Sections 8(g) and 9, and unless elected otherwise under Section 8(f)(ii), all distributions from the Plan shall be made in a cash lump sum.
9


f.    For amounts payable upon termination of employment pursuant to any other sub-section of this Section 8, a Participant may elect to receive the distribution in five substantially equal annual installments in accordance with this Section 8(f)(ii).
8.     With respect to Grandfathered Amounts, such election must be made by December 31 of the year before the year of a Participant’s termination of employment. This election shall continue in effect until changed by the Participant, provided that any such change shall be effective only if the Participant submits appropriate instructions, in accordance with administrative procedures established by the Company, on or before December 31 of the year prior to the year in which the Participant becomes entitled to a distribution.
9.     With respect to Non-Grandfathered Amounts, such election must be made by the later of (i) the date the Participant makes his or her first deferral election under the Plan, or (ii) December 31, 2008; provided, however, that any such election that applies to NEC amounts with respect to a Participant who has not otherwise made a deferral election under the Plan (if any) must be made no later than the end of the calendar year prior to the year in which such NEC amounts first apply with respect to a Participant or such other time as the Committee may designate in a manner consistent with Code Section 409A. This election is irrevocable.
10.    If installment distributions are elected, the first installment shall be paid on or as soon as practicable following the January 15 immediately following the Participant’s termination from employment, and the others on or as soon as practicable following January 15 of the second, third, fourth and fifth years following such termination. Notwithstanding the foregoing, for any employee who is a specified employee within the meaning of Treas. Reg. § 1.409A-1(i) the first distribution shall be delayed until the first normal payroll date following the date that is six months after such Participant’s termination of employment to the extent required by applicable law. The Participant shall continue to direct the investment of any amount remaining in his or her Cash Deferral Account and Participant-Directed Matching Contribution Account and the second to fifth installments shall be adjusted to take into account any earnings, losses, stock splits or dividends.
xiv. Form of Distributions. Regardless of the method of distribution required or elected under Section 8(f):
g.     Distributions from a Participant’s Cash Deferral Account, and either Matching Contribution Account shall be made in cash, unless elected otherwise under Section 8(g)(iii).
h.     Distributions of Bonus Stock and amounts allocated to a Participant’s Deferred Stock Account must be made in the form of whole shares of Common Stock in accordance with this Section. No partial shares of Common Stock shall be distributed, and cash equal to the fair market value of such fractional Common Stock shall be distributed in lieu thereof.
i.     A Participant may elect to receive all or a portion of his or her distribution from his or her Base Salary Deferral Account or either Matching Contribution Account in Common Stock; provided that such election to receive Common Stock in lieu of cash shall be effective only if the Participant submits appropriate instructions, in accordance with administrative procedures established by the Company, on or before December 31 of the year prior to the year in which the Participant becomes entitled to a distribution.
j.     Any Common Stock distributable from this Plan in accordance with this Section 8(g) shall be made under and pursuant to the applicable Omnibus Plan(s) or any successor plan(s) thereto as determined by the Compensation Committee.
10


xv.     Discretionary Contributions. Discretionary Contributions shall be distributed in the time and manner set forth in such Participant’s Discretionary Contribution Agreement. Any elections as to the time and manner of distribution shall comply with Section 409A and this Section 8. If amounts are payable due to termination of employment, the first election for amounts to be distributed upon termination shall apply.
xvi.    Treatment of Unvested Portion of Participant’s Account. Incentive Shares that are not vested at the time a Participant terminates employment shall be forfeited and may be used by the Company as determined in its sole discretion.
xvii.    Small-Benefit Cash Out. To the extent permitted by Section 409A of the Code, notwithstanding any other provision of this Plan to the contrary, if a Participant’s entire Account (plus any amounts that would be aggregated with the Account under Code Section 409A) is less than the amount specified in Section 402(g)(1)(B) of the Code when such Participant terminates employment, his or her entire Account will be paid in a single, cash lump sum six months following termination of employment.
7.     Pre-2020 Transfers of Certain Amounts to the 401(k) Plan. With respect to any Participant who is eligible for the 401(k) Plan, on or before December 31, 2019,
xviii.     The Company shall distribute from such Participant’s Base Salary deferred hereunder (but not Cash Bonuses), the maximum pre-tax amount that may be contributed to the 401(k) Plan by such Participant for such deferral year, and shall contribute such amount to the 401(k) Plan on behalf of such Participant in accordance with the limitations imposed by the Code. Such amount shall not include any earnings on the Base Salary Deferrals, but shall be adjusted for any losses.
xix.     The Company shall contribute, from such Participant’s 2007-18 Base Salary Matching Contributions an amount equal to the maximum amount such Participant could have been credited with matching contributions under the 401(k) Plan. Such amount shall not include any earnings on the Base Salary Deferrals, but shall be adjusted for any losses.
xx.     The Company shall contribute both such amounts to the 401(k) Plan as soon as practicable after the calendar year to which the election relates, but not later than March 15 of the following calendar year.     
The foregoing transfer provisions shall not apply to any amounts deferred to the Plan with respect to January 1, 2020 or later earnings.
8.     Distributions on Death; Designation of Beneficiary. Notwithstanding anything in the Plan to the contrary, if a Participant dies prior to receiving the entire balance of his or her Accounts, any balance remaining in his or her Accounts shall be paid in a cash lump sum only to the Participant’s designated beneficiary as soon as practicable after such Participant’s death, or if the Participant has not designated a beneficiary in writing to the Compensation Committee or its delegate, to such Participant’s estate. Any designation of beneficiary may be revoked or modified at any time by the Participant or his or her authorized designee.
9.    Unsecured Obligation of the Company. The Company’s obligations to establish and maintain Accounts for each Participant and to make payments of deferred compensation to him or her under this Plan shall be the general unsecured obligations of the Company. The Company shall be under no obligation to establish any separate fund, purchase any annuity contract, or in any other way make special provision or specifically earmark any funds for the payment of any amounts called for under this Plan, nor shall this Plan or any actions taken under or pursuant to this Plan be construed to create a trust of any kind, or a fiduciary relationship between the Company and any Participant, his or her designated beneficiary, executors or administrators, or any other person or entity. If the Company chooses to establish such a fund or purchase such an annuity contract or make any other arrangement to provide for the payment of any amounts called for under this Plan, such fund contract or arrangement shall remain part of the general assets of the Company, and no person claiming benefits under this Plan shall have any right, title, or interest in or to any such fund, contract or arrangement.
11


10.    Administration. The Plan will be administered by the Compensation Committee or its delegate.
i.    The Compensation Committee shall be the named fiduciary for purposes of the claims procedure pursuant to Section 13 and shall have authority to act to the full extent of its absolute discretion to:
a.    interpret the Plan;
b.    resolve and determine all disputes or questions arising under the Plan subject to the provisions of Section 12, including the power to determine the rights of Participants and their beneficiaries (designated under Section 10), and their respective benefits, and to remedy any ambiguities, inconsistencies or omissions in the Plan;
c.    create and revise rules and procedures for the administration of the Plan and prescribe such forms as may be required for Participants to make elections under, and otherwise participate in, the Plan; and
d.    take any other actions and make any other determinations as it may deem necessary and proper for the administration of the Plan.
ii.    Any expenses incurred in the administration of the Plan will be paid by the Company or the Employer.
iii.    Except as the Compensation Committee may otherwise determine (and subject to the claims procedure set forth in Section 13), all decisions and determinations by the Compensation Committee shall be final and binding upon all Participants and their designated beneficiaries.
iv.    No member of the Compensation Committee or its delegate shall participate in any matter involving any questions relating solely to his or her own participation or benefits under the Plan. The Compensation Committee shall be entitled to rely conclusively upon, and shall be fully protected in any action or omission taken by it in good faith reliance upon the advice or opinion of any persons, firms or agents retained by it, including but not limited to accountants, actuaries, counsel and other specialists. Nothing in this Plan shall preclude the Company from indemnifying the Compensation Committee or its delegate for all actions under this Plan, or from purchasing liability insurance to protect such persons with respect to the Plan.
v.    With respect to Company Stock, in the event of any (a) stock split, reverse stock split, or stock dividend, or (b) extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up or other similar change in corporate structure or capitalization or similar event, the number and kinds of shares payable hereunder shall be adjusted by the Company. The determinations and adjustments made by the Committee under this Section shall be conclusive.
vi.    The Compensation Committee shall have the full authority to delegate all of its responsibilities (other than fiduciary monitoring obligations) to a person or persons of its choosing. The delegate shall have all the powers that the Compensation Committee deems necessary for the efficient administration of the Plan.
11.    Claims Procedure.image11.jpg The Company shall administer a claims procedure as follows:
vii.    Initial Claim. A Participant or his or her beneficiary who believes that he or she is entitled to benefits under the Plan (the “Claimant”), or the Claimant’s authorized representative acting on behalf of such Claimant, must make a claim for those benefits by submitting a written notification of his or her claim of right to such benefits. Such notification must be on the form and in accordance with the procedures established by the Company. No benefit shall be paid under the Plan until a proper claim for benefits has been submitted.
12


viii.    Procedure for Review. The Compensation Committee shall establish administrative processes and safeguards to ensure that all claims for benefits are reviewed in accordance with the Plan document and that, where appropriate, Plan provisions have been applied consistently to similarly situated Claimants. Any notification to a Claimant required hereunder may be provided in writing or by electronic media, provided that any electronic notification shall comply with the applicable standards imposed under 29 C.F.R. §2520.104b1(c).
ix.    Claim Denial Procedure. If a claim is wholly or partially denied, the Compensation Committee shall notify the Claimant within a reasonable period of time, but not later than 90 days after receipt of the claim, unless the Compensation Committee determines that special circumstances require an extension of time for processing the claim. If the Compensation Committee determines that an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 90-day period. In no event shall such extension exceed a period of 180 days from receipt of the claim. The extension notice shall indicate: (i) the special circumstances necessitating the extension and (ii) the date by which the Compensation Committee expects to render a benefit determination. A benefit denial notice shall be written in a manner calculated to be understood by the Claimant and shall set forth: (i) the specific reason or reasons for the denial, (ii) the specific reference to the Plan provisions on which the denial is based, (iii) a description of any additional material or information necessary for the Claimant to perfect the claim, with reasons therefor, and (iv) the procedure for reviewing the denial of the claim and the time limits applicable to such procedures, including a statement of the Claimant’s right to bring a legal action under section 502(a) of Employee Retirement Income Security Act of 1974, as amended (“ERISA”) following an adverse benefit determination on review.
x.    Appeal Procedure. In the case of an adverse benefit determination, the Claimant or his or her representative shall have the opportunity to appeal to the Compensation Committee for review thereof by requesting such review in writing to the Board within 60 days of receipt of notification of the denial. Failure to submit a proper application for appeal within such 60 day period will cause such claim to be permanently denied. The Claimant or his or her representative shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the claim. A document, record or other information shall be deemed “relevant” to a claim in accordance with 29 C.F.R. §2560.503-1(m)(8). The Claimant or his or her representative shall also be provided the opportunity to submit written comments, documents, records and other information relating to the claim for benefits. The Board shall review the appeal taking into account all comments, documents, records and other information submitted by the Claimant or his or her representative relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.
xi.    Decision on Appeal. The Board shall notify a Claimant of its decision on appeal within a reasonable period of time, but not later than 60 days after receipt of the Claimant’s request for review, unless the Compensation Committee determines that special circumstances require an extension of time for processing the appeal. If the Compensation Committee determines that an extension of time for processing is required, written notice of the extension shall be furnished to the Claimant prior to the termination of the initial 60-day period. In no event shall such extension exceed a period of 60 days from the end of the initial period. The extension notice shall indicate: (i) the special circumstances necessitating the extension and (ii) the date by which the Compensation Committee expects to render a benefit determination. An adverse benefit decision on appeal shall be written in a manner calculated to be understood by the Claimant and shall set forth: (i) the specific reason or reasons for the adverse determination, (ii) the specific reference to the Plan provisions on which the denial is based, (iii) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records, and other information relevant to the Claimant’s claim (the relevance of a document, record or other information will be determined in accordance with 29 C.F.R. §25601(m)(8)) and (iv) a statement of the Claimant’s right to bring a legal action under section 502(a) of ERISA.
xii.    Litigation. In order to operate and administer the claims procedure in a timely and efficient manner, any Claimant whose appeal with respect to a claim for benefits has been denied, and who wants to commence a legal action with respect to such claim, must commence such action in a court of competent jurisdiction within 90 days of receipt of notification of such denial. Failure to file such action by the prescribed time will forever bar the commencement of such action.
13


xiii.    Disputes; Enforcement of Rights. All reasonable legal and other fees and expenses incurred by the Claimant in connection with any disputed claim regarding any right or benefit provided for in this Plan shall be paid by the Company, to the extent permitted by law, provided that the Claimant prevails on the merits of his or her claim in material part as the result of litigation, arbitration or settlement.
12.    Delay. Notwithstanding anything in the Plan to the contrary, to the extent permitted by Section 409A of the Code, distributions to Participants shall be delayed if (a) the ability of the Company to remain a going concern is jeopardized, (b) it is necessary to comply with applicable law, or (c) prior to a Change in Control only, to the extent necessary to ensure deduction under Section 162(m) of the Code.
13.     Acceleration to Pay Employment Taxes. To the extent permitted by Section 409A of the Code, distributions under the Plan may be accelerated to the extent required to pay employment taxes, as permitted by the Compensation Committee.
14.    Top Hat and Non-Qualified Status. This Plan is intended to be a top-hat plan within the meaning of ERISA. The Plan is an unfunded plan for purposes of ERISA and the Code and is not qualified under section 401(a) of the Code.
15.    Withholding of Taxes. The rights of a Participant (and his or her beneficiaries) to payments under this Plan shall be subject to the Company’s obligations at any time to withhold from such payments any income or other tax on such payments.
16.    Assignability. No portion of a Participant’s Account(s) may be assigned or transferred in any manner, nor shall any of the Accounts be subject to anticipation, voluntary alienation or involuntary alienation.
17.    Amendments and Termination. This Plan may be amended by the Compensation Committee of the Board. This Plan may be terminated at any time by the Board. No amendment or termination may adversely affect a Participant’s Accounts existing on the date such amendment or termination is made, nor any election previously made under the Plan as to deferrals for the calendar year in which the amendment or termination occurs.
18.    Effective Date; Section 409A. The Plan was originally effective with respect to a Participant’s Bonus Stock or Cash Compensation earned after August 30, 1994. This restatement is effective with respect to a Participant’s deferrals made on or after January 1, 2020. The Plan is intended to satisfy Code Section 409A and all of the official guidance promulgated thereunder. To the extent a provision in the Plan is inconsistent with Code Section 409A, such provisions shall be deemed amended to comply with Code Section 409A, to avoid the application of the penalty tax and interest provided thereunder.
* * *
To record the adoption of the amendment and restatement of the West Pharmaceutical Services, Inc. Non-Qualified Deferred Compensation Plan for Designated Employees effective as of January 1, 2020, West Pharmaceutical Services, Inc. has caused its authorized officer to execute this Plan document upon authorization provided by the Compensation Committee of the Board of Directors on July 13, 2020.

    WEST PHARMACEUTICAL SERVICES, INC.





14


                        By:    /s/ Annette F. Favorite        
                            Annette F. Favorite            
                            Sr. Vice President & Chief Human Resources Officer
15

 EX-31.1 3 ex311q32020.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION

I, Eric M. Green, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: October 23, 2020

EX-31.2 4 ex312q32020.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION

I, Bernard J. Birkett, certify that:
1.I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: October 23, 2020

EX-32.1 5 ex321q32020.htm EX-32.1 Document

EXHIBIT 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Eric M. Green, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Eric M. Green
Eric M. Green
President and Chief Executive Officer

Date: October 23, 2020

 EX-32.2 6 ex322q32020.htm EX-32.2 Document

EXHIBIT 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report on Form 10-Q of West Pharmaceutical Services, Inc. (the “Company”) for the period ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bernard J. Birkett, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer

Date: October 23, 2020


 EX-101.SCH 7 wst-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - New Accounting Standards (Details) link:presentationLink link:calculationLink link:definitionLink 2106103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Revenue - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Revenue - Contracts and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Revenue - Supply Chain Financing (Details) link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Revenue - Voluntary Recall (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Net Income Per Share link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - Net Income Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2415408 - Disclosure - Net Income Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2317303 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2421410 - Disclosure - Leases - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Leases - Lease Weighted Average (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Affiliated Companies link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Affiliated Companies (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2328305 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Debt - Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - Debt - Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Derivative Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Derivative Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2135110 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2336307 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2438420 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2140111 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2341308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) link:presentationLink link:calculationLink link:definitionLink 2144112 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 2345309 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2447425 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2449426 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2150114 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2351310 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2452427 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2453428 - Disclosure - Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2154115 - Disclosure - Other Expense (Income) link:presentationLink link:calculationLink link:definitionLink 2355311 - Disclosure - Other Expense (Income) (Tables) link:presentationLink link:calculationLink link:definitionLink 2456429 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2457430 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2458431 - Disclosure - Other Expense (Income) - Development and Licensing Income (Details) link:presentationLink link:calculationLink link:definitionLink 2159116 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2460432 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2161117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2162118 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2363312 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2464433 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 wst-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 wst-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 wst-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Other nonoperating (income) expense Other Nonoperating Income (Expense) Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Pension settlement charge Pension Settlement Charge Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits. Treasury Stock Treasury Stock [Member] Segments [Axis] Segments [Axis] Benefit Plans Retirement Benefits [Text Block] Schedule of Components of Accumulated Other Comprehensive Loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Commodity call options Derivative Asset Change in deferred income - decrease (increase) Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Restructuring and related charges: Restructuring Cost and Reserve [Line Items] Purchase of investment in affiliated companies in cash Payments to Acquire Interest in Subsidiaries and Affiliates Deferred income taxes Deferred Income Tax Liabilities, Net Derivative Financial Instruments Derivative Instruments and Hedging Activities Disclosure [Text Block] Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Current Fiscal Year End Date Current Fiscal Year End Date Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Sales Projections Sales Projections [Member] Sales Projections Operating profit Total operating profit Operating Income (Loss) Debt issuance costs Payments of Debt Issuance Costs Entity Address, Postal Zip Code Entity Address, Postal Zip Code Total current liabilities Liabilities, Current Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Member] Severance and post-employment benefits Severance related costs Severance Costs Schedule of Change in Contract with Customer, Asset and Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Performance Share Unit (PSUs) Performance Shares [Member] Commitments and contingencies (Note 17) Commitments and Contingencies Shares purchased under share repurchase programs Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Investment, Name [Axis] Investment, Name [Axis] Accounting Policies [Abstract] Accounting Policies [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Activity related to stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Entity Shell Company Entity Shell Company Cover [Abstract] Operating cash flows from operating leases Operating Lease, Payments Accounts payable Accounts Payable, Current Document Type Document Type Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Retained earnings Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Series C notes, due July 5, 2027 (4.02%) Senior C Notes Due 2027 [Member] Senior C Notes Due 2027 [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Product Concentration Risk Product Concentration Risk [Member] Year one Lessee, Operating Lease, Liability, to be Paid, Year One Stock repurchase program, shares purchased (in shares) Share purchased under share repurchase program (in shares) Treasury Stock, Shares, Acquired Business combination, recognized property, plant, and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Year four Lessee, Operating Lease, Liability, to be Paid, Year Four Schedule of Assets and Liabilities Measured at Fair Value Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options Held Options Held [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Customer [Axis] Customer [Axis] Derivative instruments not designated as hedging instruments, gain (loss), net Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding Preferred Stock, Value, Issued Hedging Designation [Domain] Hedging Designation [Domain] Total lease cost Lease, Cost Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Quarterly Report Document Quarterly Report Non-cash restructuring charges Restructuring Reserve, Settled without Cash Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other long-term liabilities Other Liabilities, Noncurrent Deferred income taxes Deferred Income Tax Assets, Net Other, net Payments for (Proceeds from) Other Investing Activities Work in process Inventory, Work in Process, Net of Reserves Effect of exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2020 Restructuring Plan 2020 Restructuring Plan [Member] 2020 Restructuring Plan Other unallocated items Segment Reconciling Items [Member] Contract with customer liability recognized Contract With Customer, Liability, Recognition Period Contract With Customer, Liability, Recognition Period Inventories Total inventories Inventory, Net Net sales Revenue from Contract with Customer, Excluding Assessed Tax Commodity call options Commodity [Member] Probabilities of Successful Execution of Agreement Probabilities of Successful Execution of Agreement [Member] Probabilities of Successful Execution of Agreement Sales of certain accounts receivable Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount Percentage of net sales Concentration Risk, Percentage Entity File Number Entity File Number Geographical [Domain] Geographical [Domain] Settlements Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement SGD Singapore, Dollars Long Long [Member] Generics Generics Customers [Member] Generics Customers [Member] Borrowings under revolving credit agreements Proceeds from Long-term Lines of Credit Document Fiscal Period Focus Document Fiscal Period Focus Probabilities of Successful FDA Approval Probabilities of Successful FDA Approval [Member] Probabilities of Successful FDA Approval Measurement Input Type [Domain] Measurement Input Type [Domain] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Type of Restructuring [Domain] Type of Restructuring [Domain] Interest cost Defined Benefit Plan, Interest Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Other expense (income) Foreign Currency Gain (Loss) [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Repayments under revolving credit agreements Repayments of Long-term Lines of Credit Weighted Average Weighted Average [Member] Other items Other Operating Income (Expense), Net Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net Less: unamortized debt issuance costs Unamortized Debt Issuance Expense Debt Debt Disclosure [Text Block] Schedule of Reconciliation of Basic to Diluted Net Income Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total restructuring and related charges Total restructuring and related charges Restructuring and Related Cost, Incurred Cost Balance, beginning of period Balance, end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Corporate Corporate, Non-Segment [Member] Amendment Flag Amendment Flag Shares available for issuance under the 2016 Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Long-term line of credit Long-term Line of Credit Business combination, recognized inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory PSU payout, minimum PVS Payout Minimum Percent of an employee's targeted award to be paid out, Minimum. Amounts reclassified out from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Line of credit facility, current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Development and licensing income [Line Items] Development and licensing income [Line Items] [Line Items] for Development and licensing income [Table] Amount due and payable to affiliates Due to Affiliate (Losses) gains on derivatives Gains (losses) on derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Expected return on assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Geographical [Axis] Geographical [Axis] Local Phone Number Local Phone Number Segment [Domain] Segments [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Income Statement Location [Axis] Income Statement Location [Axis] Purchase of investment in affiliated companies Stock Issued During Period, Value, Acquisitions Income Statement Location [Domain] Income Statement Location [Domain] Year two Lessee, Operating Lease, Liability, to be Paid, Year Two Stock repurchase program, average price per share (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expense Derivative, notional amount Derivative, Notional Amount Amortization of intangible assets Amortization of Intangible Assets Foreign currency hedge contracts Foreign currency contracts Foreign Exchange Contract [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Schedule of Lease, Cost Lease, Cost [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Forward treasury locks Treasury Lock [Member] Year three Lessee, Operating Lease, Liability, to be Paid, Year Three Other noncurrent assets Other Assets, Noncurrent Affiliated Companies Equity Method Investments and Joint Ventures Disclosure [Text Block] Segment Information Segment Reporting Disclosure [Text Block] Derivative, forward point components, gain (loss), recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Total Assets Assets Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Prior service credit Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Stock options, weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Income taxes payable Accrued Income Taxes, Current Pension and other postretirement benefits Assets for Plan Benefits, Defined Benefit Plan Contingent consideration payments in excess of acquisition-date liability Payment for Contingent Consideration Liability, Operating Activities Entity Small Business Entity Small Business Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Cost of goods and services sold Cost of Sales [Member] Yen Japan, Yen Interest expense Interest expense Interest Expense Stock repurchase program, shares authorized (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Entity Filer Category Entity Filer Category Product and Service [Axis] Product and Service [Axis] Total Liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Cross Currency Interest Rate Contract Cross Currency Interest Rate Contract [Member] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Stock volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Less: imputed lease interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Standard Packaging Standard Packaging [Member] Standard Packaging [Member] Position [Domain] Position [Domain] Revenue recognized that was included in the deferred income balance Contract with Customer, Liability, Revenue Recognized Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Employee stock purchase plan contributions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Level 1 Fair Value, Inputs, Level 1 [Member] Cash flow hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Change in contract assets - increase (decrease) Contract With Customer, Asset, Increase (Decrease) Contract With Customer, Asset, Increase (Decrease) Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Raw materials Inventory, Raw Materials, Net of Reserves Changes in assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net Argentina currency devaluation Foreign Currency Transaction Loss, before Tax Restructuring and related activities, period of implementation Restructuring And Related Activities, Period Of Implementation Restructuring And Related Activities, Period Of Implementation Capital in Excess of Par Value Additional Paid-in Capital [Member] Fair Value Hedges Fair Value Hedging [Member] Operating Segments Operating Segments [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Stock purchase program, cost of shares purchased Shares purchased under share repurchase program Treasury Stock, Value, Acquired, Cost Method Balance (in shares) Balance (in shares) Shares, Issued Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Foreign currency contracts Foreign Currency Contract, Asset, Fair Value Disclosure Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Carrying amount, equity-method investments Equity Method Investments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Variable lease cost Variable Lease, Cost Research and development Research and Development Expense Derivative contract term Derivative, Term of Contract Fixed asset impairments Other Asset Impairment Charges Contract-Manufactured Products Contract Manufactured Products [Member] Contract Manufactured Products [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Concentration Risk Type [Axis] Concentration Risk Type [Axis] Dilutive effect of equity awards, based on the treasury stock method (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Contract-Manufactured Products Contract-Manufactured Customers [Member] Contract-Manufactured Customers [Member] Proceeds from stock-based compensation awards Proceeds from Stock Options Exercised Property, plant and equipment Property, Plant and Equipment, Gross Restructuring Plan [Domain] Restructuring Plan [Domain] Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Foreign currency contracts and swaps Foreign Currency Contracts, Liability, Fair Value Disclosure Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Development and licensing income [Table] Development and licensing income [Table] Development and licensing income [Table] Operating lease liabilities Operating Lease, Liability, Noncurrent Business combination, recognized intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Foreign currency-denominated debt Foreign Currency, Denominated Debt [Member] Foreign currency-denominated debt designated as a hedge of our net investments in foreign operations. Current assets: Assets, Current [Abstract] Amortization Amortization Derivative, nonmonetary notional amount, volume Derivative, Nonmonetary Notional Amount, Volume Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Commodity call options Commodity Option [Member] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Asia Pacific Asia Pacific [Member] Capital expenditures Payments to Acquire Property, Plant, and Equipment Consolidation Items [Domain] Consolidation Items [Domain] Entity Tax Identification Number Entity Tax Identification Number Other Financial Instruments [Abstract] Other Financial Instruments [Abstract] -- None. No documentation exists for this element. -- Contingent consideration Business Combination, Contingent Consideration, Liability Net Investment Hedges Net Investment Hedging [Member] Equity in net income of affiliated companies Income (Loss) from Equity Method Investments Gain (loss) on derivative instruments, net, pretax Gain (Loss) on Derivative Instruments, Net, Pretax Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Trading Symbol Trading Symbol Hedging Designation [Axis] Hedging Designation [Axis] PSU payout, maximum PVS Payout Maximum Percent of an employee's targeted award to be paid out, Maximum. Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Nature of Expense [Axis] Nature of Expense [Axis] Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Designated as Hedging Instrument Designated as Hedging Instrument [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Schedule of Other Expense (Income) Schedule Of Other Income And Expense, By Component [Table Text Block] Schedule of Other Income and Expense, by Component [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table] Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table] Derivative Instruments, Gain (Loss) [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] Total debt Long-term Debt Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Service cost Defined Benefit Plan, Service Cost Other Expense (Income) Other Income and Other Expense Disclosure [Text Block] City Area Code City Area Code Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of goods and services sold Cost of goods and services sold Cost of Goods and Services Sold Equity Components [Axis] Equity Components [Axis] Title of each class Title of 12(b) Security Finished goods Inventory, Finished Goods, Net of Reserves Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Minimum Minimum [Member] Operating lease liabilities Operating Lease, Liability, Current Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings Derivative Instruments, Gain (Loss) [Table Text Block] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) U.S. plans UNITED STATES Fair Value Measurements Fair Value Disclosures [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] Sales to affiliates Sales to Equity Method Investees Sales to Equity Method Investees Customer [Domain] Customer [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Derivative [Table] Derivative [Table] Assets: Assets, Fair Value Disclosure [Abstract] Term Loan, due December 31, 2024 (1.10%) Term Loan Due 2024 Term Loan Due 2024 [Member] Term Loan Due 2024 Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Asset-related charges Asset Impairment Charges Intersegment sales elimination Intersegment Eliminations [Member] Schedule of Segment Information Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Number of reportable segments Number of Reportable Segments Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Retirement Plan Type [Domain] Retirement Plan Type [Domain] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Dividend payments Payments of Ordinary Dividends, Common Stock Consolidation Items [Axis] Consolidation Items [Axis] Forward Contracts Forward Contracts [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Operating leases liabilities payments due Lessee, Operating Lease, Liability, to be Paid High-Value Components High-Value Components [Member] High-Value Components [Member] International plans Foreign Plan [Member] Balance, December 31, 2019 Balance, September 30, 2020 Restructuring Reserve Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Daikyo Seiko, Ltd. (Daikyo) Daikyo Seiko, Ltd. (Daikyo) [Member] Daikyo Seiko, Ltd. (Daikyo) [Member] Pharma Pharma Customers [Member] Pharma Customers [Member] Restructuring Type [Axis] Restructuring Type [Axis] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Cash payments Payments for Restructuring Goodwill Business combination, recognized goodwill Goodwill Other comprehensive income (loss), net of tax Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Level 2 Fair Value, Inputs, Level 2 [Member] Short Short [Member] Other current assets Other Assets, Current Liabilities: Liabilities, Fair Value Disclosure [Abstract] Total assets at fair value Assets, Fair Value Disclosure Equity: Equity [Abstract] Equity [Abstract] Europe, Middle East, Africa EMEA [Member] Entity Central Index Key Entity Central Index Key Accounting Standards Update 2016-13 Accounting Standards Update 2016-13 [Member] Deferred income, current Contract with Customer, Liability, Current Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset [Roll Forward] Contract With Customer, Asset Entity Emerging Growth Company Entity Emerging Growth Company Stock options, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Customer Concentration Risk Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] New Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Derivative Contract Type [Domain] Derivative Contract [Domain] Diluted (in shares) Weighted average shares assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Letter of Credit Letter of Credit [Member] Basic (in dollars per share) Earnings Per Share, Basic Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Fair value and net investment hedges, amount of gain (loss) recognized in OCI Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Debt Disclosure [Abstract] Debt Disclosure [Abstract] Pension and other postretirement benefits Liability, Defined Benefit Plan, Noncurrent Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Series A notes, due July 5, 2022 (3.67%) Senior A Notes Due 2022 [Member] Senior A Notes Due 2022 [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net sales Net Sales [Member] Net sales member New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Expense Change in equity affiliate investment AOCI AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Common stock, par value $0.25 per share; 200.0 million and 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 73.9 million and 74.1 million Common Stock, Value, Issued Less: current portion of long-term debt Long-term Debt, Current Maturities Deferred compensation assets Deferred Compensation Plan Assets Increase in fair value recorded in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Notes payable and other current debt Long-term debt, current Debt, Current Restructuring and related cost, expected cost Restructuring and Related Cost, Expected Cost Position [Axis] Position [Axis] Revolving credit facility, Due 2024 Revolving credit facility, due 2024 [Member] Revolving credit facility, due 2024 [Member] All Currencies [Domain] All Currencies [Domain] Cross-currency swap Currency Swap [Member] Cash paid for amounts included in the measurement of lease liabilities: Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract] Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Activity related to stock -based compensation (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Other expense (income) Other Income Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Foreign Exchange Forward Foreign Exchange Forward [Member] Provision for product returns Provision for Product Returns Provision for Product Returns Total lease liabilities Operating Lease, Liability Long-term debt Long-term debt, net Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Interest expense Interest Expense [Member] SmartDose SmartDose [Member] SmartDose [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] 2018 Restructuring Plan 2018 Restructuring Plan [Member] 2018 Restructuring Plan [Member] Total Equity Balance, beginning of period Balance, end of period Stockholders' Equity Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Business combination, consideration transferred Business Combination, Consideration Transferred Derivative (gain) loss recognized in income, fair value hedges Gain (Loss) on Fair Value Hedges Recognized in Earnings Total Liabilities and Equity Liabilities and Equity Accrued salaries, wages and benefits Other Employee-related Liabilities, Current Repayments of long-term debt Repayments of Other Long-term Debt Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Purchase of intangibles Payments to Acquire Intangible Assets Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Operating lease cost Operating Lease, Cost Year five Lessee, Operating Lease, Liability, to be Paid, Year Five Contract-Manufactured Products Delivery Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Hedging Relationship [Axis] Hedging Relationship [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Other charges Other Restructuring Costs Type of Adoption [Domain] Accounting Standards Update [Domain] Antidilutive options excluded from computation of diluted net income per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Other non-cash items, net Other Noncash Income (Expense) Short-term lease cost Short-term Lease, Cost Delivery Devices Delivery Devices [Member] Delivery Devices [Member] Equity Component [Domain] Equity Component [Domain] Reclassification out of Accumulated Other Comprehensive Loss [Line Items] Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Entity Address, Address Line One Entity Address, Address Line One Other expense (income) (Note 15) Total other expense (income) Other Income (Expense) The total amount of other income and expense items that are associated with the entity's normal revenue producing operation. Gross profit Gross Profit Property, plant and equipment, net Property, Plant and Equipment, Net Deferred compensation liabilities Deferred Compensation Liability, Classified, Noncurrent Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net income Net income Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Other current liabilities Other Liabilities, Current Remainder of fiscal year Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Investment, Name [Domain] Investment, Name [Domain] Inventories Inventory Disclosure [Text Block] Leases [Abstract] Leases [Abstract] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Net income per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Charges Restructuring and related charges Restructuring Charges Defined benefit pension and other postretirement plans Amortization of defined benefit pension and other postretirement plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Defined benefit pension and other postretirement plan adjustments, net of tax of $0.1, $0.7, $1.2, and $0.7, respectively Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Deferred income, noncurrent Contract with Customer, Liability, Noncurrent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Stock options, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Restructuring and related cost, cumulative cost incurred Restructuring and Related Cost, Cost Incurred to Date Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Common Stock Common Stock [Member] Foreign currency translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Product and Service [Domain] Product and Service [Domain] Net (loss) gain on derivatives, net of tax of $0.2, $1.5, $0.4 and $0.7, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Net gain (loss) on derivatives, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Schedule of Reclassification out of Accumulated Other Comprehensive Loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Geographic Concentration Risk Geographic Concentration Risk [Member] Accumulated Other Comprehensive Income (Loss) [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Line of credit Facility, unused commitment level Line of Credit Facility, Remaining Borrowing Capacity Revenue Benchmark Revenue Benchmark [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Debt instrument, stated interest rate Debt Instrument, Interest Rate, Stated Percentage Series B notes, due July 5, 2024 (3.82%) Senior B Notes Due 2024 [Member] Senior B Notes Due 2024 [Member] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Currency [Axis] Currency [Axis] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Derivative (gain) loss on hedged item, fair value hedges Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate USD United States of America, Dollars Investments in affiliated companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability [Roll Forward] Contract With Customer, Liability Treasury stock, at cost (in shares) Treasury Stock, Shares Cash Flow Hedges Cash Flow Hedging [Member] Severance and benefits Employee Severance [Member] Ownership interest percentage Equity Method Investment, Ownership Percentage Revenue Revenue from Contract with Customer [Text Block] Business combination, contingent consideration, measurement input Business Combination, Contingent Consideration, Measurement Input Business Combination, Contingent Consideration, Measurement Input Carrying amount, investments not accounted for under the equity method Equity Securities without Readily Determinable Fair Value, Amount Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Actuarial losses Recognized actuarial losses (gains) Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Capital in excess of par value Additional Paid in Capital Long-term debt, fair value Long-term Debt, Fair Value Foreign exchange transaction losses (gains) Foreign Currency Transaction Gain (Loss), before Tax Schedule of Foreign Currency Contracts Schedule of Derivative Instruments [Table Text Block] Income tax expense Tax benefit (expense) Tax benefit (expense) Income Tax Expense (Benefit) Derivative, average price risk option strike price Derivative, Average Price Risk Option Strike Price Cash, including cash equivalents at beginning of period Cash, including cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Total liabilities at fair value Financial and Nonfinancial Liabilities, Fair Value Disclosure Diluted (in dollars per share) Earnings Per Share, Diluted Acquisition of business Payments to Acquire Businesses, Gross Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Americas Americas [Member] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Long-term Debt Obligations, Net of Current Maturities Schedule of Debt [Table Text Block] Schedule of Changes in Level 3 Fair Value Measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Derivative [Line Items] Derivative [Line Items] Interim Period, Costs Not Allocable [Domain] Interim Period, Costs Not Allocable [Domain] Level 3 Fair Value Measurements [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Interest income Investment Income, Net Long-term debt, gross Long-term Debt, Gross Depreciation Depreciation Deferred income, December 31, 2019 Deferred income, September 30, 2020 Deferred income Deferred income Contract with Customer, Liability Award Type [Axis] Award Type [Axis] Amount receivable from affiliates Due from Affiliates Purchases and royalty payments made to affiliates Purchases and Royalty Payments from Equity Method Investees Purchases and Royalty Payments from Equity Method Investees Maximum Maximum [Member] Security Exchange Name Security Exchange Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Dividends declared Dividends, Common Stock, Cash Retained earnings Retained Earnings [Member] Proprietary Products Packaging Systems [Member] A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Pension and other postretirement benefits Liability, Defined Benefit Plan, Current Document Transition Report Document Transition Report Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Other retirement benefits Other Postretirement Benefits Plan [Member] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Development and licensing income Development and licensing income Development And Licensing Income The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer. Biologics Biologics Customers [Member] Biologics Customers [Member] Treasury stock, at cost (1.4 million and 1.2 million shares) Treasury Stock, Value Contract assets, December 31, 2019 Contract assets, September 30, 2020 Contract with Customer, Asset, after Allowance for Credit Loss Pension benefits Pension Plan [Member] Net Income Per Share Earnings Per Share [Text Block] Current liabilities: Liabilities, Current [Abstract] New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Statement of Financial Position [Abstract] EX-101.PRE 11 wst-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image011.jpg GRAPHIC begin 644 image011.jpg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end GRAPHIC 13 image11.jpg GRAPHIC begin 644 image11.jpg MB5!.1PT*&@H -24A$4@ #@ X" 8 "HACL> "7!(67, $SE M !,Y0%USO"5 64E$051XG.W/ 0T ( S L/LW#2H>,M(JV.9\;EX';#-8 M9[#.8)W!.H-U!NL,UAFL,UAGL,Y@G<$Z@W4&ZPS6&:PS6&>PSF"=P3J#=0;K @#-89K#-89[#.8-T%NHS1T5-^Z9T 245.1*Y"8((! end XML 14 wst-20200930_htm.xml IDEA: XBRL DOCUMENT 0000105770 2020-01-01 2020-09-30 0000105770 2020-10-19 0000105770 2020-07-01 2020-09-30 0000105770 2019-07-01 2019-09-30 0000105770 2019-01-01 2019-09-30 0000105770 2020-09-30 0000105770 2019-12-31 0000105770 2018-12-31 0000105770 2019-09-30 0000105770 2019-04-01 2019-04-30 0000105770 2019-04-30 0000105770 us-gaap:AccountingStandardsUpdate201613Member 2020-01-01 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:BiologicsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:GenericsCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:PharmaCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:ContractManufacturedCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:HighValueComponentsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:StandardPackagingMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:DeliveryDevicesMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 wst:ContractManufacturedProductsMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:EMEAMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 srt:AsiaPacificMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000105770 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000105770 srt:MinimumMember 2020-01-01 2020-09-30 0000105770 srt:MaximumMember 2020-01-01 2020-09-30 0000105770 wst:SmartDoseMember 2013-06-30 0000105770 wst:SmartDoseMember 2020-09-30 0000105770 2018-10-01 2018-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2018-12-31 0000105770 wst:DaikyoSeikoLtdDaikyoMember 2019-11-01 0000105770 2019-11-01 2019-11-01 0000105770 wst:TermLoanDue2024Member 2020-09-30 0000105770 wst:TermLoanDue2024Member 2019-12-31 0000105770 wst:SeniorNotesDue2022Member 2020-09-30 0000105770 wst:SeniorNotesDue2022Member 2019-12-31 0000105770 wst:SeniorBNotesDue2024Member 2020-09-30 0000105770 wst:SeniorBNotesDue2024Member 2019-12-31 0000105770 wst:SeniorCNotesDue2027Member 2020-09-30 0000105770 wst:SeniorCNotesDue2027Member 2019-12-31 0000105770 wst:Revolvingcreditfacilitydue2024Member 2020-09-30 0000105770 us-gaap:LetterOfCreditMember wst:Revolvingcreditfacilitydue2024Member 2020-09-30 0000105770 currency:SGD us-gaap:ForwardContractsMember 2019-12-31 0000105770 currency:SGD us-gaap:ForwardContractsMember 2020-09-30 0000105770 currency:USD us-gaap:ForwardContractsMember 2020-09-30 0000105770 currency:USD us-gaap:ForwardContractsMember 2019-12-31 0000105770 us-gaap:ForeignExchangeForwardMember 2020-01-01 2020-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000105770 currency:USD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000105770 currency:JPY us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:LongMember 2020-09-30 0000105770 currency:SGD us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ShortMember 2020-09-30 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember 2019-12-31 0000105770 currency:JPY us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 currency:USD us-gaap:CrossCurrencyInterestRateContractMember 2019-12-31 0000105770 us-gaap:OptionMember 2017-11-01 2020-09-30 0000105770 us-gaap:OptionMember 2020-01-01 2020-09-30 0000105770 us-gaap:OptionMember 2020-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-09-30 0000105770 us-gaap:FairValueHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:FairValueHedgingMember 2020-01-01 2020-09-30 0000105770 us-gaap:FairValueHedgingMember 2019-07-01 2019-09-30 0000105770 us-gaap:FairValueHedgingMember 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000105770 us-gaap:CashFlowHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-07-01 2019-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-07-01 2020-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-07-01 2019-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2020-07-01 2020-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:FairValueHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember wst:NetSalesMember 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000105770 us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000105770 us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 wst:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2020-01-01 2020-09-30 0000105770 us-gaap:NetInvestmentHedgingMember 2019-01-01 2019-09-30 0000105770 wst:NetSalesMember 2020-07-01 2020-09-30 0000105770 wst:NetSalesMember 2019-07-01 2019-09-30 0000105770 wst:NetSalesMember 2020-01-01 2020-09-30 0000105770 wst:NetSalesMember 2019-01-01 2019-09-30 0000105770 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000105770 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000105770 us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0000105770 us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000105770 us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0000105770 us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000105770 us-gaap:CommodityOptionMember us-gaap:NondesignatedMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000105770 us-gaap:NondesignatedMember 2020-07-01 2020-09-30 0000105770 us-gaap:NondesignatedMember 2019-07-01 2019-09-30 0000105770 us-gaap:NondesignatedMember 2020-01-01 2020-09-30 0000105770 us-gaap:NondesignatedMember 2019-01-01 2019-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2020-09-30 0000105770 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000105770 us-gaap:FairValueInputsLevel3Member 2020-09-30 0000105770 us-gaap:CommodityMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CommodityMember 2020-09-30 0000105770 us-gaap:CurrencySwapMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CurrencySwapMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CurrencySwapMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CurrencySwapMember 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2020-09-30 0000105770 us-gaap:FairValueInputsLevel1Member 2019-12-31 0000105770 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000105770 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000105770 us-gaap:CommodityMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CommodityMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CommodityMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CommodityMember 2019-12-31 0000105770 us-gaap:CurrencySwapMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:CurrencySwapMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:CurrencySwapMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:CurrencySwapMember 2019-12-31 0000105770 us-gaap:ForeignExchangeContractMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2019-12-31 0000105770 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2019-12-31 0000105770 srt:MinimumMember wst:SalesProjectionsMember 2020-09-30 0000105770 srt:MaximumMember wst:SalesProjectionsMember 2020-09-30 0000105770 srt:WeightedAverageMember wst:SalesProjectionsMember 2020-09-30 0000105770 srt:MinimumMember wst:ProbabilitiesOfSuccessfulFDAApprovalMember 2020-09-30 0000105770 srt:MaximumMember wst:ProbabilitiesOfSuccessfulFDAApprovalMember 2020-09-30 0000105770 srt:MinimumMember wst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember 2020-09-30 0000105770 srt:MaximumMember wst:ProbabilitiesOfSuccessfulExecutionOfAgreementMember 2020-09-30 0000105770 us-gaap:MeasurementInputDiscountRateMember 2020-09-30 0000105770 2019-01-01 2019-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000105770 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000105770 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0000105770 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000105770 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000105770 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000105770 us-gaap:CommonStockMember 2019-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000105770 us-gaap:TreasuryStockMember 2019-12-31 0000105770 us-gaap:RetainedEarningsMember 2019-12-31 0000105770 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0000105770 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000105770 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000105770 2020-01-01 2020-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000105770 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000105770 us-gaap:CommonStockMember 2020-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000105770 us-gaap:TreasuryStockMember 2020-03-31 0000105770 us-gaap:RetainedEarningsMember 2020-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000105770 2020-03-31 0000105770 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000105770 2020-04-01 2020-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000105770 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000105770 us-gaap:CommonStockMember 2020-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000105770 us-gaap:TreasuryStockMember 2020-06-30 0000105770 us-gaap:RetainedEarningsMember 2020-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000105770 2020-06-30 0000105770 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000105770 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000105770 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000105770 us-gaap:CommonStockMember 2020-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000105770 us-gaap:TreasuryStockMember 2020-09-30 0000105770 us-gaap:RetainedEarningsMember 2020-09-30 0000105770 us-gaap:CommonStockMember 2018-12-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000105770 us-gaap:TreasuryStockMember 2018-12-31 0000105770 us-gaap:RetainedEarningsMember 2018-12-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000105770 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000105770 2019-01-01 2019-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000105770 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000105770 us-gaap:CommonStockMember 2019-03-31 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000105770 us-gaap:TreasuryStockMember 2019-03-31 0000105770 us-gaap:RetainedEarningsMember 2019-03-31 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000105770 2019-03-31 0000105770 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000105770 2019-04-01 2019-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000105770 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000105770 us-gaap:CommonStockMember 2019-06-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000105770 us-gaap:TreasuryStockMember 2019-06-30 0000105770 us-gaap:RetainedEarningsMember 2019-06-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000105770 2019-06-30 0000105770 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000105770 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000105770 us-gaap:CommonStockMember 2019-09-30 0000105770 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000105770 us-gaap:TreasuryStockMember 2019-09-30 0000105770 us-gaap:RetainedEarningsMember 2019-09-30 0000105770 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000105770 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000105770 us-gaap:PerformanceSharesMember 2020-09-30 0000105770 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 country:US 2020-07-01 2020-09-30 0000105770 country:US 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember 2020-07-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember 2019-07-01 2019-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 country:US 2020-01-01 2020-09-30 0000105770 country:US 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000105770 us-gaap:ForeignPlanMember 2020-01-01 2020-09-30 0000105770 us-gaap:ForeignPlanMember 2019-01-01 2019-09-30 0000105770 wst:A2020RestructuringPlanMember 2020-07-01 2020-07-31 0000105770 srt:MinimumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 srt:MaximumMember wst:A2020RestructuringPlanMember 2020-07-31 0000105770 wst:A2020RestructuringPlanMember 2020-07-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2019-12-31 0000105770 wst:A2020RestructuringPlanMember 2019-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2019-01-01 2019-09-30 0000105770 wst:A2020RestructuringPlanMember 2019-01-01 2019-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2020RestructuringPlanMember 2020-09-30 0000105770 wst:A2020RestructuringPlanMember 2020-09-30 0000105770 wst:A2018RestructuringPlanMember 2018-02-01 2018-02-28 0000105770 wst:A2018RestructuringPlanMember 2018-02-28 0000105770 wst:A2018RestructuringPlanMember 2020-09-30 0000105770 wst:A2018RestructuringPlanMember 2019-07-01 2019-09-30 0000105770 wst:A2018RestructuringPlanMember 2019-01-01 2019-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2019-12-31 0000105770 wst:A2018RestructuringPlanMember 2019-12-31 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2020-01-01 2020-09-30 0000105770 wst:A2018RestructuringPlanMember 2020-01-01 2020-09-30 0000105770 us-gaap:EmployeeSeveranceMember wst:A2018RestructuringPlanMember 2020-09-30 0000105770 wst:SmartDoseMember 2020-07-01 2020-09-30 0000105770 wst:SmartDoseMember 2019-07-01 2019-09-30 0000105770 wst:SmartDoseMember 2020-01-01 2020-09-30 0000105770 wst:SmartDoseMember 2019-01-01 2019-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2020-07-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2019-07-01 2019-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2020-01-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:PackagingSystemsMember 2019-01-01 2019-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2020-07-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2019-07-01 2019-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2020-01-01 2020-09-30 0000105770 us-gaap:OperatingSegmentsMember wst:DeliverySystemsMember 2019-01-01 2019-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000105770 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000105770 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000105770 us-gaap:MaterialReconcilingItemsMember 2020-07-01 2020-09-30 0000105770 us-gaap:MaterialReconcilingItemsMember 2019-07-01 2019-09-30 0000105770 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-09-30 0000105770 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:SGD iso4217:EUR iso4217:JPY utr:bbl iso4217:USD wst:bbl wst:segment 0000105770 --12-31 2020 Q3 false 10-Q true 2020-09-30 false 1-8036 WEST PHARMACEUTICAL SERVICES, INC. PA 23-1210010 530 Herman O. West Drive Exton PA 19341-0645 610 594-2900 Common Stock, par value $0.25 per share WST NYSE Yes Yes Large Accelerated Filer false false false 73927188 548000000.0 456100000 1566700000 1369300000 353400000 308300000 1010000000.0 916800000 194600000 147800000 556700000 452500000 12500000 9300000 34000000.0 28700000 76200000 64800000 225700000 203700000 -6700000 -6400000 -6200000 -1600000 99200000 67300000 290800000 218500000 2100000 2100000 6100000 6400000 200000 1000000.0 1200000 2500000 400000 -1300000 300000 -200000 97700000 64900000 286200000 214400000 21100000 10900000 52100000 42500000 5700000 2300000 13700000 5900000 82300000 56300000 247800000 177800000 1.11 0.76 3.35 2.40 1.09 0.75 3.28 2.36 73900000 74000000.0 73900000 73900000 75800000 75500000 75600000 75300000 82300000 56300000 247800000 177800000 29400000 -23800000 -4900000 -20100000 -100000 -700000 -1200000 -700000 200000 -2400000 4000000.0 -2200000 200000 1500000 400000 700000 -900000 3200000 -1000000.0 1700000 28300000 -18200000 -9900000 -16200000 110600000 38100000 237900000 161600000 519400000 439100000 373000000.0 319300000 294900000 235700000 51000000.0 64600000 1238300000 1058700000 1939100000 1820100000 1055700000 980800000 883400000 839300000 67500000 70100000 209600000 192700000 109300000 107800000 30600000 29800000 22300000 14000000.0 0 4300000 21800000 24700000 2582800000 2341400000 2300000 2300000 180300000 156800000 2200000 2200000 96100000 73000000.0 30200000 6400000 9900000 9600000 126700000 91300000 447700000 341600000 253400000 255000000.0 4500000 15500000 51600000 52500000 59900000 62400000 46800000 41200000 863900000 768200000 3000000.0 3000000.0 0 0 0 0 0 0 0.25 0.25 200000000.0 100000000.0 75300000 75300000 73900000 74100000 18800000 18800000 268200000 272700000 1773400000 1549400000 -159500000 -149600000 1400000 1200000 182000000.0 118100000 1718900000 1573200000 2582800000 2341400000 247800000 177800000 77300000 74600000 3300000 2500000 27600000 18800000 0 1600000 3400000 2700000 700000 300000 9500000 600000 25400000 16300000 323800000 260800000 116700000 88800000 0 18900000 3800000 0 1400000 -300000 -121900000 -107400000 0 28000000.0 0 28000000.0 1700000 0 0 900000 35500000 33300000 19700000 25500000 4600000 4000000.0 115500000 83100000 -128400000 -87800000 6800000 -7000000.0 80300000 58600000 439100000 337400000 519400000 396000000.0 Basis of Presentation and Summary of Significant Accounting Policies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2020, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “</span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577020000015/wst-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">2019 Annual Report</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div>In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2020, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “</span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577020000015/wst-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">2019 Annual Report</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">”). The results of operations for any interim period are not necessarily indicative of results for the full year.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders.</span></div>In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date. 18900000 4500000 600000 2600000 11200000 New Accounting Standards<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Financial Accounting Standards Board (“FASB”) issued guidance which clarifies and improves areas related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The adoption did not have a material impact on our financial statements. Please refer to Note 10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Fair Value Measurements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under the previous guidance, an entity reflected credit losses on financial assets measured on an amortized cost basis only when it was probable that losses had incurred, generally considering only past events and current conditions when determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a modified retrospective basis, to the accounts receivable and contract asset balances as of January 1, 2020. Under the current expected credit loss model, we have adopted a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. The effect of the adoption on the financial statement line items of accounts receivable and contract assets was not material as of January 1, 2020. As a result of our adoption, we recorded a cumulative-effect adjustment of $0.1 million within retained earnings in our condensed consolidated balance sheet as of January 1, 2020, to reflect the incremental estimated lifetime expected credit losses on the accounts receivable balance as of January 1, 2020. We have not presented the amortized cost basis within each credit quality indicator by year of origination as all of our accounts receivable are due within one year or less.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluat</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ng</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the impact to our financial statements, the transition, and disclosure requirements of this guidance</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740 and by clarifying and amending existing ASC Topic 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recently Adopted Standards</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Financial Accounting Standards Board (“FASB”) issued guidance which clarifies and improves areas related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The adoption did not have a material impact on our financial statements. Please refer to Note 10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Fair Value Measurements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under the previous guidance, an entity reflected credit losses on financial assets measured on an amortized cost basis only when it was probable that losses had incurred, generally considering only past events and current conditions when determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a modified retrospective basis, to the accounts receivable and contract asset balances as of January 1, 2020. Under the current expected credit loss model, we have adopted a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. The effect of the adoption on the financial statement line items of accounts receivable and contract assets was not material as of January 1, 2020. As a result of our adoption, we recorded a cumulative-effect adjustment of $0.1 million within retained earnings in our condensed consolidated balance sheet as of January 1, 2020, to reflect the incremental estimated lifetime expected credit losses on the accounts receivable balance as of January 1, 2020. We have not presented the amortized cost basis within each credit quality indicator by year of origination as all of our accounts receivable are due within one year or less.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Standards Issued Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluat</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ng</span><span style="background-color:rgb(255,255,255, 0.0);color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> the impact to our financial statements, the transition, and disclosure requirements of this guidance</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740 and by clarifying and amending existing ASC Topic 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.</span></div> 100000 RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service. <div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by market group:</span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biologics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">32 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">26 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">29 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">20 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">20 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">30 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">31 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by product category: </span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">High-Value Components</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">47 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">43 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard Packaging</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">26 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">29 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delivery Devices</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Americas</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">48 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">48 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Europe, Middle East, Africa</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">43 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asia Pacific</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contract Assets and Liabilities</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:</span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.957%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contract assets, September 30, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in contract assets - increase (decrease)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred income, September 30, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in deferred income - decrease (increase)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has entered into new capacity reservation agreements, receiving cash up-front to be able to meet customer demand, which caused an increase in the Contract Liability account balance. The Company expects revenue related to the capacity reservation agreements to be recognized over the next 1 to 2 years. </span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2020, $23.0 million of revenue was recognized that was included in deferred income at the beginning of the year. </span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> technology platform within a specific therapeutic area. As of September 30, 2020, there was $5.0 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.1 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Supply Chain Financing</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of September 30, 2020 and 2019, we derecognized accounts receivable of $8.9 million and $7.9 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our condensed consolidated income statements for the nine months ended September 30, 2020 and 2019 were not material.</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Voluntary Recall</span></div><div style="margin-bottom:1pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On January 24, 2019, we issued a voluntary recall of our Vial2Bag</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold, reflecting our inventory balance for these devices at December 31, 2018. During three and nine months ended September 30, 2019, we recorded a provision of $0.9 million and $4.9 million, respectively, for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the product back on the market, and on October 21, 2020 we received market clearance from the Food and Drug Administration ("FDA") for our Vial2BagAdvanced</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">™ </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">20mm Admixture Device.</span></div> <div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by market group:</span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Biologics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">32 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">26 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">29 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Generics</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> 18 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">20 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">19 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">20 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharma</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">27 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">30 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">31 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by product category: </span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">High-Value Components</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">47 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">45 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">43 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Standard Packaging</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">25 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">28 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">26 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">29 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Delivery Devices</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">4 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">23 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">24 %</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div><div style="margin-bottom:1pt;"><span><br/></span></div><div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the approximate percentage of our net sales by geographic location: </span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Americas</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">48 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">49 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">48 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Europe, Middle East, Africa</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">42 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">43 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">44 %</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asia Pacific</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">9 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">8 %</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">100 %</span></div></td></tr></table></div> 0.32 0.26 0.29 0.25 0.18 0.20 0.19 0.20 0.27 0.30 0.28 0.31 0.23 0.24 0.24 0.24 1 1 1 1 0.47 0.42 0.45 0.43 0.25 0.28 0.26 0.29 0.05 0.06 0.05 0.04 0.23 0.24 0.24 0.24 1 1 1 1 0.49 0.48 0.49 0.48 0.42 0.44 0.43 0.44 0.09 0.08 0.08 0.08 1 1 1 1 <div style="margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:</span></div><div style="margin-bottom:1pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.957%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract assets, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Contract assets, September 30, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in contract assets - increase (decrease)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Deferred income, September 30, 2020</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in deferred income - decrease (increase)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(21.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 9800000 16200000 6400000 34900000 56700000 -21800000 P1Y P2Y 23000000.0 20000000.0 5000000.0 900000 4100000 8900000 7900000 11300000 900000 4900000 Net Income Per Share<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares assuming dilution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended September 30, 2020 and 2019, there were 0.0 million and 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.2 million and 0.3 million antidilutive shares outstanding during the nine months ended September 30, 2020 and 2019, respectively.</span></div>In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2020. During the nine months ended September 30, 2020, we purchased 761,500 shares of our common stock under the program at a cost of $115.5 million, or an average price of $151.65 per share. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">247.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">177.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dilutive effect of equity awards, based on the treasury stock method</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares assuming dilution</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 82300000 56300000 247800000 177800000 73900000 74000000.0 73900000 73900000 1900000 1500000 1700000 1400000 75800000 75500000 75600000 75300000 0.0 100000 200000 300000 848000 0 761500 115500000 151.65 Inventories<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.355%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.611%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.933%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:58.355%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.611%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.933%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">113.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">294.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">235.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 125400000 100900000 55800000 37400000 113700000 97400000 294900000 235700000 Leases<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.361%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.807%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to leases were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.002%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.807%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the weighted average remaining lease term for operating leases was 11.2 years and 11.7 years, respectively. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020 and December 31, 2019, the weighted average discount rate was 3.74% and 3.76%, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of operating lease liabilities were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining three months)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed lease interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of lease expense were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:37.361%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.807%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Short-term lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Variable lease cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Supplemental cash flow information related to leases were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:38.002%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.807%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating cash flows from operating leases</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div> 3100000 3400000 9300000 9700000 300000 100000 600000 500000 1200000 800000 2800000 2300000 4600000 4300000 12700000 12500000 3200000 3200000 9600000 9400000 300000 300000 4600000 8400000 P11Y2M12D P11Y8M12D 0.0374 0.0376 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Maturities of operating lease liabilities were as follows:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:70.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020 (remaining three months)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2024</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thereafter</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">84.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed lease interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 3400000 12100000 11800000 10400000 9700000 8600000 8700000 7800000 8200000 7300000 42600000 41800000 84400000 88000000.0 14600000 16000000.0 69800000 72000000.0 Affiliated Companies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At September 30, 2020 and December 31, 2019, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $194.2 million and $179.3 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $15.4 million and $13.4 million at September 30, 2020 and December 31, 2019, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo Seiko, Ltd. (“Daikyo”), we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our purchases from, and royalty payments made to, affiliates totaled $36.6 million and $97.0 million, respectively, for the three and nine months ended September 30, 2020, as compared to $33.0 million and $85.2 million, respectively, for the same period in 2019. As of September 30, 2020 and December 31, 2019, the payable balance due to affiliates was $28.5 million and $20.8 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales to affiliates were $2.7 million and $7.7 million, respectively, for the three and nine months ended September 30, 2020, as compared to $2.2 million and $6.9 million, respectively, for the same periods in 2019. As of September 30, 2020 and December 31, 2019, the receivable balance due from affiliates was $1.7 million and $1.9 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 7, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Affiliated Companies</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to the consolidated financial statements in our </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577020000015/wst-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">2019 Annual Report</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for additional details.</span></div> 194200000 179300000 15400000 13400000 0.25 0.49 85100000 4900000 36600000 97000000.0 33000000.0 85200000 28500000 20800000 2700000 7700000 2200000 6900000 1700000 1900000 Debt<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"><tr><td style="width:1.0%;"/><td style="width:69.982%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.957%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Term Loan, due December 31, 2024 (1.10%)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 8, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, to the consolidated financial statements in our </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577020000015/wst-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">2019 Annual Report</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for additional details regarding our debt agreements.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Agreement - Credit Facility </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At September 30, 2020, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.5 million, was $297.5 million. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Credit Agreement Amendment - Term Loan</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At September 30, 2020, we had $88.4 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $86.1 million was classified as long-term. Please refer to Note 9, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Derivative Financial Instruments</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for a discussion of the foreign currency hedge associated with the Term Loan.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2020.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.198%;"><tr><td style="width:1.0%;"/><td style="width:69.982%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.954%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.607%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.957%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Term Loan, due December 31, 2024 (1.10%)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series A notes, due July 5, 2022 (3.67%)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series B notes, due July 5, 2024 (3.82%)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Series C notes, due July 5, 2027 (4.02%) </span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: unamortized debt issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">257.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion of long-term debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term debt, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 0.0110 88400000 90000000.0 0.0367 42000000.0 42000000.0 0.0382 53000000.0 53000000.0 0.0402 73000000.0 73000000.0 256400000 258000000.0 700000 700000 255700000 257300000 2300000 2300000 253400000 255000000.0 300000000.0 2500000 297500000 88400000 2300000 86100000 Derivative Financial Instruments<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Foreign Exchange Rate Risk</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2020 and December 31, 2019, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2020, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.878%;"><tr><td style="width:1.0%;"/><td style="width:33.421%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.455%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.610%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.455%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.459%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sell</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Yen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,876.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SGD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commodity Price Risk</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From November 2017 through September 2020, we purchased several series of call options for a total of 439,732 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of September 30, 2020, we had outstanding contracts to purchase 137,035 barrels of crude oil from October 2020 to March 2022, at a weighted-average strike price of $60.47 per barrel.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Effects of Derivative Instruments on Financial Position and Results of Operations</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Fair Value Measurements</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for the balance sheet location and fair values of our derivative instruments as of September 30, 2020 and December 31, 2019.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.585%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.063%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Hedged item (intercompany loan)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Derivative designated as hedging instrument </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amount excluded from effectiveness testing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2020 and 2019 were $1.3 million, $5.0 million, and $2.2 million, $6.4 million, respectively.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%;"><tr><td style="width:1.0%;"/><td style="width:26.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.227%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Loss) Gain Recognized in OCI for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%;"><tr><td style="width:1.0%;"/><td style="width:26.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.227%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:40.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.444%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.913%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:21.175%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.473%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss Recognized in Income for the </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three and nine months ended September 30, 2020 and 2019, there was no material ineffectiveness related to our hedges.</span></div> 601500000 601500000 13400000 13400000 P18M As of September 30, 2020, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.878%;"><tr><td style="width:1.0%;"/><td style="width:33.421%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.455%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.610%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.455%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:20.459%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sell</span></td><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Currency</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Euro</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">USD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Yen</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,876.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">SGD</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr></table> 74700000 0 64800000 9876600000 55900000 32500000 57900000 33300000 7200000 90000000 9800000000 90000000 439732 137035 60.47 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.585%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.063%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss (Gain) Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Hedged item (intercompany loan)</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Derivative designated as hedging instrument </span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Amount excluded from effectiveness testing</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%;"><tr><td style="width:1.0%;"/><td style="width:26.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.227%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Loss) Gain Recognized in OCI for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income) </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.358%;"><tr><td style="width:1.0%;"/><td style="width:26.803%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.706%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.867%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:24.227%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Gain (Loss) Recognized in OCI for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location of (Gain) Loss Reclassified from Accumulated OCI into Income</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Hedges</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash Flow Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency hedge contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net Investment Hedges:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency-denominated debt</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.519%;"><tr><td style="width:1.0%;"/><td style="width:40.606%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.605%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.909%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.444%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.913%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:21.175%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.637%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:30.473%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss Recognized in Income for the</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount of Loss Recognized in Income for the </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> -9300000 8400000 -25100000 14100000 9300000 -8400000 25100000 -14100000 1900000 -4300000 5900000 5000000.0 1900000 -4300000 5900000 5000000.0 1300000 5000000.0 2200000 6400000 -100000 -600000 700000 -2900000 -100000 -600000 700000 -2900000 -500000 700000 -200000 300000 0 600000 -100000 200000 0 0 -100000 -100000 -500000 1300000 -400000 400000 0 700000 0 0 -3000000.0 0 0 0 -3000000.0 700000 0 0 2800000 3900000 3300000 3300000 2800000 3900000 3300000 3300000 0 1000000.0 300000 700000 -300000 1100000 100000 500000 0 0 -200000 -200000 -300000 2100000 200000 1000000.0 0 500000 0 0 -2000000.0 0 0 0 -2000000.0 500000 0 0 200000 -300000 -300000 -700000 100000 -200000 -100000 -500000 100000 100000 200000 200000 -700000 2900000 -3300000 -3300000 100000 100000 300000 300000 100000 100000 300000 300000 Fair Value Measurements<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:</span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;padding-left:14.5pt;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.726%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.845%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.726%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.845%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 9, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_58" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Derivative Financial Instruments</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for further discussion of our derivatives.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Level 3 Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The fair value of the contingent consideration liability related to the SmartDose technology platform (the “SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of changes in our Level 3 fair value measurements:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.957%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Financial Instruments</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2020, the estimated fair value of long-term debt was $266.4 million compared to a carrying amount of $253.4 million. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million and the carrying amount was $255.0 million.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following tables present the assets and liabilities recorded at fair value on a recurring basis:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.726%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.845%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:40.726%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.845%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basis of Fair Value Measurements</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 3</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Assets:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commodity call options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Liabilities:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cross-currency swap</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 11200000 11200000 0 0 1100000 0 1100000 0 100000 0 100000 0 12400000 11200000 1200000 0 3500000 0 0 3500000 12800000 12800000 0 0 4000000.0 0 4000000.0 0 13700000 0 13700000 0 34000000.0 12800000 17700000 3500000 11300000 11300000 0 0 7700000 0 7700000 0 100000 0 100000 0 19100000 11300000 7800000 0 3300000 0 0 3300000 12800000 12800000 0 0 1400000 0 0 1400000 0 300000 0 300000 0 17800000 12800000 1700000 3300000 0.10 0.50 0.40 0.19 1 0.25 1 0.19 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a summary of changes in our Level 3 fair value measurements:</span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:84.957%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.843%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Increase in fair value recorded in earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 1700000 -2100000 500000 3300000 -900000 700000 3500000 266400000 253400000 263300000 255000000.0 Accumulated Other Comprehensive Loss <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.746%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.598%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.726%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.291%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.957%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.878%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(159.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.598%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.912%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.269%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Detail of components</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Benefit Plans</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:27.746%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.598%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.726%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.291%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.957%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:7.878%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Losses) gains on<br/>derivatives</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in equity affiliate investment AOCI</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Defined benefit<br/>pension and other <br/>postretirement plans</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign <br/>currency <br/>translation</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(108.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amounts reclassified out from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:4.5pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(44.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(113.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(159.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> -800000 400000 -40300000 -108900000 -149600000 2500000 0 -6200000 -4900000 -8600000 3500000 0 -2200000 0 1300000 -1000000.0 0 -4000000.0 -4900000 -9900000 -1800000 400000 -44300000 -113800000 -159500000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:35.598%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.441%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.592%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.912%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.269%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Location on Statement of Income</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Detail of components</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gains (losses) on derivatives:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods and services sold</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency contracts</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other expense (income)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forward treasury locks</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of defined benefit pension and other postretirement plans:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prior service credit</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(a)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total before tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net of tax</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total reclassifications for the period, net of tax</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_73" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Benefit Plans</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional details.</span></div> -300000 300000 300000 800000 100000 -300000 -300000 -800000 1100000 -4300000 5100000 5000000.0 100000 100000 300000 300000 600000 -3800000 5400000 6300000 300000 -1300000 1900000 2000000.0 300000 -2500000 3500000 4300000 -100000 -100000 -400000 -400000 -200000 -200000 0 -200000 -1100000 -2700000 -3400000 -2700000 -800000 -2400000 -3000000.0 -2100000 -300000 -600000 -800000 -500000 -500000 -1800000 -2200000 -1600000 -200000 -4300000 1300000 2700000 Shareholders<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">’</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Equity</span><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.696%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.728%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.844%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.886%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.423%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.728%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.844%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.474%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.431%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Shares Issued</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in Excess of Par Value</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Treasury Shares</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,549.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,573.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of modified retrospective application of a new accounting standard (see Note 2)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares purchased under share repurchase program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(115.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(115.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(215.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,611.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">263.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(190.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,703.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(187.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,606.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(182.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,773.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(159.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,718.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.421%;"><tr><td style="width:1.0%;"/><td style="width:32.310%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.768%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.884%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.932%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.768%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.884%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.541%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.473%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Shares Issued</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in Excess of Par Value</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Treasury Shares</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,353.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,396.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares purchased under share repurchase program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.15 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">278.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(172.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(153.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.15 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(147.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,452.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(152.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,445.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,497.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(170.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,487.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:32.696%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.728%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.844%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.886%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.423%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.728%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.844%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.474%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.378%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.431%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Shares Issued</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in Excess of Par Value</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Treasury Shares</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">272.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(118.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,549.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(149.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,573.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of modified retrospective application of a new accounting standard (see Note 2)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares purchased under share repurchase program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(115.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(115.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(215.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,611.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(192.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,490.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">91.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">263.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(190.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,703.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(187.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,606.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(182.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,773.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(159.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,718.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.421%;"><tr><td style="width:1.0%;"/><td style="width:32.310%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.768%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.884%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.932%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.466%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.768%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:5.884%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.541%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.382%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:6.473%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Shares Issued</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital in Excess of Par Value</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Treasury Shares</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Treasury Stock</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss</span></td><td colspan="3" style="height:18pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;height:18pt;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">282.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(103.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,353.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(154.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,396.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares purchased under share repurchase program</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(83.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.15 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">278.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(172.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,398.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(153.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.15 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, June 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">273.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(147.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,452.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(152.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,445.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Activity related to stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Dividends declared ($0.16 per share)</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss, net of tax</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(18.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">268.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(126.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,497.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(170.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,487.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 75300000 18800000 272700000 1200000 -118100000 1549400000 -149600000 1573200000 -100000 -100000 74300000 74300000 -5100000 -300000 17900000 12800000 800000 115500000 115500000 0.16 11800000 11800000 -42700000 -42700000 75300000 18800000 267600000 1700000 -215700000 1611800000 -192300000 1490200000 91200000 91200000 -4500000 -200000 24900000 20400000 4500000 4500000 75300000 18800000 263100000 1500000 -190800000 1703000000.0 -187800000 1606300000 82300000 82300000 0 0 5100000 -100000 8800000 13900000 0.16 11900000 11900000 28300000 28300000 75300000 18800000 268200000 1400000 -182000000.0 1773400000 -159500000 1718900000 75300000 18800000 282000000.0 1200000 -103700000 1353400000 -154200000 1396300000 55400000 55400000 -3500000 -200000 14200000 10700000 -800000 83100000 83100000 0.15 10600000 10600000 800000 800000 75300000 18800000 278500000 1800000 -172600000 1398200000 -153400000 1369500000 66100000 66100000 -5100000 -200000 24800000 19700000 0.15 11400000 11400000 1200000 1200000 75300000 18800000 273400000 1600000 -147800000 1452900000 -152200000 1445100000 56300000 56300000 -4900000 -300000 21200000 16300000 0.16 11900000 11900000 -18200000 -18200000 75300000 18800000 268500000 1300000 -126600000 1497300000 -170400000 1487600000 Stock-Based Compensation<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2020, there were 2,756,301 shares remaining in the 2016 Plan for future grants.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2020, we granted 230,580 stock options at a weighted average exercise price of $175.22 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $39.58 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.3%; expected life of 5.7 years based on prior experience; stock volatility of 22.3% based on historical data; and a dividend yield of 0.4%. Stock option expense is recognized over the vesting period, net of forfeitures.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2020, we granted 52,187 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $175.18 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2020, we granted 8,072 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $194.21 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. </span></div>Stock-based compensation expense was $10.0 million and $27.6 million for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, stock-based compensation expense was $5.4 million and $18.8 million, respectively. 2756301 230580 175.22 39.58 0.013 P5Y8M12D 0.223 0.004 52187 175.18 0 2 8072 194.21 10000000.0 27600000 5400000 18800000 Benefit Plans<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognized actuarial losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognized actuarial losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three and nine months ended September 30, 2020, we recorded a $1.1 million and $3.4 million pension settlement charge, respectively, within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified and non-qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.</span></div> <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost for the three months ended September 30 were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognized actuarial losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of net periodic benefit cost for the nine months ended September 30 were as follows:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest cost</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected return on assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of prior service credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognized actuarial losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Settlements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.839%;"><tr><td style="width:1.0%;"/><td style="width:32.286%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.975%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.012%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.602%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.018%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pension benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other retirement benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. plans</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International plans</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net periodic benefit cost</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 400000 400000 0 0 400000 400000 1700000 1900000 0 100000 1700000 2000000.0 2800000 3100000 0 0 2800000 3100000 100000 100000 -200000 -200000 -100000 -100000 -400000 -500000 600000 700000 200000 200000 -1100000 -2700000 0 0 -1100000 -2700000 900000 2500000 -800000 -800000 100000 1700000 500000 2000000.0 -800000 -800000 -300000 1200000 400000 500000 0 0 400000 500000 900000 2500000 -800000 -800000 100000 1700000 1000000.0 1100000 0 0 1000000.0 1100000 5500000 6800000 100000 200000 5600000 7000000.0 8800000 8900000 0 0 8800000 8900000 100000 100000 -500000 -500000 -400000 -400000 -1400000 -1600000 1400000 1800000 0 200000 -3400000 -2700000 0 0 -3400000 -2700000 2600000 3400000 -1800000 -2100000 800000 1300000 1500000 1900000 -1800000 -2100000 -300000 -200000 1100000 1500000 0 0 1100000 1500000 2600000 3400000 -1800000 -2100000 800000 1300000 -1100000 -3400000 Other Expense (Income) <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other expense (income) consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and related charges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and post-employment benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total restructuring and related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Argentina currency devaluation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed asset impairments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development and licensing income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other expense (income)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Restructuring and Related Charges</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $15 million to $17 million. Since its approval, we recorded a net pre-tax amount equal to $4.5 million in restructuring related charges associated with this plan. All charges recorded to date are severance related and recorded w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">ithin other expense (income) in the condensed consolidated statements of income. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.938%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.720%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.241%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance<br/>and benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan was considered complete as of December 31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended September 30, 2019, we recorded $1.8 million in restructuring and related charges associated with this plan, consisting of $0.6 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.1 million for other non-cash charges. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the nine months ended September 30, 2019, we recorded $3.8 million in restructuring and related charges associated with this plan, consisting of $2.2 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.5 million for other non-cash charges. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.457%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.720%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.722%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance<br/>and benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. Our remaining restructuring obligations related to the 2016 restructuring plan are complete.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Other Items</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During both the three and nine months ended September 30, 2020 and 2019, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_40" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Revenue</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for additional information.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 10, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_61" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Fair Value Measurements</a></span>, for additional details. <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other expense (income) consists of:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restructuring and related charges:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance and post-employment benefits</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total restructuring and related charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Argentina currency devaluation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed asset impairments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Development and licensing income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign exchange transaction losses (gains)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other expense (income)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 4500000 600000 4500000 2200000 0 100000 0 100000 0 1100000 0 1500000 4500000 1800000 4500000 3800000 0 1000000.0 0 1000000.0 900000 800000 7200000 2300000 200000 200000 600000 600000 800000 100000 900000 400000 -1000000.0 -5100000 4500000 3500000 300000 2200000 1300000 1800000 -6700000 -6400000 -6200000 -1600000 P24M 15000000 17000000 4500000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.938%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.720%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:11.241%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance<br/>and benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Charges</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"/></tr></table><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:72.457%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.720%;"/><td style="width:0.1%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.722%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severance<br/>and benefits</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, September 30, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 0 0 4500000 4500000 0 0 4500000 4500000 P24M 16000000 13700000 1800000 600000 100000 1100000 3800000 2200000 100000 1500000 1400000 1400000 1200000 1200000 200000 200000 200000 200000 600000 600000 20000000.0 Income TaxesThe tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.The provision for income taxes was $21.1 million and $10.9 million for the three months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 21.6% and 16.8%, respectively. The provision for income taxes was $52.1 million and $42.5 million for the nine months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 18.2% and 19.8%, respectively. 21100000 10900000 0.216 0.168 52100000 42500000 0.182 0.198 Commitments and Contingencies<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no significant changes to the commitments and contingencies included in our </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/105770/000010577020000015/wst-20191231.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">2019 Annual Report</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div> Segment Information<div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab and other services, to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Chief Operating Decision Maker (“CODM”) evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">345.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,194.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,045.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">372.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">323.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intersegment sales elimination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">456.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,566.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit (loss):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other unallocated items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating (income) expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other unallocated items during the three months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges and $0.2 million of amortization expense associated with an acquisition of an intangible asset. Other unallocated items during the nine months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges, $2.2 million in severance related costs, and $0.4 million of amortization expense associated with an acquisition of an intangible asset. </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other unallocated items during the three and nine months ended September 30, 2019 consisted of $1.8 million and $3.8 million, respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2019, other unallocated items included a charge of $1.0 million as a result of the continued devaluation of Argentina's currency. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to Note 15, </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a href="#i459829f687b0401f8a6d4e6e9c602914_76" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">Other Expense (Income)</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, for further discussion of certain unallocated items referenced above.</span></div> 2 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents information about our reportable segments, reconciled to consolidated totals:</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:43.932%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.842%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.239%;"/><td style="width:0.1%;"/><td style="width:0.1%;"/><td style="width:0.601%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.242%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">($ in millions)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net sales:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">421.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">345.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,194.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,045.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">111.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">372.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">323.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intersegment sales elimination</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated net sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">548.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">456.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,566.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,369.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating profit (loss):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proprietary Products</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">312.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">238.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract-Manufactured Products</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(67.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(48.9)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other unallocated items</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating profit</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">290.8 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.1 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other nonoperating (income) expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income before income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">97.7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64.9 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">214.4 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"/></tr></table></div> 421500000 345200000 1194500000 1045900000 126600000 111100000 372500000 323600000 -100000 -200000 -300000 -200000 548000000.0 456100000 1566700000 1369300000 107500000 72900000 312900000 238700000 18800000 11600000 52100000 33500000 -22400000 -14400000 -67100000 -48900000 -4700000 -2800000 -7100000 -4800000 99200000 67300000 290800000 218500000 2100000 2100000 6100000 6400000 200000 1000000.0 1200000 2500000 400000 -1300000 300000 -200000 97700000 64900000 286200000 214400000 4500000 200000 4500000 2200000 400000 1800000 3800000 1000000.0 1000000.0 XML 15 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2020
Oct. 19, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 1-8036  
Entity Registrant Name WEST PHARMACEUTICAL SERVICES, INC.  
Entity Incorporation, State or Country Code PA  
Entity Tax Identification Number 23-1210010  
Entity Address, Address Line One 530 Herman O. West Drive  
Entity Address, City or Town Exton  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19341-0645  
City Area Code 610  
Local Phone Number 594-2900  
Title of each class Common Stock, par value $0.25 per share  
Trading Symbol WST  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   73,927,188
Entity Central Index Key 0000105770  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Net sales $ 548.0 $ 456.1 $ 1,566.7 $ 1,369.3
Cost of goods and services sold 353.4 308.3 1,010.0 916.8
Gross profit 194.6 147.8 556.7 452.5
Research and development 12.5 9.3 34.0 28.7
Selling, general and administrative expenses 76.2 64.8 225.7 203.7
Other expense (income) (Note 15) 6.7 6.4 6.2 1.6
Operating profit 99.2 67.3 290.8 218.5
Interest expense 2.1 2.1 6.1 6.4
Interest income (0.2) (1.0) (1.2) (2.5)
Other nonoperating (income) expense (0.4) 1.3 (0.3) 0.2
Income before income taxes 97.7 64.9 286.2 214.4
Income tax expense 21.1 10.9 52.1 42.5
Equity in net income of affiliated companies (5.7) (2.3) (13.7) (5.9)
Net income $ 82.3 $ 56.3 $ 247.8 $ 177.8
Net income per share:        
Basic (in dollars per share) $ 1.11 $ 0.76 $ 3.35 $ 2.40
Diluted (in dollars per share) $ 1.09 $ 0.75 $ 3.28 $ 2.36
Weighted average shares outstanding:        
Basic (in shares) 73.9 74.0 73.9 73.9
Diluted (in shares) 75.8 75.5 75.6 75.3
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net income $ 82.3 $ 56.3 $ 247.8 $ 177.8
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustments 29.4 (23.8) (4.9) (20.1)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.1, $0.7, $1.2, and $0.7, respectively (0.2) 2.4 (4.0) 2.2
Net (loss) gain on derivatives, net of tax of $0.2, $1.5, $0.4 and $0.7, respectively (0.9) 3.2 (1.0) 1.7
Other comprehensive income (loss), net of tax 28.3 (18.2) (9.9) (16.2)
Comprehensive income $ 110.6 $ 38.1 $ 237.9 $ 161.6
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent $ 0.1 $ 0.7 $ 1.2 $ 0.7
Net gain (loss) on derivatives, tax $ 0.2 $ 1.5 $ 0.4 $ 0.7
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 519.4 $ 439.1
Accounts receivable, net 373.0 319.3
Inventories 294.9 235.7
Other current assets 51.0 64.6
Total current assets 1,238.3 1,058.7
Property, plant and equipment 1,939.1 1,820.1
Less: accumulated depreciation and amortization 1,055.7 980.8
Property, plant and equipment, net 883.4 839.3
Operating lease right-of-use assets 67.5 70.1
Investments in affiliated companies 209.6 192.7
Goodwill 109.3 107.8
Intangible assets, net 30.6 29.8
Deferred income taxes 22.3 14.0
Pension and other postretirement benefits 0.0 4.3
Other noncurrent assets 21.8 24.7
Total Assets 2,582.8 2,341.4
Current liabilities:    
Notes payable and other current debt 2.3 2.3
Accounts payable 180.3 156.8
Pension and other postretirement benefits 2.2 2.2
Accrued salaries, wages and benefits 96.1 73.0
Income taxes payable 30.2 6.4
Operating lease liabilities 9.9 9.6
Other current liabilities 126.7 91.3
Total current liabilities 447.7 341.6
Long-term debt 253.4 255.0
Deferred income taxes 4.5 15.5
Pension and other postretirement benefits 51.6 52.5
Operating lease liabilities 59.9 62.4
Other long-term liabilities 46.8 41.2
Total Liabilities 863.9 768.2
Commitments and contingencies (Note 17)
Equity:    
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding 0.0 0.0
Common stock, par value $0.25 per share; 200.0 million and 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 73.9 million and 74.1 million 18.8 18.8
Capital in excess of par value 268.2 272.7
Retained earnings 1,773.4 1,549.4
Accumulated other comprehensive loss (159.5) (149.6)
Treasury stock, at cost (1.4 million and 1.2 million shares) (182.0) (118.1)
Total Equity 1,718.9 1,573.2
Total Liabilities and Equity $ 2,582.8 $ 2,341.4
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, shares authorized (in shares) 3,000,000.0 3,000,000.0
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.25 $ 0.25
Common stock, shares authorized (in shares) 200,000,000.0 100,000,000.0
Common stock, shares issued (in shares) 75,300,000 75,300,000
Common stock, shares outstanding (in shares) 73,900,000 74,100,000
Treasury stock, at cost (in shares) 1,400,000 1,200,000
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net income $ 247.8 $ 177.8
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation 77.3 74.6
Amortization 3.3 2.5
Stock-based compensation 27.6 18.8
Non-cash restructuring charges 0.0 1.6
Pension settlement charge 3.4 2.7
Contingent consideration payments in excess of acquisition-date liability (0.7) (0.3)
Other non-cash items, net (9.5) (0.6)
Changes in assets and liabilities (25.4) (16.3)
Net cash provided by operating activities 323.8 260.8
Cash flows from investing activities:    
Capital expenditures (116.7) (88.8)
Acquisition of business 0.0 (18.9)
Purchase of intangibles (3.8) 0.0
Other, net (1.4) 0.3
Net cash used in investing activities (121.9) (107.4)
Cash flows from financing activities:    
Borrowings under revolving credit agreements 0.0 28.0
Repayments under revolving credit agreements 0.0 (28.0)
Repayments of long-term debt (1.7) 0.0
Debt issuance costs 0.0 (0.9)
Dividend payments (35.5) (33.3)
Proceeds from stock-based compensation awards 19.7 25.5
Employee stock purchase plan contributions 4.6 4.0
Shares purchased under share repurchase programs (115.5) (83.1)
Net cash used in financing activities (128.4) (87.8)
Effect of exchange rates on cash 6.8 (7.0)
Net increase (decrease) in cash and cash equivalents 80.3 58.6
Cash, including cash equivalents at beginning of period 439.1 337.4
Cash, including cash equivalents at end of period $ 519.4 $ 396.0
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2020, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders.
In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.20.2
New Accounting Standards
 9 Months Ended
Sep. 30, 2020
Accounting Standards Update and Change in Accounting Principle [Abstract]  
New Accounting Standards New Accounting Standards
Recently Adopted Standards

In April 2019, the Financial Accounting Standards Board (“FASB”) issued guidance which clarifies and improves areas related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020.
The adoption did not have a material impact on our financial statements. Please refer to Note 10, Fair Value Measurements, for additional details.

In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under the previous guidance, an entity reflected credit losses on financial assets measured on an amortized cost basis only when it was probable that losses had incurred, generally considering only past events and current conditions when determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a modified retrospective basis, to the accounts receivable and contract asset balances as of January 1, 2020. Under the current expected credit loss model, we have adopted a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. The effect of the adoption on the financial statement line items of accounts receivable and contract assets was not material as of January 1, 2020. As a result of our adoption, we recorded a cumulative-effect adjustment of $0.1 million within retained earnings in our condensed consolidated balance sheet as of January 1, 2020, to reflect the incremental estimated lifetime expected credit losses on the accounts receivable balance as of January 1, 2020. We have not presented the amortized cost basis within each credit quality indicator by year of origination as all of our accounts receivable are due within one year or less.

Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance.

In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740 and by clarifying and amending existing ASC Topic 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue RevenueOur revenue results from the sale of goods or services and reflects the consideration to which we expect to be entitled in exchange for those goods or services. We record revenue based on a five-step model, in accordance with ASC Topic 606. Following the identification of a contract with a customer, we identify the performance obligations (goods or services) in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize the revenue when (or as) we satisfy the performance obligations by transferring the promised goods or services to our customers. A good or service is transferred when (or as) the customer obtains control of that good or service.
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Biologics
32 %
26 %
29 %
25 %
Generics
 18 %
20 %
19 %
20 %
Pharma
27 %
30 %
28 %
31 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
High-Value Components
47 %
42 %
45 %
43 %
Standard Packaging
25 %
28 %
26 %
29 %
Delivery Devices
5 %
6 %
5 %
4 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Americas
49 %
48 %
49 %
48 %
Europe, Middle East, Africa
42 %
44 %
43 %
44 %
Asia Pacific
9 %
8 %
8 %
8 %
100 %
100 %
100 %
100 %

Contract Assets and Liabilities

The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2019$9.8 
Contract assets, September 30, 2020
16.2 
Change in contract assets - increase (decrease)$6.4 
Deferred income, December 31, 2019$(34.9)
Deferred income, September 30, 2020
(56.7)
Change in deferred income - decrease (increase)$(21.8)

The Company has entered into new capacity reservation agreements, receiving cash up-front to be able to meet customer demand, which caused an increase in the Contract Liability account balance. The Company expects revenue related to the capacity reservation agreements to be recognized over the next 1 to 2 years.
During the nine months ended September 30, 2020, $23.0 million of revenue was recognized that was included in deferred income at the beginning of the year.

The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose® technology platform within a specific therapeutic area. As of September 30, 2020, there was $5.0 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $4.1 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer.

Supply Chain Financing

We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of September 30, 2020 and 2019, we derecognized accounts receivable of $8.9 million and $7.9 million, respectively, under these agreements. Discount fees related to the sale of such accounts receivable on our condensed consolidated income statements for the nine months ended September 30, 2020 and 2019 were not material.

Voluntary Recall

On January 24, 2019, we issued a voluntary recall of our Vial2Bag® product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold, reflecting our inventory balance for these devices at December 31, 2018. During three and nine months ended September 30, 2019, we recorded a provision of $0.9 million and $4.9 million, respectively, for inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the product back on the market, and on October 21, 2020 we received market clearance from the Food and Drug Administration ("FDA") for our Vial2BagAdvanced™ 20mm Admixture Device.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Net Income Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Net Income Per Share Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2020201920202019
Net income$82.3 $56.3 $247.8 $177.8 
Weighted average common shares outstanding73.9 74.0 73.9 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.5 1.7 1.4 
Weighted average shares assuming dilution75.8 75.5 75.6 75.3 

During the three months ended September 30, 2020 and 2019, there were 0.0 million and 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.2 million and 0.3 million antidilutive shares outstanding during the nine months ended September 30, 2020 and 2019, respectively.
In December 2019, we announced a share repurchase program for calendar-year 2020 authorizing the repurchase of up to 848,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2020. During the nine months ended September 30, 2020, we purchased 761,500 shares of our common stock under the program at a cost of $115.5 million, or an average price of $151.65 per share.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:

($ in millions)September 30,
2020		December 31,
2019
Raw materials$125.4 $100.9 
Work in process55.8 37.4 
Finished goods113.7 97.4 
 $294.9 $235.7 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Leases
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Leases Leases
A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise.

The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Operating lease cost$3.1 $3.4 $9.3 $9.7 
Short-term lease cost0.3 0.1 0.6 0.5 
Variable lease cost1.2 0.8 2.8 2.3 
Total lease cost$4.6 $4.3 $12.7 $12.5 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.2 $3.2 $9.6 $9.4 
Right-of-use assets obtained in exchange for new operating lease liabilities$0.3 $0.3 $4.6 $8.4 
As of September 30, 2020 and December 31, 2019, the weighted average remaining lease term for operating leases was 11.2 years and 11.7 years, respectively.

As of September 30, 2020 and December 31, 2019, the weighted average discount rate was 3.74% and 3.76%, respectively.

Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20202019
2020 (remaining three months)$3.4 $12.1 
202111.8 10.4 
20229.7 8.6 
20238.7 7.8 
20248.2 7.3 
Thereafter42.6 41.8 
84.4 88.0 
Less: imputed lease interest(14.6)(16.0)
Total lease liabilities$69.8 $72.0 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Affiliated Companies
 9 Months Ended
Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]  
Affiliated Companies Affiliated Companies
At September 30, 2020 and December 31, 2019, the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $194.2 million and $179.3 million, respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $15.4 million and $13.4 million at September 30, 2020 and December 31, 2019, respectively. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable.

On November 1, 2019, in connection with the amendment of certain commercial agreements with Daikyo Seiko, Ltd. (“Daikyo”), we increased our ownership interest from 25% to 49% in Daikyo in exchange for $85.1 million in cash and $4.9 million in shares of our treasury stock to certain stockholders of Daikyo. We believe that the increase in ownership interest will not have a material impact on our financial statements.

Our purchases from, and royalty payments made to, affiliates totaled $36.6 million and $97.0 million, respectively, for the three and nine months ended September 30, 2020, as compared to $33.0 million and $85.2 million, respectively, for the same period in 2019. As of September 30, 2020 and December 31, 2019, the payable balance due to affiliates was $28.5 million and $20.8 million, respectively. The majority of these transactions related to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.

Sales to affiliates were $2.7 million and $7.7 million, respectively, for the three and nine months ended September 30, 2020, as compared to $2.2 million and $6.9 million, respectively, for the same periods in 2019. As of September 30, 2020 and December 31, 2019, the receivable balance due from affiliates was $1.7 million and $1.9 million, respectively.

Please refer to Note 7, Affiliated Companies, to the consolidated financial statements in our 2019 Annual Report for additional details.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Debt
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2020.

($ in millions)September 30,
2020		December 31,
2019
Term Loan, due December 31, 2024 (1.10%)
$88.4 $90.0 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
256.4 258.0 
Less: unamortized debt issuance costs0.7 0.7 
Total debt255.7 257.3 
Less: current portion of long-term debt2.3 2.3 
Long-term debt, net$253.4 $255.0 

Please refer to Note 8, Debt, to the consolidated financial statements in our 2019 Annual Report for additional details regarding our debt agreements.

Credit Agreement - Credit Facility

At September 30, 2020, the borrowing capacity available under our $300.0 million multi-currency revolving credit facility (the “Credit Facility”), including outstanding letters of credit of $2.5 million, was $297.5 million.

Credit Agreement Amendment - Term Loan

At September 30, 2020, we had $88.4 million in borrowings under the Term Loan, of which $2.3 million was classified as current and $86.1 million was classified as long-term. Please refer to Note 9, Derivative Financial Instruments, for a discussion of the foreign currency hedge associated with the Term Loan.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Financial Instruments
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments Derivative Financial Instruments
Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value.

Foreign Exchange Rate Risk

We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of both September 30, 2020 and December 31, 2019, the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million.
In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2020, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:

(in millions)Sell
CurrencyPurchaseUSDEuro
USD74.7 — 64.8 
Yen9,876.6 55.9 32.5 
SGD57.9 33.3 7.2 

In December 2019, we entered into the cross-currency swap for $90 million, which we designated as a hedge of our net investment in Daikyo. The notional amount of the cross-currency swap is ¥9.8 billion ($90 million) and the swap termination date is December 31, 2024. Under the cross-currency swap, we receive floating interest rate payments based on three-month U.S. Dollar (“USD”) LIBOR plus a margin, in return for paying floating interest rate payments based on three-month Japanese Yen (“Yen”) LIBOR plus a margin.

Commodity Price Risk

Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception.

From November 2017 through September 2020, we purchased several series of call options for a total of 439,732 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases.

As of September 30, 2020, we had outstanding contracts to purchase 137,035 barrels of crude oil from October 2020 to March 2022, at a weighted-average strike price of $60.47 per barrel.

Effects of Derivative Instruments on Financial Position and Results of Operations

Please refer to Note 10, Fair Value Measurements, for the balance sheet location and fair values of our derivative instruments as of September 30, 2020 and December 31, 2019.
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Loss (Gain) Recognized in Income for theAmount of Loss (Gain) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Fair Value Hedges:
Hedged item (intercompany loan)
$9.3 $(8.4)$25.1 $(14.1)Other expense (income)
Derivative designated as hedging instrument
$(9.3)$8.4 $(25.1)$14.1 Other expense (income)
Amount excluded from effectiveness testing
$(1.9)$4.3 $(5.9)$(5.0)Other expense (income)
Total$(1.9)$4.3 $(5.9)$(5.0)

We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The amounts recognized in earnings, pre-tax, for forward point components for the three and nine months ended September 30, 2020 and 2019 were $1.3 million, $5.0 million, and $2.2 million, $6.4 million, respectively.

The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of (Loss) Gain Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$(0.1)$(0.6)$(0.7)$2.9 Other expense (income)
Total$(0.1)$(0.6)$(0.7)$2.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$0.7 $0.2 $(0.3)Net sales
Foreign currency hedge contracts— 0.6 0.1 (0.2)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.5)$1.3 $0.4 $(0.4) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.7 $— $— Other expense (income)
Cross-currency swap(3.0)— — — Other expense (income)
Total$(3.0)$0.7 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$2.8 $3.9 $(3.3)$(3.3)Other expense (income)
Total$2.8 $3.9 $(3.3)$(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$— $1.0 $(0.3)$(0.7)Net sales
Foreign currency hedge contracts(0.3)1.1 (0.1)(0.5)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(0.3)$2.1 $(0.2)$(1.0) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.5 $— $— Other (income)
Cross-currency swap(2.0)— — — Other (income)
Total$(2.0)$0.5 $— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales$0.2 $(0.3)$(0.3)$(0.7)
Cost of goods and services sold0.1 (0.2)(0.1)(0.5)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)(0.7)2.9 (3.3)(3.3)


The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Loss Recognized in Income for theAmount of Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Commodity call options$0.1 $0.1 $0.3 $0.3 Cost of goods and services sold
Total$0.1 $0.1 $0.3 $0.3 

For the three and nine months ended September 30, 2020 and 2019, there was no material ineffectiveness related to our hedges.
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:

•Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.
•Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.2 $11.2 $— $— 
Foreign currency contracts1.1 — 1.1 — 
Commodity call options0.1 — 0.1 — 
 $12.4 $11.2 $1.2 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap4.0 — 4.0 — 
Foreign currency contracts13.7 — 13.7 — 
 $34.0 $12.8 $17.7 $3.5 

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2019		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.3 $11.3 $— $— 
Foreign currency contracts7.7 — 7.7 — 
Commodity call options0.1 — 0.1 — 
 $19.1 $11.3 $7.8 $— 
Liabilities:    
Contingent consideration$3.3 $— $— $3.3 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap1.4 — 1.4 — 
Foreign currency contracts0.3 — 0.3 — 
 $17.8 $12.8 $1.7 $3.3 
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. The fair value of the cross-currency swap, included within other long-term liabilities, is valued using a market approach. Please refer to Note 9, Derivative Financial Instruments, for further discussion of our derivatives.

Level 3 Fair Value Measurements

The fair value of the contingent consideration liability related to the SmartDose technology platform (the “SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. Sales projections were derived using upside, base and downside forecasted cases for each partnership and applying probability-weighted scenarios of 10%, 50% and 40% to the three cases, respectively, to reflect the likelihood of West meeting the estimated sales projection targets. The probability of success factors included the probabilities of successful FDA approval for each partnership drug, which was estimated in a range of 19% to 100% based on the development phase of each respective drug, and the probability of the successful execution of supply agreements with each partnership, which was estimated in the range of 25% to 100% based on historical, current, and future supply agreements with the respective partnerships. The fair value of this liability utilized a risk-adjusted discount rate of 19% to present value the cash flows. The discount rate is calculated by determining the after-tax required returns on debt and equity and weighting each return by the respective percent of debt and equity to total capital. Key inputs for the discount rate include the risk-free rate on the 20-Year United States Treasury maturity, equity risk premium, company-specific risk premium, pre-tax cost of debt, and U.S. tax rate, among others. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration.

The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2018$1.7 
Increase in fair value recorded in earnings2.1 
Payments(0.5)
Balance, December 31, 20193.3 
Increase in fair value recorded in earnings0.9 
Payments(0.7)
Balance, September 30, 2020$3.5 
Other Financial Instruments

We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities.

The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2020, the estimated fair value of long-term debt was $266.4 million compared to a carrying amount of $253.4 million. At December 31, 2019, the estimated fair value of long-term debt was $263.3 million and the carrying amount was $255.0 million.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Loss
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss

The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2020:

($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2019$(0.8)$0.4 $(40.3)$(108.9)$(149.6)
Other comprehensive income (loss) before reclassifications2.5 — (6.2)(4.9)(8.6)
Amounts reclassified out from accumulated other comprehensive income (loss)(3.5)— 2.2 — (1.3)
Other comprehensive income (loss), net of tax(1.0)— (4.0)(4.9)(9.9)
Balance, September 30, 2020$(1.8)$0.4 $(44.3)$(113.8)$(159.5)

A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:

($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2020201920202019
Gains (losses) on derivatives:
Foreign currency contracts$(0.3)$0.3 $0.3 $0.8 Net sales
Foreign currency contracts(0.1)0.3 0.3 0.8 Cost of goods and services sold
Foreign currency contracts1.1 (4.3)5.1 5.0 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax0.6 (3.8)5.4 6.3 
Tax benefit (expense)(0.3)1.3 (1.9)(2.0)
Net of tax$0.3 $(2.5)$3.5 $4.3 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.4 $0.4 (a)
Actuarial losses0.2 0.2 — 0.2 (a)
Settlements(1.1)(2.7)(3.4)(2.7)(a)
Total before tax(0.8)(2.4)(3.0)(2.1)
Tax benefit (expense)0.3 0.6 0.8 0.5 
Net of tax$(0.5)$(1.8)$(2.2)$(1.6)
Total reclassifications for the period, net of tax$(0.2)$(4.3)$1.3 $2.7 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Shareholders' Equity Shareholders’ Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard (see Note 2)— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive income, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201875.3 $18.8 $282.0 1.2 $(103.7)$1,353.4 $(154.2)$1,396.3 
Net income— — — — — 55.4 — 55.4 
Activity related to stock-based compensation— — (3.5)(0.2)14.2 — — 10.7 
Shares purchased under share repurchase program— — — 0.8 (83.1)— — (83.1)
Dividends declared ($0.15 per share)
— — — — — (10.6)— (10.6)
Other comprehensive income, net of tax— — — — — — 0.8 0.8 
Balance, March 31, 201975.3 $18.8 $278.5 1.8 $(172.6)$1,398.2 $(153.4)$1,369.5 
Net income— — — — — 66.1 — 66.1 
Activity related to stock-based compensation— — (5.1)(0.2)24.8 — — 19.7 
Dividends declared ($0.15 per share)
— — — — — (11.4)— (11.4)
Other comprehensive income, net of tax— — — — — — 1.2 1.2 
Balance, June 30, 201975.3 $18.8 $273.4 1.6 $(147.8)$1,452.9 $(152.2)$1,445.1 
Net income— — — — — 56.3 — 56.3 
Activity related to stock-based compensation— — (4.9)(0.3)21.2 — — 16.3 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — (18.2)(18.2)
Balance, September 30, 201975.3 $18.8 $268.5 1.3 $(126.6)$1,497.3 $(170.4)$1,487.6 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2020, there were 2,756,301 shares remaining in the 2016 Plan for future grants.

During the nine months ended September 30, 2020, we granted 230,580 stock options at a weighted average exercise price of $175.22 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $39.58 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.3%; expected life of 5.7 years based on prior experience; stock volatility of 22.3% based on historical data; and a dividend yield of 0.4%. Stock option expense is recognized over the vesting period, net of forfeitures.

During the nine months ended September 30, 2020, we granted 52,187 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $175.18 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures.

During the nine months ended September 30, 2020, we granted 8,072 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $194.21 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures.
Stock-based compensation expense was $10.0 million and $27.6 million for the three and nine months ended September 30, 2020, respectively. For the three and nine months ended September 30, 2019, stock-based compensation expense was $5.4 million and $18.8 million, respectively.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Benefit Plans
 9 Months Ended
Sep. 30, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Benefit Plans Benefit Plans
The components of net periodic benefit cost for the three months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$0.4 $0.4 $— $— $0.4 $0.4 
Interest cost1.7 1.9 — 0.1 1.7 2.0 
Expected return on assets(2.8)(3.1)— — (2.8)(3.1)
Amortization of prior service credit0.1 0.1 (0.2)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.4 0.5 (0.6)(0.7)(0.2)(0.2)
Settlements1.1 2.7 — — 1.1 2.7 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$0.5 $2.0 $(0.8)$(0.8)$(0.3)$1.2 
International plans0.4 0.5 — — 0.4 0.5 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$1.0 $1.1 $— $— $1.0 $1.1 
Interest cost5.5 6.8 0.1 0.2 5.6 7.0 
Expected return on assets(8.8)(8.9)— — (8.8)(8.9)
Amortization of prior service credit0.1 0.1 (0.5)(0.5)(0.4)(0.4)
Recognized actuarial losses (gains)1.4 1.6 (1.4)(1.8)— (0.2)
Settlements3.4 2.7 — — 3.4 2.7 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$1.5 $1.9 $(1.8)$(2.1)$(0.3)$(0.2)
International plans1.1 1.5 — — 1.1 1.5 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 

During the three and nine months ended September 30, 2020, we recorded a $1.1 million and $3.4 million pension settlement charge, respectively, within other nonoperating (income) expense, as we determined that normal-course lump-sum payments for our U.S. qualified and non-qualified defined benefit pension plan exceeded the threshold for settlement accounting under U.S. GAAP for the year.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income)
 9 Months Ended
Sep. 30, 2020
Other Income and Expenses [Abstract]  
Other Expense (Income) Other Expense (Income)
Other expense (income) consists of:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Restructuring and related charges:
Severance and post-employment benefits$4.5 $0.6 $4.5 $2.2 
Asset-related charges— 0.1 — 0.1 
Other charges— 1.1 — 1.5 
Total restructuring and related charges4.5 1.8 4.5 3.8 
Argentina currency devaluation— 1.0 — 1.0 
Fixed asset impairments0.9 0.8 7.2 2.3 
Development and licensing income(0.2)(0.2)(0.6)(0.6)
Contingent consideration0.8 0.1 0.9 0.4 
Foreign exchange transaction losses (gains)1.0 5.1 (4.5)(3.5)
Other items(0.3)(2.2)(1.3)(1.8)
Total other expense (income)$6.7 $6.4 $6.2 $1.6 

Restructuring and Related Charges

In July 2020, our Board of Directors approved a restructuring plan designed to optimize certain organizational structures within the Company to better support our continued growth and business priorities. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan is expected to require restructuring and related charges of approximately $15 million to $17 million. Since its approval, we recorded a net pre-tax amount equal to $4.5 million in restructuring related charges associated with this plan. All charges recorded to date are severance related and recorded within other expense (income) in the condensed consolidated statements of income.

The following table presents activity related to our restructuring obligations related to our 2020 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$— $— 
Charges4.5 4.5 
Cash payments— — 
Balance, September 30, 2020$4.5 $4.5 

In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes were expected to be implemented over a period of up to twenty-four months from the date of approval. The plan was expected to require restructuring and related charges of approximately $16 million. Since its approval, we have recorded $13.7 million in restructuring and related charges associated with this plan. The plan was considered complete as of December 31, 2019.

During the three months ended September 30, 2019, we recorded $1.8 million in restructuring and related charges associated with this plan, consisting of $0.6 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.1 million for other non-cash charges.
During the nine months ended September 30, 2019, we recorded $3.8 million in restructuring and related charges associated with this plan, consisting of $2.2 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.5 million for other non-cash charges.

The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$1.4 $1.4 
Cash payments(1.2)(1.2)
Balance, September 30, 2020$0.2 $0.2 

On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. Our remaining restructuring obligations related to the 2016 restructuring plan are complete.

Other Items

During both the three and nine months ended September 30, 2020 and 2019, we recorded development income of $0.2 million and $0.6 million, respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue, for additional information.
Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 10, Fair Value Measurements, for additional details.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items.The provision for income taxes was $21.1 million and $10.9 million for the three months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 21.6% and 16.8%, respectively. The provision for income taxes was $52.1 million and $42.5 million for the nine months ended September 30, 2020 and 2019, respectively, and the effective tax rate was 18.2% and 19.8%, respectively.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity.

There have been no significant changes to the commitments and contingencies included in our 2019 Annual Report.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment Information Segment Information
Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab and other services, to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

The Chief Operating Decision Maker (“CODM”) evaluates the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that the CODM considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items.

The following table presents information about our reportable segments, reconciled to consolidated totals:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales:    
Proprietary Products$421.5 $345.2 $1,194.5 $1,045.9 
Contract-Manufactured Products126.6 111.1 372.5 323.6 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.2)
Consolidated net sales$548.0 $456.1 $1,566.7 $1,369.3 
Operating profit (loss):   
Proprietary Products$107.5 $72.9 $312.9 $238.7 
Contract-Manufactured Products18.8 11.6 52.1 33.5 
Corporate(22.4)(14.4)(67.1)(48.9)
Other unallocated items(4.7)(2.8)(7.1)(4.8)
Total operating profit$99.2 $67.3 $290.8 $218.5 
Interest expense2.1 2.1 6.1 6.4 
Interest income(0.2)(1.0)(1.2)(2.5)
Other nonoperating (income) expense(0.4)1.3 (0.3)0.2 
Income before income taxes$97.7 $64.9 $286.2 $214.4 

The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments.

Other unallocated items during the three months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges and $0.2 million of amortization expense associated with an acquisition of an intangible asset. Other unallocated items during the nine months ended September 30, 2020 consisted of $4.5 million in restructuring and related charges, $2.2 million in severance related costs, and $0.4 million of amortization expense associated with an acquisition of an intangible asset.
Other unallocated items during the three and nine months ended September 30, 2019 consisted of $1.8 million and $3.8 million, respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2019, other unallocated items included a charge of $1.0 million as a result of the continued devaluation of Argentina's currency.

Please refer to Note 15, Other Expense (Income), for further discussion of certain unallocated items referenced above.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2020, should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West,” the “Company,” “we,” “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year.

West has been actively monitoring the novel coronavirus (“COVID-19”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID-19 pandemic, other than for enhanced safety measures intended to prevent the spread of the virus and higher levels of production at certain plant locations to meet additional customer demand. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders.
In April 2019, we acquired the business of our distributor in South Korea for $18.9 million. As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million, $0.6 million, $2.6 million and $11.2 million, respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date.
New Accounting Standards
Recently Adopted Standards

In April 2019, the Financial Accounting Standards Board (“FASB”) issued guidance which clarifies and improves areas related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a prospective basis. The adoption did not have a material impact on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020.
The adoption did not have a material impact on our financial statements. Please refer to Note 10, Fair Value Measurements, for additional details.

In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity, including accounts receivable, at each reporting date. Under the previous guidance, an entity reflected credit losses on financial assets measured on an amortized cost basis only when it was probable that losses had incurred, generally considering only past events and current conditions when determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable and supportable forecasts. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. We adopted this guidance as of January 1, 2020, on a modified retrospective basis, to the accounts receivable and contract asset balances as of January 1, 2020. Under the current expected credit loss model, we have adopted a provision matrix approach, utilizing historical loss rates based on the number of days past due, adjusted to reflect current economic conditions and forecasts of future economic conditions. The effect of the adoption on the financial statement line items of accounts receivable and contract assets was not material as of January 1, 2020. As a result of our adoption, we recorded a cumulative-effect adjustment of $0.1 million within retained earnings in our condensed consolidated balance sheet as of January 1, 2020, to reflect the incremental estimated lifetime expected credit losses on the accounts receivable balance as of January 1, 2020. We have not presented the amortized cost basis within each credit quality indicator by year of origination as all of our accounts receivable are due within one year or less.

Standards Issued Not Yet Adopted

In March 2020, the FASB issued guidance which provides optional expedients and exceptions to address the impact of reference rate reform where contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate need to be discontinued. This guidance was effective upon issuance and generally can be applied through December 31, 2022. We are currently evaluating the impact to our financial statements, the transition, and disclosure requirements of this guidance.

In December 2019, the FASB issued guidance which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (“ASC”) Topic 740 and by clarifying and amending existing ASC Topic 740 guidance. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption is permitted. We are currently evaluating our adoption timing and the impact that this guidance may have on our financial statements.

In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table presents the approximate percentage of our net sales by market group:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Biologics
32 %
26 %
29 %
25 %
Generics
 18 %
20 %
19 %
20 %
Pharma
27 %
30 %
28 %
31 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by product category:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
High-Value Components
47 %
42 %
45 %
43 %
Standard Packaging
25 %
28 %
26 %
29 %
Delivery Devices
5 %
6 %
5 %
4 %
Contract-Manufactured Products
23 %
24 %
24 %
24 %
100 %
100 %
100 %
100 %

The following table presents the approximate percentage of our net sales by geographic location:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Americas
49 %
48 %
49 %
48 %
Europe, Middle East, Africa
42 %
44 %
43 %
44 %
Asia Pacific
9 %
8 %
8 %
8 %
100 %
100 %
100 %
100 %
Schedule of Change in Contract with Customer, Asset and Liability
The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net:
($ in millions)
Contract assets, December 31, 2019$9.8 
Contract assets, September 30, 2020
16.2 
Change in contract assets - increase (decrease)$6.4 
Deferred income, December 31, 2019$(34.9)
Deferred income, September 30, 2020
(56.7)
Change in deferred income - decrease (increase)$(21.8)
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Net Income Per Share (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic to Diluted Net Income Per Share
The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2020201920202019
Net income$82.3 $56.3 $247.8 $177.8 
Weighted average common shares outstanding73.9 74.0 73.9 73.9 
Dilutive effect of equity awards, based on the treasury stock method
1.9 1.5 1.7 1.4 
Weighted average shares assuming dilution75.8 75.5 75.6 75.3 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows:

($ in millions)September 30,
2020		December 31,
2019
Raw materials$125.4 $100.9 
Work in process55.8 37.4 
Finished goods113.7 97.4 
 $294.9 $235.7 
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Schedule of Lease, Cost
The components of lease expense were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Operating lease cost$3.1 $3.4 $9.3 $9.7 
Short-term lease cost0.3 0.1 0.6 0.5 
Variable lease cost1.2 0.8 2.8 2.3 
Total lease cost$4.6 $4.3 $12.7 $12.5 

Supplemental cash flow information related to leases were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$3.2 $3.2 $9.6 $9.4 
Right-of-use assets obtained in exchange for new operating lease liabilities$0.3 $0.3 $4.6 $8.4 
Schedule of Lessee, Operating Lease, Liability, Maturity
Maturities of operating lease liabilities were as follows:
($ in millions)September 30,December 31,
Year20202019
2020 (remaining three months)$3.4 $12.1 
202111.8 10.4 
20229.7 8.6 
20238.7 7.8 
20248.2 7.3 
Thereafter42.6 41.8 
84.4 88.0 
Less: imputed lease interest(14.6)(16.0)
Total lease liabilities$69.8 $72.0 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Obligations, Net of Current Maturities
The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2020.

($ in millions)September 30,
2020		December 31,
2019
Term Loan, due December 31, 2024 (1.10%)
$88.4 $90.0 
Series A notes, due July 5, 2022 (3.67%)
42.0 42.0 
Series B notes, due July 5, 2024 (3.82%)
53.0 53.0 
Series C notes, due July 5, 2027 (4.02%)
73.0 73.0 
256.4 258.0 
Less: unamortized debt issuance costs0.7 0.7 
Total debt255.7 257.3 
Less: current portion of long-term debt2.3 2.3 
Long-term debt, net$253.4 $255.0 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Foreign Currency Contracts As of September 30, 2020, we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows:
(in millions)Sell
CurrencyPurchaseUSDEuro
USD74.7 — 64.8 
Yen9,876.6 55.9 32.5 
SGD57.9 33.3 7.2 
Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings
The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income:
Amount of Loss (Gain) Recognized in Income for theAmount of Loss (Gain) Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Fair Value Hedges:
Hedged item (intercompany loan)
$9.3 $(8.4)$25.1 $(14.1)Other expense (income)
Derivative designated as hedging instrument
$(9.3)$8.4 $(25.1)$14.1 Other expense (income)
Amount excluded from effectiveness testing
$(1.9)$4.3 $(5.9)$(5.0)Other expense (income)
Total$(1.9)$4.3 $(5.9)$(5.0)
The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax:
 Amount of (Loss) Gain Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Three Months Ended
September 30,		Three Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$(0.1)$(0.6)$(0.7)$2.9 Other expense (income)
Total$(0.1)$(0.6)$(0.7)$2.9 
Cash Flow Hedges:     
Foreign currency hedge contracts$(0.5)$0.7 $0.2 $(0.3)Net sales
Foreign currency hedge contracts— 0.6 0.1 (0.2)Cost of goods and services sold
Forward treasury locks— — 0.1 0.1 Interest expense
Total$(0.5)$1.3 $0.4 $(0.4) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.7 $— $— Other expense (income)
Cross-currency swap(3.0)— — — Other expense (income)
Total$(3.0)$0.7 $— $—  
 Amount of Gain (Loss) Recognized in OCI for theAmount of (Gain) Loss Reclassified from Accumulated OCI into Income for theLocation of (Gain) Loss Reclassified from Accumulated OCI into Income
Nine Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019 
Fair Value Hedges
Foreign currency hedge contracts$2.8 $3.9 $(3.3)$(3.3)Other expense (income)
Total$2.8 $3.9 $(3.3)$(3.3)
Cash Flow Hedges:     
Foreign currency hedge contracts$— $1.0 $(0.3)$(0.7)Net sales
Foreign currency hedge contracts(0.3)1.1 (0.1)(0.5)Cost of goods and services sold
Forward treasury locks— — 0.2 0.2 Interest expense
Total$(0.3)$2.1 $(0.2)$(1.0) 
Net Investment Hedges:     
Foreign currency-denominated debt$— $0.5 $— $— Other (income)
Cross-currency swap(2.0)— — — Other (income)
Total$(2.0)$0.5 $— $—  

The following table summarizes the effects of derivative instruments designated as fair value, cash flow, and net investment hedges by line item in our condensed consolidated statements of income:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales$0.2 $(0.3)$(0.3)$(0.7)
Cost of goods and services sold0.1 (0.2)(0.1)(0.5)
Interest expense0.1 0.1 0.2 0.2 
Other expense (income)(0.7)2.9 (3.3)(3.3)


The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income:
Amount of Loss Recognized in Income for theAmount of Loss Recognized in Income for the
Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
($ in millions)2020201920202019
Commodity call options$0.1 $0.1 $0.3 $0.3 Cost of goods and services sold
Total$0.1 $0.1 $0.3 $0.3 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
 Balance atBasis of Fair Value Measurements
($ in millions)September 30,
2020		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.2 $11.2 $— $— 
Foreign currency contracts1.1 — 1.1 — 
Commodity call options0.1 — 0.1 — 
 $12.4 $11.2 $1.2 $— 
Liabilities:    
Contingent consideration$3.5 $— $— $3.5 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap4.0 — 4.0 — 
Foreign currency contracts13.7 — 13.7 — 
 $34.0 $12.8 $17.7 $3.5 

 Balance atBasis of Fair Value Measurements
($ in millions)December 31,
2019		Level 1Level 2Level 3
Assets:    
Deferred compensation assets$11.3 $11.3 $— $— 
Foreign currency contracts7.7 — 7.7 — 
Commodity call options0.1 — 0.1 — 
 $19.1 $11.3 $7.8 $— 
Liabilities:    
Contingent consideration$3.3 $— $— $3.3 
Deferred compensation liabilities12.8 12.8 — — 
Cross-currency swap1.4 — 1.4 — 
Foreign currency contracts0.3 — 0.3 — 
 $17.8 $12.8 $1.7 $3.3 
Schedule of Changes in Level 3 Fair Value Measurements
The following table provides a summary of changes in our Level 3 fair value measurements:
($ in millions)
Balance, December 31, 2018$1.7 
Increase in fair value recorded in earnings2.1 
Payments(0.5)
Balance, December 31, 20193.3 
Increase in fair value recorded in earnings0.9 
Payments(0.7)
Balance, September 30, 2020$3.5 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Loss (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Components of Accumulated Other Comprehensive Loss
The following table presents the changes in the components of accumulated other comprehensive income ("AOCI") (loss), net of tax, for the nine months ended September 30, 2020:

($ in millions)(Losses) gains on
derivatives		Change in equity affiliate investment AOCIDefined benefit
pension and other
postretirement plans		Foreign
currency
translation		Total
Balance, December 31, 2019$(0.8)$0.4 $(40.3)$(108.9)$(149.6)
Other comprehensive income (loss) before reclassifications2.5 — (6.2)(4.9)(8.6)
Amounts reclassified out from accumulated other comprehensive income (loss)(3.5)— 2.2 — (1.3)
Other comprehensive income (loss), net of tax(1.0)— (4.0)(4.9)(9.9)
Balance, September 30, 2020$(1.8)$0.4 $(44.3)$(113.8)$(159.5)
Schedule of Reclassification out of Accumulated Other Comprehensive Loss
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table:

($ in millions)Three Months Ended
September 30,		Nine Months Ended
September 30,		Location on Statement of Income
Detail of components2020201920202019
Gains (losses) on derivatives:
Foreign currency contracts$(0.3)$0.3 $0.3 $0.8 Net sales
Foreign currency contracts(0.1)0.3 0.3 0.8 Cost of goods and services sold
Foreign currency contracts1.1 (4.3)5.1 5.0 Other expense (income)
Forward treasury locks(0.1)(0.1)(0.3)(0.3)Interest expense
Total before tax0.6 (3.8)5.4 6.3 
Tax benefit (expense)(0.3)1.3 (1.9)(2.0)
Net of tax$0.3 $(2.5)$3.5 $4.3 
Amortization of defined benefit pension and other postretirement plans:
Prior service credit$0.1 $0.1 $0.4 $0.4 (a)
Actuarial losses0.2 0.2 — 0.2 (a)
Settlements(1.1)(2.7)(3.4)(2.7)(a)
Total before tax(0.8)(2.4)(3.0)(2.1)
Tax benefit (expense)0.3 0.6 0.8 0.5 
Net of tax$(0.5)$(1.8)$(2.2)$(1.6)
Total reclassifications for the period, net of tax$(0.2)$(4.3)$1.3 $2.7 

(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans, for additional details.
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Schedule of Stockholders Equity
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2020:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201975.3 $18.8 $272.7 1.2 $(118.1)$1,549.4 $(149.6)$1,573.2 
Effect of modified retrospective application of a new accounting standard (see Note 2)— — — — — (0.1)— (0.1)
Net income— — — — — 74.3 — 74.3 
Activity related to stock-based compensation— — (5.1)(0.3)17.9 — — 12.8 
Shares purchased under share repurchase program— — — 0.8 (115.5)— — (115.5)
Dividends declared ($0.16 per share)
— — — — — (11.8)— (11.8)
Other comprehensive loss, net of tax— — — — — — (42.7)(42.7)
Balance, March 31, 202075.3 $18.8 $267.6 1.7 $(215.7)$1,611.8 $(192.3)$1,490.2 
Net income— — — — — 91.2 — 91.2 
Activity related to stock-based compensation— — (4.5)(0.2)24.9 — — 20.4 
Other comprehensive income, net of tax— — — — — — 4.5 4.5 
Balance, June 30, 202075.3 $18.8 $263.1 1.5 $(190.8)$1,703.0 $(187.8)$1,606.3 
Net income— — — — — 82.3 — 82.3 
Activity related to stock-based compensation— — 5.1 (0.1)8.8 — — 13.9 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive income, net of tax— — — — — — 28.3 28.3 
Balance, September 30, 202075.3 $18.8 $268.2 1.4 $(182.0)$1,773.4 $(159.5)$1,718.9 
The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019:

Common Shares IssuedCommon StockCapital in Excess of Par ValueNumber of Treasury SharesTreasury StockRetained earningsAccumulated other comprehensive lossTotal
(in millions)
Balance, December 31, 201875.3 $18.8 $282.0 1.2 $(103.7)$1,353.4 $(154.2)$1,396.3 
Net income— — — — — 55.4 — 55.4 
Activity related to stock-based compensation— — (3.5)(0.2)14.2 — — 10.7 
Shares purchased under share repurchase program— — — 0.8 (83.1)— — (83.1)
Dividends declared ($0.15 per share)
— — — — — (10.6)— (10.6)
Other comprehensive income, net of tax— — — — — — 0.8 0.8 
Balance, March 31, 201975.3 $18.8 $278.5 1.8 $(172.6)$1,398.2 $(153.4)$1,369.5 
Net income— — — — — 66.1 — 66.1 
Activity related to stock-based compensation— — (5.1)(0.2)24.8 — — 19.7 
Dividends declared ($0.15 per share)
— — — — — (11.4)— (11.4)
Other comprehensive income, net of tax— — — — — — 1.2 1.2 
Balance, June 30, 201975.3 $18.8 $273.4 1.6 $(147.8)$1,452.9 $(152.2)$1,445.1 
Net income— — — — — 56.3 — 56.3 
Activity related to stock-based compensation— — (4.9)(0.3)21.2 — — 16.3 
Dividends declared ($0.16 per share)
— — — — — (11.9)— (11.9)
Other comprehensive loss, net of tax— — — — — — (18.2)(18.2)
Balance, September 30, 201975.3 $18.8 $268.5 1.3 $(126.6)$1,497.3 $(170.4)$1,487.6 
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The components of net periodic benefit cost for the three months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$0.4 $0.4 $— $— $0.4 $0.4 
Interest cost1.7 1.9 — 0.1 1.7 2.0 
Expected return on assets(2.8)(3.1)— — (2.8)(3.1)
Amortization of prior service credit0.1 0.1 (0.2)(0.2)(0.1)(0.1)
Recognized actuarial losses (gains)0.4 0.5 (0.6)(0.7)(0.2)(0.2)
Settlements1.1 2.7 — — 1.1 2.7 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$0.5 $2.0 $(0.8)$(0.8)$(0.3)$1.2 
International plans0.4 0.5 — — 0.4 0.5 
Net periodic benefit cost$0.9 $2.5 $(0.8)$(0.8)$0.1 $1.7 

The components of net periodic benefit cost for the nine months ended September 30 were as follows:

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
Service cost$1.0 $1.1 $— $— $1.0 $1.1 
Interest cost5.5 6.8 0.1 0.2 5.6 7.0 
Expected return on assets(8.8)(8.9)— — (8.8)(8.9)
Amortization of prior service credit0.1 0.1 (0.5)(0.5)(0.4)(0.4)
Recognized actuarial losses (gains)1.4 1.6 (1.4)(1.8)— (0.2)
Settlements3.4 2.7 — — 3.4 2.7 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 

 Pension benefitsOther retirement benefitsTotal
($ in millions)202020192020201920202019
U.S. plans$1.5 $1.9 $(1.8)$(2.1)$(0.3)$(0.2)
International plans1.1 1.5 — — 1.1 1.5 
Net periodic benefit cost$2.6 $3.4 $(1.8)$(2.1)$0.8 $1.3 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income) (Tables)
 9 Months Ended
Sep. 30, 2020
Other Income and Expenses [Abstract]  
Schedule of Other Expense (Income)
Other expense (income) consists of:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Restructuring and related charges:
Severance and post-employment benefits$4.5 $0.6 $4.5 $2.2 
Asset-related charges— 0.1 — 0.1 
Other charges— 1.1 — 1.5 
Total restructuring and related charges4.5 1.8 4.5 3.8 
Argentina currency devaluation— 1.0 — 1.0 
Fixed asset impairments0.9 0.8 7.2 2.3 
Development and licensing income(0.2)(0.2)(0.6)(0.6)
Contingent consideration0.8 0.1 0.9 0.4 
Foreign exchange transaction losses (gains)1.0 5.1 (4.5)(3.5)
Other items(0.3)(2.2)(1.3)(1.8)
Total other expense (income)$6.7 $6.4 $6.2 $1.6 
Schedule of Restructuring Reserve
($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$— $— 
Charges4.5 4.5 
Cash payments— — 
Balance, September 30, 2020$4.5 $4.5 
The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan:

($ in millions)Severance
and benefits		Total
Balance, December 31, 2019$1.4 $1.4 
Cash payments(1.2)(1.2)
Balance, September 30, 2020$0.2 $0.2 
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table presents information about our reportable segments, reconciled to consolidated totals:

Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Net sales:    
Proprietary Products$421.5 $345.2 $1,194.5 $1,045.9 
Contract-Manufactured Products126.6 111.1 372.5 323.6 
Intersegment sales elimination(0.1)(0.2)(0.3)(0.2)
Consolidated net sales$548.0 $456.1 $1,566.7 $1,369.3 
Operating profit (loss):   
Proprietary Products$107.5 $72.9 $312.9 $238.7 
Contract-Manufactured Products18.8 11.6 52.1 33.5 
Corporate(22.4)(14.4)(67.1)(48.9)
Other unallocated items(4.7)(2.8)(7.1)(4.8)
Total operating profit$99.2 $67.3 $290.8 $218.5 
Interest expense2.1 2.1 6.1 6.4 
Interest income(0.2)(1.0)(1.2)(2.5)
Other nonoperating (income) expense(0.4)1.3 (0.3)0.2 
Income before income taxes$97.7 $64.9 $286.2 $214.4 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)
$ in Millions
 1 Months Ended
Apr. 30, 2019
Sep. 30, 2020
Dec. 31, 2019
Accounting Policies [Abstract]      
Business combination, consideration transferred $ 18.9    
Business combination, recognized inventory 4.5    
Business combination, recognized property, plant, and equipment 0.6    
Business combination, recognized goodwill 2.6 $ 109.3 $ 107.8
Business combination, recognized intangible assets $ 11.2    
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.20.2
New Accounting Standards (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Jan. 01, 2020
Dec. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Retained earnings (accumulated deficit) $ 1,773.4   $ 1,549.4
Accounting Standards Update 2016-13      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Retained earnings (accumulated deficit)   $ 0.1  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Revenue Recognition (Details) - Revenue Benchmark
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 100.00% 100.00% 100.00% 100.00%
Americas | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 49.00% 48.00% 49.00% 48.00%
Europe, Middle East, Africa | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 42.00% 44.00% 43.00% 44.00%
Asia Pacific | Geographic Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 9.00% 8.00% 8.00% 8.00%
High-Value Components | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 47.00% 42.00% 45.00% 43.00%
Standard Packaging | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 25.00% 28.00% 26.00% 29.00%
Delivery Devices | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 5.00% 6.00% 5.00% 4.00%
Contract-Manufactured Products | Product Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 23.00% 24.00% 24.00% 24.00%
Biologics | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 32.00% 26.00% 29.00% 25.00%
Generics | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 18.00% 20.00% 19.00% 20.00%
Pharma | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 27.00% 30.00% 28.00% 31.00%
Contract-Manufactured Products | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Percentage of net sales 23.00% 24.00% 24.00% 24.00%
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Contracts and Liabilities (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
Contract With Customer, Asset [Roll Forward]  
Contract assets, December 31, 2019 $ 9.8
Contract assets, September 30, 2020 16.2
Change in contract assets - increase (decrease) 6.4
Contract With Customer, Liability [Roll Forward]  
Deferred income, December 31, 2019 (34.9)
Deferred income, September 30, 2020 (56.7)
Change in deferred income - decrease (increase) $ (21.8)
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Contracts and Liabilities, Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Jun. 30, 2013
Disaggregation of Revenue [Line Items]      
Revenue recognized that was included in the deferred income balance $ 23.0    
Deferred income 56.7 $ 34.9  
SmartDose      
Disaggregation of Revenue [Line Items]      
Deferred income 5.0   $ 20.0
Deferred income, current 0.9    
Deferred income, noncurrent $ 4.1    
Minimum      
Disaggregation of Revenue [Line Items]      
Contract with customer liability recognized 1 year    
Maximum      
Disaggregation of Revenue [Line Items]      
Contract with customer liability recognized 2 years    
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Supply Chain Financing (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]    
Sales of certain accounts receivable $ 8.9 $ 7.9
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Voluntary Recall (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]      
Provision for product returns $ 0.9 $ 11.3 $ 4.9
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Net Income Per Share (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Earnings Per Share [Abstract]                  
Net income $ 82.3 $ 91.2 $ 74.3 $ 56.3 $ 66.1 $ 55.4 $ 247.8 $ 177.8  
Weighted average common shares outstanding (in shares) 73,900,000     74,000,000.0     73,900,000 73,900,000  
Dilutive effect of equity awards, based on the treasury stock method (in shares) 1,900,000     1,500,000     1,700,000 1,400,000  
Weighted average shares assuming dilution (in shares) 75,800,000     75,500,000     75,600,000 75,300,000  
Antidilutive options excluded from computation of diluted net income per share (in shares) 0.0     100,000     200,000 300,000  
Stock repurchase program, shares authorized (in shares)                 848,000
Stock repurchase program, shares purchased (in shares) 0           761,500    
Stock purchase program, cost of shares purchased     $ 115.5     $ 83.1 $ 115.5    
Stock repurchase program, average price per share (in dollars per share)             $ 151.65    
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 125.4 $ 100.9
Work in process 55.8 37.4
Finished goods 113.7 97.4
Total inventories $ 294.9 $ 235.7
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Lease Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Leases [Abstract]        
Operating lease cost $ 3.1 $ 3.4 $ 9.3 $ 9.7
Short-term lease cost 0.3 0.1 0.6 0.5
Variable lease cost 1.2 0.8 2.8 2.3
Total lease cost $ 4.6 $ 4.3 $ 12.7 $ 12.5
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Lease Cash Flow and Supplemental Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases $ 3.2 $ 3.2 $ 9.6 $ 9.4
Right-of-use assets obtained in exchange for new operating lease liabilities $ 0.3 $ 0.3 $ 4.6 $ 8.4
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Lease Weighted Average (Details)
Sep. 30, 2020
Dec. 31, 2019
Leases [Abstract]    
Weighted average remaining lease term 11 years 2 months 12 days 11 years 8 months 12 days
Weighted average discount rate 3.74% 3.76%
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Leases [Abstract]    
Remainder of fiscal year $ 3.4  
Year one 11.8 $ 12.1
Year two 9.7 10.4
Year three 8.7 8.6
Year four 8.2 7.8
Thereafter 42.6  
Year five   7.3
Thereafter   41.8
Operating leases liabilities payments due 84.4 88.0
Less: imputed lease interest (14.6) (16.0)
Total lease liabilities $ 69.8 $ 72.0
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Affiliated Companies (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Nov. 01, 2019
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]              
Carrying amount, equity-method investments   $ 194.2   $ 194.2   $ 179.3  
Carrying amount, investments not accounted for under the equity method   15.4   15.4   13.4  
Purchase of investment in affiliated companies in cash $ 85.1            
Purchase of investment in affiliated companies $ 4.9            
Purchases and royalty payments made to affiliates   36.6 $ 33.0 97.0 $ 85.2    
Amount due and payable to affiliates   28.5   28.5   20.8  
Sales to affiliates   2.7 $ 2.2 7.7 $ 6.9    
Amount receivable from affiliates   $ 1.7   $ 1.7   $ 1.9  
Daikyo Seiko, Ltd. (Daikyo)              
Schedule of Equity Method Investments [Line Items]              
Ownership interest percentage 49.00%           25.00%
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Debt Instrument [Line Items]    
Long-term debt, gross $ 256.4 $ 258.0
Less: unamortized debt issuance costs 0.7 0.7
Total debt 255.7 257.3
Less: current portion of long-term debt 2.3 2.3
Long-term debt, net $ 253.4 255.0
Term Loan, due December 31, 2024 (1.10%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 1.10%  
Long-term debt, gross $ 88.4 90.0
Long-term debt, net $ 86.1  
Series A notes, due July 5, 2022 (3.67%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.67%  
Long-term debt, gross $ 42.0 42.0
Series B notes, due July 5, 2024 (3.82%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 3.82%  
Long-term debt, gross $ 53.0 53.0
Series C notes, due July 5, 2027 (4.02%)    
Debt Instrument [Line Items]    
Debt instrument, stated interest rate 4.02%  
Long-term debt, gross $ 73.0 $ 73.0
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Debt - Credit Agreement (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Line of Credit Facility [Line Items]    
Long-term debt, gross $ 256.4 $ 258.0
Long-term debt, current 2.3 2.3
Long-term debt 253.4 255.0
Revolving credit facility, Due 2024    
Line of Credit Facility [Line Items]    
Line of credit facility, current borrowing capacity 300.0  
Line of credit Facility, unused commitment level 297.5  
Revolving credit facility, Due 2024 | Letter of Credit    
Line of Credit Facility [Line Items]    
Long-term line of credit 2.5  
Term Loan Due 2024    
Line of Credit Facility [Line Items]    
Long-term debt, gross 88.4 $ 90.0
Long-term debt, current 2.3  
Long-term debt $ 86.1  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)
€ in Millions, ¥ in Millions, $ in Millions
 9 Months Ended 35 Months Ended
Sep. 30, 2020
SGD ($)
$ / bbl
bbl
Sep. 30, 2020
SGD ($)
$ / bbl
bbl
Sep. 30, 2020
USD ($)
$ / bbl
Sep. 30, 2020
EUR (€)
$ / bbl
Sep. 30, 2020
JPY (¥)
$ / bbl
Dec. 31, 2019
SGD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2019
JPY (¥)
Foreign Exchange Forward                
Derivative [Line Items]                
Derivative contract term 18 months              
Options Held                
Derivative [Line Items]                
Derivative, nonmonetary notional amount, volume | bbl 137,035 439,732            
Derivative, average price risk option strike price | $ / bbl 60.47 60.47 60.47 60.47 60.47      
USD | Forward Contracts                
Derivative [Line Items]                
Derivative, notional amount     $ 13,400,000       $ 13,400,000  
USD | Foreign Exchange Forward | Long | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount     74,700,000          
USD | Foreign Exchange Forward | Short | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount     0 € 64.8        
USD | Cross Currency Interest Rate Contract                
Derivative [Line Items]                
Derivative, notional amount             90,000,000  
USD | Cross Currency Interest Rate Contract | Net Investment Hedges                
Derivative [Line Items]                
Derivative, notional amount             $ 90,000,000  
Yen | Foreign Exchange Forward | Long | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount | ¥         ¥ 9,876.6      
Yen | Foreign Exchange Forward | Short | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount     55,900,000 32.5        
Yen | Cross Currency Interest Rate Contract                
Derivative [Line Items]                
Derivative, notional amount | ¥               ¥ 9,800.0
SGD | Forward Contracts                
Derivative [Line Items]                
Derivative, notional amount $ 601.5 $ 601.5       $ 601.5    
SGD | Foreign Exchange Forward | Long | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount $ 57.9 $ 57.9            
SGD | Foreign Exchange Forward | Short | Designated as Hedging Instrument                
Derivative [Line Items]                
Derivative, notional amount     $ 33,300,000 € 7.2        
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss recognized in income, fair value hedges $ (1.9) $ 4.3 $ (5.9) $ (5.0)
Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net 0.1 0.1 0.3 0.3
Fair Value Hedges        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative, forward point components, gain (loss), recognized in earnings 1.3 2.2 5.0 6.4
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.1) (0.6) 2.8 3.9
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income (0.7) 2.9 (3.3) (3.3)
Cash Flow Hedges        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (0.5) 1.3 (0.3) 2.1
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.4 (0.4) (0.2) (1.0)
Net Investment Hedges        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (3.0) 0.7 (2.0) 0.5
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Other expense (income)        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative (gain) loss on hedged item, fair value hedges 9.3 (8.4) 25.1 (14.1)
Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges (9.3) 8.4 (25.1) 14.1
Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges (1.9) 4.3 (5.9) (5.0)
Gain (loss) on derivative instruments, net, pretax (0.7) 2.9 (3.3) (3.3)
Other expense (income) | Fair Value Hedges | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (0.1) (0.6) 2.8 3.9
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income (0.7) 2.9 (3.3) (3.3)
Other expense (income) | Net Investment Hedges | Foreign currency-denominated debt        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI 0.0 0.7 0.0 0.5
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Other expense (income) | Net Investment Hedges | Cross-currency swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Fair value and net investment hedges, amount of gain (loss) recognized in OCI (3.0) 0.0 (2.0) 0.0
Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.0 0.0 0.0 0.0
Net sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 0.2 (0.3) (0.3) (0.7)
Net sales | Cash Flow Hedges | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI (0.5) 0.7 0.0 1.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.2 (0.3) (0.3) (0.7)
Cost of goods and services sold        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 0.1 (0.2) (0.1) (0.5)
Cost of goods and services sold | Commodity call options | Not Designated as Hedging Instrument        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedging instruments, gain (loss), net 0.1 0.1 0.3 0.3
Cost of goods and services sold | Cash Flow Hedges | Foreign currency hedge contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.6 (0.3) 1.1
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income 0.1 (0.2) (0.1) (0.5)
Interest expense        
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (loss) on derivative instruments, net, pretax 0.1 0.1 0.2 0.2
Interest expense | Cash Flow Hedges | Forward treasury locks        
Derivative Instruments, Gain (Loss) [Line Items]        
Cash flow hedges, amount of gain (loss) recognized in OCI 0.0 0.0 0.0 0.0
Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income $ 0.1 $ 0.1 $ 0.2 $ 0.2
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Assets:    
Deferred compensation assets $ 11.2 $ 11.3
Foreign currency contracts 1.1 7.7
Total assets at fair value 12.4 19.1
Liabilities:    
Contingent consideration 3.5 3.3
Deferred compensation liabilities 12.8 12.8
Total liabilities at fair value 34.0 17.8
Commodity call options    
Assets:    
Commodity call options 0.1 0.1
Cross-currency swap    
Liabilities:    
Foreign currency contracts and swaps 4.0 1.4
Foreign currency contracts    
Liabilities:    
Foreign currency contracts and swaps 13.7 0.3
Level 1    
Assets:    
Deferred compensation assets 11.2 11.3
Foreign currency contracts 0.0 0.0
Total assets at fair value 11.2 11.3
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 12.8 12.8
Total liabilities at fair value 12.8 12.8
Level 1 | Commodity call options    
Assets:    
Commodity call options 0.0 0.0
Level 1 | Cross-currency swap    
Liabilities:    
Foreign currency contracts and swaps 0.0 0.0
Level 1 | Foreign currency contracts    
Liabilities:    
Foreign currency contracts and swaps 0.0 0.0
Level 2    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts 1.1 7.7
Total assets at fair value 1.2 7.8
Liabilities:    
Contingent consideration 0.0 0.0
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 17.7 1.7
Level 2 | Commodity call options    
Assets:    
Commodity call options 0.1 0.1
Level 2 | Cross-currency swap    
Liabilities:    
Foreign currency contracts and swaps 4.0 1.4
Level 2 | Foreign currency contracts    
Liabilities:    
Foreign currency contracts and swaps 13.7 0.3
Level 3    
Assets:    
Deferred compensation assets 0.0 0.0
Foreign currency contracts 0.0 0.0
Total assets at fair value 0.0 0.0
Liabilities:    
Contingent consideration 3.5 3.3
Deferred compensation liabilities 0.0 0.0
Total liabilities at fair value 3.5 3.3
Level 3 | Commodity call options    
Assets:    
Commodity call options 0.0 0.0
Level 3 | Cross-currency swap    
Liabilities:    
Foreign currency contracts and swaps 0.0 0.0
Level 3 | Foreign currency contracts    
Liabilities:    
Foreign currency contracts and swaps $ 0.0 $ 0.0
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Level 3 Fair Value Measurements (Details) - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Level 3 Fair Value Measurements [Roll Forward]    
Balance, beginning of period $ 3.3 $ 1.7
Increase in fair value recorded in earnings 0.9 2.1
Payments (0.7) (0.5)
Balance, end of period $ 3.5 $ 3.3
Sales Projections | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 10.00%  
Sales Projections | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 50.00%  
Sales Projections | Weighted Average    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 40.00%  
Probabilities of Successful FDA Approval | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 19.00%  
Probabilities of Successful FDA Approval | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 100.00%  
Probabilities of Successful Execution of Agreement | Minimum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 25.00%  
Probabilities of Successful Execution of Agreement | Maximum    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 100.00%  
Measurement Input, Discount Rate    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]    
Business combination, contingent consideration, measurement input 19.00%  
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurement - Other Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Other Financial Instruments [Abstract]    
Long-term debt, fair value $ 266.4 $ 263.3
Long-term debt $ 253.4 $ 255.0
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period $ 1,606.3 $ 1,490.2 $ 1,573.2 $ 1,445.1 $ 1,369.5 $ 1,396.3 $ 1,573.2 $ 1,396.3
Other comprehensive income (loss) before reclassifications             (8.6)  
Amounts reclassified out from accumulated other comprehensive income (loss)             (1.3)  
Other comprehensive income (loss), net of tax 28.3 4.5 (42.7) (18.2) 1.2 0.8 (9.9) (16.2)
Balance, end of period 1,718.9 1,606.3 1,490.2 1,487.6 1,445.1 1,369.5 1,718.9 1,487.6
(Losses) gains on derivatives                
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period     (0.8)       (0.8)  
Other comprehensive income (loss) before reclassifications             2.5  
Amounts reclassified out from accumulated other comprehensive income (loss)             (3.5)  
Other comprehensive income (loss), net of tax             (1.0)  
Balance, end of period (1.8)           (1.8)  
Change in equity affiliate investment AOCI                
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period     0.4       0.4  
Other comprehensive income (loss) before reclassifications             0.0  
Amounts reclassified out from accumulated other comprehensive income (loss)             0.0  
Other comprehensive income (loss), net of tax             0.0  
Balance, end of period 0.4           0.4  
Defined benefit pension and other postretirement plans                
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period     (40.3)       (40.3)  
Other comprehensive income (loss) before reclassifications             (6.2)  
Amounts reclassified out from accumulated other comprehensive income (loss)             2.2  
Other comprehensive income (loss), net of tax             (4.0)  
Balance, end of period (44.3)           (44.3)  
Foreign currency translation                
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period     (108.9)       (108.9)  
Other comprehensive income (loss) before reclassifications             (4.9)  
Amounts reclassified out from accumulated other comprehensive income (loss)             0.0  
Other comprehensive income (loss), net of tax             (4.9)  
Balance, end of period (113.8)           (113.8)  
Accumulated other comprehensive loss                
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]                
Balance, beginning of period (187.8) (192.3) (149.6) (152.2) (153.4) (154.2) (149.6) (154.2)
Other comprehensive income (loss), net of tax 28.3 4.5 (42.7) (18.2) 1.2 0.8    
Balance, end of period $ (159.5) $ (187.8) $ (192.3) $ (170.4) $ (152.2) $ (153.4) $ (159.5) $ (170.4)
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net sales $ 548.0     $ 456.1     $ 1,566.7 $ 1,369.3
Cost of goods and services sold (353.4)     (308.3)     (1,010.0) (916.8)
Interest expense (2.1)     (2.1)     (6.1) (6.4)
Prior service credit 0.1     0.1     0.4 0.4
Actuarial losses (0.2)     (0.2)     0.0 (0.2)
Settlements (1.1)     (2.7)     (3.4) (2.7)
Income before income taxes 97.7     64.9     286.2 214.4
Tax benefit (expense) (21.1)     (10.9)     (52.1) (42.5)
Net income 82.3 $ 91.2 $ 74.3 56.3 $ 66.1 $ 55.4 247.8 177.8
Reclassification out of Accumulated Other Comprehensive Loss                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net income (0.2)     (4.3)     1.3 2.7
Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Income before income taxes 0.6     (3.8)     5.4 6.3
Tax benefit (expense) (0.3)     1.3     (1.9) (2.0)
Net income 0.3     (2.5)     3.5 4.3
Reclassification out of Accumulated Other Comprehensive Loss | Amortization of defined benefit pension and other postretirement plans                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Prior service credit 0.1     0.1     0.4 0.4
Actuarial losses 0.2     0.2     0.0 0.2
Settlements (1.1)     (2.7)     (3.4) (2.7)
Income before income taxes (0.8)     (2.4)     (3.0) (2.1)
Tax benefit (expense) 0.3     0.6     0.8 0.5
Net income (0.5)     (1.8)     (2.2) (1.6)
Foreign currency contracts | Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Net sales (0.3)     0.3     0.3 0.8
Cost of goods and services sold (0.1)     0.3     0.3 0.8
Other expense (income) 1.1     (4.3)     5.1 5.0
Forward treasury locks | Reclassification out of Accumulated Other Comprehensive Loss | Gains (losses) on derivatives                
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]                
Interest expense $ (0.1)     $ (0.1)     $ (0.3) $ (0.3)
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholder's Equity - Change in Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period $ 1,606.3 $ 1,490.2 $ 1,573.2 $ 1,445.1 $ 1,369.5 $ 1,396.3 $ 1,573.2 $ 1,396.3
Net income 82.3 91.2 74.3 56.3 66.1 55.4 $ 247.8 177.8
Activity related to stock-based compensation $ 13.9 20.4 12.8 16.3 19.7 10.7    
Share purchased under share repurchase program (in shares) 0           761,500  
Shares purchased under share repurchase program     (115.5)     (83.1) $ (115.5)  
Dividends declared $ (11.9)   (11.8) (11.9) (11.4) (10.6)    
Other comprehensive income (loss), net of tax 28.3 4.5 (42.7) (18.2) 1.2 0.8 (9.9) (16.2)
Balance, end of period $ 1,718.9 $ 1,606.3 $ 1,490.2 $ 1,487.6 $ 1,445.1 $ 1,369.5 1,718.9 $ 1,487.6
Dividends declared per share (in dollars per share) $ 0.16   $ 0.16 $ 0.16 $ 0.15 $ 0.15    
Cumulative Effect, Period of Adoption, Adjustment                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period     $ (0.1)       $ (0.1)  
Common Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Balance, beginning of period $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Activity related to stock-based compensation $ 0.0              
Activity related to stock -based compensation (in shares) 0              
Balance (in shares) 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000 75,300,000
Balance, end of period $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8 $ 18.8
Capital in Excess of Par Value                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period 263.1 267.6 272.7 273.4 278.5 282.0 272.7 282.0
Activity related to stock-based compensation 5.1 (4.5) (5.1) (4.9) (5.1) (3.5)    
Balance, end of period $ 268.2 $ 263.1 $ 267.6 $ 268.5 $ 273.4 $ 278.5 $ 268.2 $ 268.5
Treasury Stock                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance (in shares) 1,500,000 1,700,000 1,200,000 1,600,000 1,800,000 1,200,000 1,200,000 1,200,000
Balance, beginning of period $ (190.8) $ (215.7) $ (118.1) $ (147.8) $ (172.6) $ (103.7) $ (118.1) $ (103.7)
Activity related to stock-based compensation $ 8.8 $ 24.9 $ 17.9 $ 21.2 $ 24.8 $ 14.2    
Activity related to stock -based compensation (in shares) (100,000) (200,000) (300,000) (300,000) (200,000) (200,000)    
Share purchased under share repurchase program (in shares)     800,000     (800,000)    
Shares purchased under share repurchase program     $ (115.5)     $ (83.1)    
Balance (in shares) 1,400,000 1,500,000 1,700,000 1,300,000 1,600,000 1,800,000 1,400,000 1,300,000
Balance, end of period $ (182.0) $ (190.8) $ (215.7) $ (126.6) $ (147.8) $ (172.6) $ (182.0) $ (126.6)
Retained earnings                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period 1,703.0 1,611.8 1,549.4 1,452.9 1,398.2 1,353.4 1,549.4 1,353.4
Net income 82.3 91.2 74.3 56.3 66.1 55.4    
Dividends declared (11.9)   (11.8) (11.9) (11.4) (10.6)    
Balance, end of period 1,773.4 1,703.0 1,611.8 1,497.3 1,452.9 1,398.2 1,773.4 1,497.3
Retained earnings | Cumulative Effect, Period of Adoption, Adjustment                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period     (0.1)       (0.1)  
Accumulated other comprehensive loss                
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Balance, beginning of period (187.8) (192.3) (149.6) (152.2) (153.4) (154.2) (149.6) (154.2)
Other comprehensive income (loss), net of tax 28.3 4.5 (42.7) (18.2) 1.2 0.8    
Balance, end of period $ (159.5) $ (187.8) $ (192.3) $ (170.4) $ (152.2) $ (153.4) $ (159.5) $ (170.4)
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Shareholder's Equity - Supplemental Equity Information (Details) - $ / shares
 3 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Equity [Abstract]          
Dividends declared per share (in dollars per share) $ 0.16 $ 0.16 $ 0.16 $ 0.15 $ 0.15
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Stock-Based Compensation (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares available for issuance under the 2016 Plan (in shares) 2,756,301   2,756,301  
Stock options, granted (in shares)     230,580  
Stock options, weighted average exercise price (in dollars per share)     $ 175.22  
Stock options, weighted average grant date fair value (in dollars per share)     $ 39.58  
Risk-free interest rate     1.30%  
Expected life     5 years 8 months 12 days  
Stock volatility     22.30%  
Dividend yield     0.40%  
Stock-based compensation expense $ 10.0 $ 5.4 $ 27.6 $ 18.8
Performance Share Unit (PSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     52,187  
Grant date fair value (in dollars per share)     $ 175.18  
PSU payout, minimum 0.00%   0.00%  
PSU payout, maximum 200.00%   200.00%  
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares)     8,072  
Grant date fair value (in dollars per share)     $ 194.21  
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost $ 0.4 $ 0.4 $ 1.0 $ 1.1
Interest cost 1.7 2.0 5.6 7.0
Expected return on assets (2.8) (3.1) (8.8) (8.9)
Amortization of prior service credit (0.1) (0.1) (0.4) (0.4)
Recognized actuarial losses (gains) (0.2) (0.2) 0.0 (0.2)
Settlements 1.1 2.7 3.4 2.7
Net periodic benefit cost 0.1 1.7 0.8 1.3
U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.3) 1.2 (0.3) (0.2)
International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.4 0.5 1.1 1.5
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.4 0.4 1.0 1.1
Interest cost 1.7 1.9 5.5 6.8
Expected return on assets (2.8) (3.1) (8.8) (8.9)
Amortization of prior service credit 0.1 0.1 0.1 0.1
Recognized actuarial losses (gains) 0.4 0.5 1.4 1.6
Settlements 1.1 2.7 3.4 2.7
Net periodic benefit cost 0.9 2.5 2.6 3.4
Pension benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.5 2.0 1.5 1.9
Pension benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost 0.4 0.5 1.1 1.5
Other retirement benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Service cost 0.0 0.0 0.0 0.0
Interest cost 0.0 0.1 0.1 0.2
Expected return on assets 0.0 0.0 0.0 0.0
Amortization of prior service credit (0.2) (0.2) (0.5) (0.5)
Recognized actuarial losses (gains) (0.6) (0.7) (1.4) (1.8)
Settlements 0.0 0.0 0.0 0.0
Net periodic benefit cost (0.8) (0.8) (1.8) (2.1)
Other retirement benefits | U.S. plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost (0.8) (0.8) (1.8) (2.1)
Other retirement benefits | International plans        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Net periodic benefit cost $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 1.1 $ 2.7 $ 3.4 $ 2.7
Pension benefits        
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]        
Settlements $ 1.1 $ 2.7 $ 3.4 $ 2.7
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income) - Other Expense (Income) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring and related charges:        
Severance and post-employment benefits $ 4.5 $ 0.6 $ 4.5 $ 2.2
Asset-related charges 0.0 0.1 0.0 0.1
Other charges 0.0 1.1 0.0 1.5
Total restructuring and related charges 4.5 1.8 4.5 3.8
Argentina currency devaluation 0.0 1.0 0.0 1.0
Fixed asset impairments 0.9 0.8 7.2 2.3
Development and licensing income (0.2) (0.2) (0.6) (0.6)
Contingent consideration 0.8 0.1 0.9 0.4
Foreign exchange transaction losses (gains) 1.0 5.1 (4.5) (3.5)
Other items (0.3) (2.2) (1.3) (1.8)
Total other expense (income) $ 6.7 6.4 $ 6.2 1.6
2018 Restructuring Plan        
Restructuring and related charges:        
Severance and post-employment benefits   0.6   2.2
Asset-related charges   0.1   0.1
Other charges   1.1   1.5
Total restructuring and related charges   $ 1.8   $ 3.8
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income) - Restructuring and Related Charges (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2020
Feb. 28, 2018
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring and related charges:            
Total restructuring and related charges     $ 4.5 $ 1.8 $ 4.5 $ 3.8
Severance and post-employment benefits     4.5 0.6 4.5 2.2
Asset-related charges     0.0 0.1 0.0 0.1
Other charges     0.0 1.1 0.0 1.5
2020 Restructuring Plan            
Restructuring and related charges:            
Restructuring and related activities, period of implementation 24 months          
Restructuring and related cost, cumulative cost incurred $ 4.5          
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2019         0.0  
Charges           4.5
Cash payments           0.0
Balance, September 30, 2020     4.5   4.5  
2020 Restructuring Plan | Severance and benefits            
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2019         0.0  
Charges           4.5
Cash payments           0.0
Balance, September 30, 2020     4.5   4.5  
2018 Restructuring Plan            
Restructuring and related charges:            
Restructuring and related activities, period of implementation   24 months        
Restructuring and related cost, expected cost   $ 16.0        
Restructuring and related cost, cumulative cost incurred     13.7   13.7  
Total restructuring and related charges       1.8   3.8
Severance and post-employment benefits       0.6   2.2
Asset-related charges       0.1   0.1
Other charges       $ 1.1   $ 1.5
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2019         1.4  
Cash payments         (1.2)  
Balance, September 30, 2020     0.2   0.2  
2018 Restructuring Plan | Severance and benefits            
Restructuring Reserve [Roll Forward]            
Balance, December 31, 2019         1.4  
Cash payments         (1.2)  
Balance, September 30, 2020     $ 0.2   $ 0.2  
Minimum | 2020 Restructuring Plan            
Restructuring and related charges:            
Restructuring and related cost, expected cost 15.0          
Maximum | 2020 Restructuring Plan            
Restructuring and related charges:            
Restructuring and related cost, expected cost $ 17.0          
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Other Expense (Income) - Development and Licensing Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Jun. 30, 2013
Development and licensing income [Line Items]            
Development and licensing income $ 0.2 $ 0.2 $ 0.6 $ 0.6    
Deferred income 56.7   56.7   $ 34.9  
SmartDose            
Development and licensing income [Line Items]            
Deferred income 5.0   5.0     $ 20.0
SmartDose            
Development and licensing income [Line Items]            
Development and licensing income $ 0.2 $ 0.2 $ 0.6 $ 0.6    
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Disclosure [Abstract]        
Tax benefit (expense) $ 21.1 $ 10.9 $ 52.1 $ 42.5
Effective income tax rate 21.60% 16.80% 18.20% 19.80%
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
USD ($)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Number of reportable segments | segment     2  
Net sales $ 548.0 $ 456.1 $ 1,566.7 $ 1,369.3
Total operating profit 99.2 67.3 290.8 218.5
Interest expense 2.1 2.1 6.1 6.4
Interest income (0.2) (1.0) (1.2) (2.5)
Other nonoperating (income) expense (0.4) 1.3 (0.3) 0.2
Income before income taxes 97.7 64.9 286.2 214.4
Severance related costs 4.5 0.6 4.5 2.2
Argentina currency devaluation 0.0 1.0 0.0 1.0
Intersegment sales elimination        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales (0.1) (0.2) (0.3) (0.2)
Corporate        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating profit (22.4) (14.4) (67.1) (48.9)
Other unallocated items        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Total operating profit (4.7) (2.8) (7.1) (4.8)
Restructuring and related charges 4.5 1.8 4.5 3.8
Amortization of intangible assets 0.2   0.4  
Severance related costs     2.2  
Argentina currency devaluation   1.0   1.0
Proprietary Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 421.5 345.2 1,194.5 1,045.9
Total operating profit 107.5 72.9 312.9 238.7
Contract-Manufactured Products | Operating Segments        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Net sales 126.6 111.1 372.5 323.6
Total operating profit $ 18.8 $ 11.6 $ 52.1 $ 33.5
EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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`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end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 388 366 1 false 87 0 false 10 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.westpharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2104102 - Disclosure - New Accounting Standards Sheet http://www.westpharma.com/role/NewAccountingStandards New Accounting Standards Notes 9 false false R10.htm 2106103 - Disclosure - Revenue Sheet http://www.westpharma.com/role/Revenue Revenue Notes 10 false false R11.htm 2113104 - Disclosure - Net Income Per Share Sheet http://www.westpharma.com/role/NetIncomePerShare Net Income Per Share Notes 11 false false R12.htm 2116105 - Disclosure - Inventories Sheet http://www.westpharma.com/role/Inventories Inventories Notes 12 false false R13.htm 2119106 - Disclosure - Leases Sheet http://www.westpharma.com/role/Leases Leases Notes 13 false false R14.htm 2125107 - Disclosure - Affiliated Companies Sheet http://www.westpharma.com/role/AffiliatedCompanies Affiliated Companies Notes 14 false false R15.htm 2127108 - Disclosure - Debt Sheet http://www.westpharma.com/role/Debt Debt Notes 15 false false R16.htm 2131109 - Disclosure - Derivative Financial Instruments Sheet http://www.westpharma.com/role/DerivativeFinancialInstruments Derivative Financial Instruments Notes 16 false false R17.htm 2135110 - Disclosure - Fair Value Measurements Sheet http://www.westpharma.com/role/FairValueMeasurements Fair Value Measurements Notes 17 false false R18.htm 2140111 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 18 false false R19.htm 2144112 - Disclosure - Shareholders' Equity Sheet http://www.westpharma.com/role/ShareholdersEquity Shareholders' Equity Notes 19 false false R20.htm 2148113 - Disclosure - Stock-Based Compensation Sheet http://www.westpharma.com/role/StockBasedCompensation Stock-Based Compensation Notes 20 false false R21.htm 2150114 - Disclosure - Benefit Plans Sheet http://www.westpharma.com/role/BenefitPlans Benefit Plans Notes 21 false false R22.htm 2154115 - Disclosure - Other Expense (Income) Sheet http://www.westpharma.com/role/OtherExpenseIncome Other Expense (Income) Notes 22 false false R23.htm 2159116 - Disclosure - Income Taxes Sheet http://www.westpharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2161117 - Disclosure - Commitments and Contingencies Sheet http://www.westpharma.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 24 false false R25.htm 2162118 - Disclosure - Segment Information Sheet http://www.westpharma.com/role/SegmentInformation Segment Information Notes 25 false false R26.htm 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 26 false false R27.htm 2307301 - Disclosure - Revenue (Tables) Sheet http://www.westpharma.com/role/RevenueTables Revenue (Tables) Tables http://www.westpharma.com/role/Revenue 27 false false R28.htm 2314302 - Disclosure - Net Income Per Share (Tables) Sheet http://www.westpharma.com/role/NetIncomePerShareTables Net Income Per Share (Tables) Tables http://www.westpharma.com/role/NetIncomePerShare 28 false false R29.htm 2317303 - Disclosure - Inventories (Tables) Sheet http://www.westpharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.westpharma.com/role/Inventories 29 false false R30.htm 2320304 - Disclosure - Leases (Tables) Sheet http://www.westpharma.com/role/LeasesTables Leases (Tables) Tables http://www.westpharma.com/role/Leases 30 false false R31.htm 2328305 - Disclosure - Debt (Tables) Sheet http://www.westpharma.com/role/DebtTables Debt (Tables) Tables http://www.westpharma.com/role/Debt 31 false false R32.htm 2332306 - Disclosure - Derivative Financial Instruments (Tables) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables Derivative Financial Instruments (Tables) Tables http://www.westpharma.com/role/DerivativeFinancialInstruments 32 false false R33.htm 2336307 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.westpharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.westpharma.com/role/FairValueMeasurements 33 false false R34.htm 2341308 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss 34 false false R35.htm 2345309 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.westpharma.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.westpharma.com/role/ShareholdersEquity 35 false false R36.htm 2351310 - Disclosure - Benefit Plans (Tables) Sheet http://www.westpharma.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.westpharma.com/role/BenefitPlans 36 false false R37.htm 2355311 - Disclosure - Other Expense (Income) (Tables) Sheet http://www.westpharma.com/role/OtherExpenseIncomeTables Other Expense (Income) (Tables) Tables http://www.westpharma.com/role/OtherExpenseIncome 37 false false R38.htm 2363312 - Disclosure - Segment Information (Tables) Sheet http://www.westpharma.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.westpharma.com/role/SegmentInformation 38 false false R39.htm 2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details) Sheet http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails Basis of Presentation and Summary of Significant Accounting Policies (Details) Details http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies 39 false false R40.htm 2405402 - Disclosure - New Accounting Standards (Details) Sheet http://www.westpharma.com/role/NewAccountingStandardsDetails New Accounting Standards (Details) Details http://www.westpharma.com/role/NewAccountingStandards 40 false false R41.htm 2408403 - Disclosure - Revenue - Revenue Recognition (Details) Sheet http://www.westpharma.com/role/RevenueRevenueRecognitionDetails Revenue - Revenue Recognition (Details) Details 41 false false R42.htm 2409404 - Disclosure - Revenue - Contracts and Liabilities (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails Revenue - Contracts and Liabilities (Details) Details 42 false false R43.htm 2410405 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details) Sheet http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails Revenue - Contracts and Liabilities, Narrative (Details) Details 43 false false R44.htm 2411406 - Disclosure - Revenue - Supply Chain Financing (Details) Sheet http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails Revenue - Supply Chain Financing (Details) Details 44 false false R45.htm 2412407 - Disclosure - Revenue - Voluntary Recall (Details) Sheet http://www.westpharma.com/role/RevenueVoluntaryRecallDetails Revenue - Voluntary Recall (Details) Details 45 false false R46.htm 2415408 - Disclosure - Net Income Per Share (Details) Sheet http://www.westpharma.com/role/NetIncomePerShareDetails Net Income Per Share (Details) Details http://www.westpharma.com/role/NetIncomePerShareTables 46 false false R47.htm 2418409 - Disclosure - Inventories (Details) Sheet http://www.westpharma.com/role/InventoriesDetails Inventories (Details) Details http://www.westpharma.com/role/InventoriesTables 47 false false R48.htm 2421410 - Disclosure - Leases - Lease Cost (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCostDetails Leases - Lease Cost (Details) Details 48 false false R49.htm 2422411 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details) Sheet http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails Leases - Lease Cash Flow and Supplemental Information (Details) Details 49 false false R50.htm 2423412 - Disclosure - Leases - Lease Weighted Average (Details) Sheet http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails Leases - Lease Weighted Average (Details) Details 50 false false R51.htm 2424413 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details) Sheet http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails Leases - Maturities of Operating Lease Liabilities (Details) Details 51 false false R52.htm 2426414 - Disclosure - Affiliated Companies (Details) Sheet http://www.westpharma.com/role/AffiliatedCompaniesDetails Affiliated Companies (Details) Details http://www.westpharma.com/role/AffiliatedCompanies 52 false false R53.htm 2429415 - Disclosure - Debt - Long-term Debt (Details) Sheet http://www.westpharma.com/role/DebtLongtermDebtDetails Debt - Long-term Debt (Details) Details 53 false false R54.htm 2430416 - Disclosure - Debt - Credit Agreement (Details) Sheet http://www.westpharma.com/role/DebtCreditAgreementDetails Debt - Credit Agreement (Details) Details 54 false false R55.htm 2433417 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails Derivative Financial Instruments - Foreign Exchange Rate Risk (Details) Details 55 false false R56.htm 2434418 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Sheet http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details) Details 56 false false R57.htm 2437419 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details) Details 57 false false R58.htm 2438420 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails Fair Value Measurement - Level 3 Fair Value Measurements (Details) Details 58 false false R59.htm 2439421 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details) Sheet http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails Fair Value Measurement - Other Financial Instruments (Details) Details 59 false false R60.htm 2442422 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details) Details 60 false false R61.htm 2443423 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Sheet http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details) Details 61 false false R62.htm 2446424 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details) Sheet http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails Shareholder's Equity - Change in Shareholders' Equity (Details) Details 62 false false R63.htm 2447425 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details) Sheet http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails Shareholder's Equity - Supplemental Equity Information (Details) Details 63 false false R64.htm 2449426 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.westpharma.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.westpharma.com/role/StockBasedCompensation 64 false false R65.htm 2452427 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Sheet http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details) Details 65 false false R66.htm 2453428 - Disclosure - Benefit Plans - Narrative (Details) Sheet http://www.westpharma.com/role/BenefitPlansNarrativeDetails Benefit Plans - Narrative (Details) Details 66 false false R67.htm 2456429 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails Other Expense (Income) - Other Expense (Income) (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 67 false false R68.htm 2457430 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails Other Expense (Income) - Restructuring and Related Charges (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 68 false false R69.htm 2458431 - Disclosure - Other Expense (Income) - Development and Licensing Income (Details) Sheet http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails Other Expense (Income) - Development and Licensing Income (Details) Details http://www.westpharma.com/role/OtherExpenseIncomeTables 69 false false R70.htm 2460432 - Disclosure - Income Taxes (Details) Sheet http://www.westpharma.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.westpharma.com/role/IncomeTaxes 70 false false R71.htm 2464433 - Disclosure - Segment Information (Details) Sheet http://www.westpharma.com/role/SegmentInformationDetails Segment Information (Details) Details http://www.westpharma.com/role/SegmentInformationTables 71 false false All Reports Book All Reports wst-20200930.htm ex10102020amendedresta.htm ex311q32020.htm ex312q32020.htm ex321q32020.htm ex322q32020.htm wst-20200930.xsd wst-20200930_cal.xml wst-20200930_def.xml wst-20200930_lab.xml wst-20200930_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/currency/2020-01-31 true true JSON 91 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wst-20200930.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 388, "dts": { "calculationLink": { "local": [ "wst-20200930_cal.xml" ] }, "definitionLink": { "local": [ "wst-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "wst-20200930.htm" ] }, "labelLink": { "local": [ "wst-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "wst-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "wst-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 519, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 5 }, "keyCustom": 14, "keyStandard": 352, "memberCustom": 24, "memberStandard": 60, "nsprefix": "wst", "nsuri": "http://www.westpharma.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.westpharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106103 - Disclosure - Revenue", "role": "http://www.westpharma.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Net Income Per Share", "role": "http://www.westpharma.com/role/NetIncomePerShare", "shortName": "Net Income Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Inventories", "role": "http://www.westpharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Leases", "role": "http://www.westpharma.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Affiliated Companies", "role": "http://www.westpharma.com/role/AffiliatedCompanies", "shortName": "Affiliated Companies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Debt", "role": "http://www.westpharma.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Derivative Financial Instruments", "role": "http://www.westpharma.com/role/DerivativeFinancialInstruments", "shortName": "Derivative Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135110 - Disclosure - Fair Value Measurements", "role": "http://www.westpharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144112 - Disclosure - Shareholders' Equity", "role": "http://www.westpharma.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - Stock-Based Compensation", "role": "http://www.westpharma.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150114 - Disclosure - Benefit Plans", "role": "http://www.westpharma.com/role/BenefitPlans", "shortName": "Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154115 - Disclosure - Other Expense (Income)", "role": "http://www.westpharma.com/role/OtherExpenseIncome", "shortName": "Other Expense (Income)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159116 - Disclosure - Income Taxes", "role": "http://www.westpharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2161117 - Disclosure - Commitments and Contingencies", "role": "http://www.westpharma.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162118 - Disclosure - Segment Information", "role": "http://www.westpharma.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Revenue (Tables)", "role": "http://www.westpharma.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - Net Income Per Share (Tables)", "role": "http://www.westpharma.com/role/NetIncomePerShareTables", "shortName": "Net Income Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Inventories (Tables)", "role": "http://www.westpharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Leases (Tables)", "role": "http://www.westpharma.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328305 - Disclosure - Debt (Tables)", "role": "http://www.westpharma.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Derivative Financial Instruments (Tables)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables", "shortName": "Derivative Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336307 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.westpharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341308 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345309 - Disclosure - Shareholders' Equity (Tables)", "role": "http://www.westpharma.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351310 - Disclosure - Benefit Plans (Tables)", "role": "http://www.westpharma.com/role/BenefitPlansTables", "shortName": "Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2355311 - Disclosure - Other Expense (Income) (Tables)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeTables", "shortName": "Other Expense (Income) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2363312 - Disclosure - Segment Information (Tables)", "role": "http://www.westpharma.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "ic618275ba02e4518a64df0d50c85368c_D20190401-20190430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "ic618275ba02e4518a64df0d50c85368c_D20190401-20190430", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - New Accounting Standards (Details)", "role": "http://www.westpharma.com/role/NewAccountingStandardsDetails", "shortName": "New Accounting Standards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i0f3873c7578e4bf982df3ff7d68d91d2_I20200101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i24acdf7689e441febb6bd58f1fdd593b_D20200701-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Revenue - Revenue Recognition (Details)", "role": "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails", "shortName": "Revenue - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i24acdf7689e441febb6bd58f1fdd593b_D20200701-20200930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "icf8049d7f4a345e4aa96810711993023_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Revenue - Contracts and Liabilities (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "shortName": "Revenue - Contracts and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "icf8049d7f4a345e4aa96810711993023_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Revenue - Contracts and Liabilities, Narrative (Details)", "role": "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "shortName": "Revenue - Contracts and Liabilities, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411406 - Disclosure - Revenue - Supply Chain Financing (Details)", "role": "http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails", "shortName": "Revenue - Supply Chain Financing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i40bba3303e0e450a9888e8787f38b036_D20190701-20190930", "decimals": "-5", "first": true, "lang": "en-US", "name": "wst:ProvisionForProductReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Revenue - Voluntary Recall (Details)", "role": "http://www.westpharma.com/role/RevenueVoluntaryRecallDetails", "shortName": "Revenue - Voluntary Recall (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i40bba3303e0e450a9888e8787f38b036_D20190701-20190930", "decimals": "-5", "first": true, "lang": "en-US", "name": "wst:ProvisionForProductReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415408 - Disclosure - Net Income Per Share (Details)", "role": "http://www.westpharma.com/role/NetIncomePerShareDetails", "shortName": "Net Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Inventories (Details)", "role": "http://www.westpharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421410 - Disclosure - Leases - Lease Cost (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCostDetails", "shortName": "Leases - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Leases - Lease Cash Flow and Supplemental Information (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails", "shortName": "Leases - Lease Cash Flow and Supplemental Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Leases - Lease Weighted Average (Details)", "role": "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails", "shortName": "Leases - Lease Weighted Average (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)", "role": "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Affiliated Companies (Details)", "role": "http://www.westpharma.com/role/AffiliatedCompaniesDetails", "shortName": "Affiliated Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "icf8049d7f4a345e4aa96810711993023_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Debt - Long-term Debt (Details)", "role": "http://www.westpharma.com/role/DebtLongtermDebtDetails", "shortName": "Debt - Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - Debt - Credit Agreement (Details)", "role": "http://www.westpharma.com/role/DebtCreditAgreementDetails", "shortName": "Debt - Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i512d3d64a2c74f2caa03e70632d557e8_I20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i97823b050e714b3c8c50d9630b4dbbc9_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails", "shortName": "Derivative Financial Instruments - Foreign Exchange Rate Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i97823b050e714b3c8c50d9630b4dbbc9_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "role": "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "shortName": "Derivative Financial Instruments - Effects of Derivative Instruments on OCI and Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Recorded at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredCompensationPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "icf8049d7f4a345e4aa96810711993023_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438420 - Disclosure - Fair Value Measurement - Level 3 Fair Value Measurements (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "shortName": "Fair Value Measurement - Level 3 Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "ia5d2afd4359a418a9ca20dd3c5ef0254_I20181231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Fair Value Measurement - Other Financial Instruments (Details)", "role": "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails", "shortName": "Fair Value Measurement - Other Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i41f156cca72041a682673986190e7e60_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "role": "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "shortName": "Accumulated Other Comprehensive Loss - Other Comprehensive Loss Reclassifications (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i203468f1cd9240e6a4c34d1186a312d9_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i41f156cca72041a682673986190e7e60_I20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Shareholder's Equity - Change in Shareholders' Equity (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "shortName": "Shareholder's Equity - Change in Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - Shareholder's Equity - Supplemental Equity Information (Details)", "role": "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails", "shortName": "Shareholder's Equity - Supplemental Equity Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "iefbbf4af335d489e97a4f34123e3da61_I20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449426 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.westpharma.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452427 - Disclosure - Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "role": "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails", "shortName": "Benefit Plans - Schedule of Components of Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453428 - Disclosure - Benefit Plans - Narrative (Details)", "role": "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "shortName": "Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456429 - Disclosure - Other Expense (Income) - Other Expense (Income) (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "shortName": "Other Expense (Income) - Other Expense (Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457430 - Disclosure - Other Expense (Income) - Restructuring and Related Charges (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "shortName": "Other Expense (Income) - Restructuring and Related Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i08a0b425d9d14aa8abceb2d05f150401_D20200701-20200731", "decimals": null, "lang": "en-US", "name": "wst:RestructuringAndRelatedActivitiesPeriodOfImplementation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "wst:ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "wst:DevelopmentAndLicensingIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458431 - Disclosure - Other Expense (Income) - Development and Licensing Income (Details)", "role": "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "shortName": "Other Expense (Income) - Development and Licensing Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i858803a5d4c942df9fa0016714778153_D20200701-20200930", "decimals": "-5", "lang": "en-US", "name": "wst:DevelopmentAndLicensingIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460432 - Disclosure - Income Taxes (Details)", "role": "http://www.westpharma.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i7bb3c5ac0a014ec5b7b67ffa536abfbc_D20200701-20200930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464433 - Disclosure - Segment Information (Details)", "role": "http://www.westpharma.com/role/SegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - New Accounting Standards", "role": "http://www.westpharma.com/role/NewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "wst-20200930.htm", "contextRef": "i8b4b7fa9ed4e4b66b346f51d18449a7c_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 87, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. plans" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_JPY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Japan, Yen", "terseLabel": "Yen" } } }, "localname": "JPY", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_SGD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Singapore, Dollars", "terseLabel": "SGD" } } }, "localname": "SGD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r665" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r666" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r668" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r663" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r664" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.westpharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Americas [Member]", "terseLabel": "Americas" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r167", "r179", "r180", "r181", "r182", "r183", "r185", "r189" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r167", "r179", "r180", "r181", "r182", "r183", "r185", "r189" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r117", "r128", "r213", "r423", "r424", "r425", "r442", "r443" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r117", "r128", "r213", "r423", "r424", "r425", "r442", "r443" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r117", "r128", "r213", "r423", "r424", "r425", "r442", "r443" ], "lang": { "en-US": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r196", "r294", "r300", "r636" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r397", "r402", "r565", "r566", "r567", "r568", "r569", "r570", "r590", "r633", "r637" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r397", "r402", "r565", "r566", "r567", "r568", "r569", "r570", "r590", "r633", "r637" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r196", "r294", "r300", "r636" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r192", "r294", "r298", "r591", "r632", "r634" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r192", "r294", "r298", "r591", "r632", "r634" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r338", "r397", "r402", "r565", "r566", "r567", "r568", "r569", "r570", "r590", "r633", "r637" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r338", "r397", "r402", "r565", "r566", "r567", "r568", "r569", "r570", "r590", "r633", "r637" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r193", "r194", "r294", "r299", "r635", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r193", "r194", "r294", "r299", "r635", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r565", "r567", "r570" ], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update 2016-13 [Member]", "terseLabel": "Accounting Standards Update 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r18", "r198", "r199" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r13", "r601", "r616" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r59", "r65", "r66", "r469" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined benefit pension and other postretirement plans", "verboseLabel": "Amortization of defined benefit pension and other postretirement plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r239" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r65", "r73", "r468" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "(Losses) gains on derivatives", "verboseLabel": "Gains (losses) on derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r56", "r57", "r58", "r65", "r66" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Change in equity affiliate investment AOCI" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r62", "r64", "r65", "r618", "r645", "r649" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r530", "r531", "r532", "r533", "r534", "r536" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r61", "r65", "r66", "r114", "r115", "r116", "r469", "r640", "r641" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r54", "r65", "r66", "r469", "r531", "r532", "r533", "r534", "r536" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r427" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r114", "r115", "r116", "r423", "r424", "r425" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Capital in Excess of Par Value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r101", "r235" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r120", "r121", "r122", "r124", "r210", "r211", "r212", "r213", "r216", "r217", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r440", "r441", "r442", "r443", "r592", "r593", "r594", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-US": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r405", "r416", "r429" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r101", "r233", "r235" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive options excluded from computation of diluted net income per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r101", "r236" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Asset-related charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r175", "r181", "r187", "r207", "r466", "r470", "r524", "r600", "r615" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r51", "r107", "r207", "r466", "r470", "r524" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r511" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r407", "r417" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r457", "r458", "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business combination, consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r100", "r463" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 5.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r456", "r459", "r462" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r454", "r455" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business combination, recognized intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r454", "r455" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Business combination, recognized inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r454", "r455" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Business combination, recognized property, plant, and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r103" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r98", "r103", "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, including cash equivalents at end of period", "periodStartLabel": "Cash, including cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r98", "r529" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r478" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r507" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 2.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivative (gain) loss on derivative designed as hedging instrument, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r507" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 1.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Derivative (gain) loss on hedged item, fair value hedges" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r261", "r605", "r622" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 17)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r258", "r259", "r260", "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommodityMember": { "auth_ref": [ "r501" ], "lang": { "en-US": { "role": { "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity [Member]", "terseLabel": "Commodity call options" } } }, "localname": "CommodityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommodityOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Option contract in which the underlying asset is a commodity.", "label": "Commodity Option [Member]", "terseLabel": "Commodity call options" } } }, "localname": "CommodityOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails", "http://www.westpharma.com/role/ShareholdersEquitySupplementalEquityInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r114", "r115" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r270" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.25 per share; 200.0\u00a0million and 100.0 million shares authorized; shares issued: 75.3\u00a0million and 75.3 million; shares outstanding: 73.9\u00a0million and 74.1 million" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r69", "r71", "r72", "r78", "r609", "r628" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r77", "r86", "r608", "r627" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r160", "r161", "r196", "r522", "r523" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r160", "r161", "r196", "r522", "r523", "r650" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r160", "r161", "r196", "r522", "r523", "r650" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r160", "r161", "r196", "r522", "r523" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of net sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r160", "r161", "r196", "r522", "r523" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Change in Contract with Customer, Asset and Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r281", "r283", "r295" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "periodEndLabel": "Contract assets, September\u00a030, 2020", "periodStartLabel": "Contract assets, December 31, 2019" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r281", "r282", "r295" ], "calculation": { "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "negatedPeriodEndLabel": "Deferred income, September\u00a030, 2020", "negatedPeriodStartLabel": "Deferred income, December 31, 2019", "terseLabel": "Deferred income", "totalLabel": "Deferred income" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Change in deferred income - decrease (increase)" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r281", "r282", "r295" ], "calculation": { "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred income, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r281", "r282", "r295" ], "calculation": { "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred income, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized that was included in the deferred income balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r189", "r191" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r81", "r591" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "negatedTerseLabel": "Cost of goods and services sold", "verboseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of goods and services sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r339", "r497" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r157", "r196" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Long-term debt, current", "verboseLabel": "Notes payable and other current debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r264", "r602", "r613" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r43", "r109", "r271", "r274", "r275", "r276", "r538", "r539", "r541", "r612" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred Compensation Liability, Classified, Noncurrent", "terseLabel": "Deferred compensation liabilities" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r35" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation assets" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r322" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedLabel": "Actuarial losses", "negatedTerseLabel": "Recognized actuarial losses (gains)" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r315", "r355", "r382", "r387", "r388" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "negatedTerseLabel": "Prior service credit", "terseLabel": "Amortization of prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r12", "r313", "r314", "r337", "r387", "r599", "r614" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r315", "r353", "r380", "r387", "r388" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r315", "r320", "r352", "r379", "r387", "r388" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r350", "r377", "r387", "r388" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r316", "r357", "r384" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlements", "terseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r318", "r351", "r378", "r387", "r388" ], "calculation": { "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r371", "r372", "r375", "r376", "r387" ], "lang": { "en-US": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r101", "r237" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r52", "r53", "r521" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Commodity call options" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAveragePriceRiskOptionStrikePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The average strike price on the group of price risk option contracts such as put options or call options.", "label": "Derivative, Average Price Risk Option Strike Price", "terseLabel": "Derivative, average price risk option strike price" } } }, "localname": "DerivativeAveragePriceRiskOptionStrikePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "perUnitItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r488", "r505" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "terseLabel": "Derivative, forward point components, gain (loss), recognized in earnings" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r482", "r484", "r491", "r499" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "verboseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r480", "r482", "r491" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r480", "r482", "r491", "r499", "r500", "r504", "r509" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r489", "r492" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative instruments not designated as hedging instruments, gain (loss), net" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNonmonetaryNotionalAmountVolume": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nominal volume used to calculate payments on a derivative instrument.", "label": "Derivative, Nonmonetary Notional Amount, Volume", "terseLabel": "Derivative, nonmonetary notional amount, volume" } } }, "localname": "DerivativeNonmonetaryNotionalAmountVolume", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "volumeItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r474", "r476" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r473", "r475", "r476", "r480", "r481", "r485", "r491", "r502", "r503", "r509" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative contract term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r294", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails", "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r277" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r111", "r556", "r557", "r624" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Amount receivable from affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToAffiliateCurrentAndNoncurrent": { "auth_ref": [ "r111", "r556", "r558", "r604", "r623", "r651" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due to Affiliate", "terseLabel": "Amount due and payable to affiliates" } } }, "localname": "DueToAffiliateCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East, Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Net income per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r79", "r126", "r127", "r128", "r129", "r130", "r137", "r139", "r144", "r145", "r146", "r150", "r151", "r610", "r629" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r79", "r126", "r127", "r128", "r129", "r130", "r139", "r144", "r145", "r146", "r150", "r151", "r610", "r629" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r147", "r148", "r149", "r152" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r529" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance and benefits" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]", "verboseLabel": "Equity:" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r114", "r115", "r116", "r121", "r131", "r133", "r154", "r213", "r270", "r277", "r423", "r424", "r425", "r442", "r443", "r530", "r531", "r532", "r533", "r534", "r536", "r640", "r641", "r642" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Ownership interest percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r32", "r176", "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Carrying amount, equity-method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]", "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "terseLabel": "Affiliated Companies" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompanies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r203" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Carrying amount, investments not accounted for under the equity method" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r511", "r512", "r513", "r520" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r387", "r512", "r562", "r563", "r564" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]" } } }, "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "auth_ref": [ "r519" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value.", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]" } } }, "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r518" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair Value Hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r339", "r341", "r346", "r387", "r512", "r562" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r339", "r341", "r346", "r387", "r512", "r563" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r387", "r512", "r564" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Level 3 Fair Value Measurements [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r515", "r520" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Changes in Level 3 Fair Value Measurements" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r516" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Increase in fair value recorded in earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r515" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r387", "r562", "r563", "r564" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.", "label": "Foreign Currency Contract, Asset, Fair Value Disclosure", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "terseLabel": "Foreign currency contracts and swaps" } } }, "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Other expense (income)" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r525", "r526", "r527", "r528" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 6.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedTerseLabel": "Foreign exchange transaction losses (gains)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionLossBeforeTax": { "auth_ref": [ "r527", "r528" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 2.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.", "label": "Foreign Currency Transaction Loss, before Tax", "terseLabel": "Argentina currency devaluation" } } }, "localname": "ForeignCurrencyTransactionLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r339", "r496" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency hedge contracts", "verboseLabel": "Foreign currency contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Exchange Forward" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r392", "r396", "r401" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International plans" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r495" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": { "auth_ref": [ "r488", "r508" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": 3.0, "parentTag": "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.", "label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net", "negatedTerseLabel": "Derivative (gain) loss on amount excluded from effectiveness testing, fair value hedges" } } }, "localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "auth_ref": [ "r482" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (loss) on derivative instruments, net, pretax" } } }, "localname": "GainLossOnDerivativeInstrumentsNetPretax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r486" ], "calculation": { "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "negatedTotalLabel": "Derivative (gain) loss recognized in income, fair value hedges" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r229", "r230", "r598" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Business combination, recognized goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r80", "r107", "r175", "r180", "r183", "r186", "r189", "r207", "r524" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r480", "r500" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r110", "r175", "r180", "r183", "r186", "r189" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r75", "r101", "r172", "r204", "r606", "r625" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "negatedTerseLabel": "Equity in net income of affiliated companies" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r437", "r438", "r439", "r447", "r449", "r451", "r452", "r453" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r108", "r132", "r133", "r173", "r435", "r448", "r450", "r630" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Tax benefit (expense)", "terseLabel": "Tax benefit (expense)", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r100" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r140", "r141", "r142", "r146" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of equity awards, based on the treasury stock method (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r232", "r234" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r74", "r169", "r537", "r540", "r611" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r498" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]", "terseLabel": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r167", "r179", "r180", "r181", "r182", "r183", "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment sales elimination" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r25", "r227" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r49" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.westpharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r27", "r227" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r26", "r227" ], "calculation": { "http://www.westpharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r83", "r84" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "negatedTerseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "auth_ref": [ "r32" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "terseLabel": "Investments in affiliated companies" } } }, "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r552", "r554" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r552" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r553" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Operating leases liabilities payments due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year one" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "Year five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of fiscal year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r553" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed lease interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r555" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r107", "r182", "r207", "r467", "r470", "r471", "r524" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r107", "r207", "r524", "r603", "r620" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r41", "r107", "r207", "r467", "r470", "r471", "r524" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r511" ], "calculation": { "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r14", "r602", "r613" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Current Borrowing Capacity", "terseLabel": "Line of credit facility, current borrowing capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r37" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit Facility, unused commitment level" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r37", "r109" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates an ownership position in, or purchase of, a security.", "label": "Long [Member]", "terseLabel": "Long" } } }, "localname": "LongMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r265", "r602", "r617" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less: current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "verboseLabel": "Long-term debt, fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.westpharma.com/role/DebtLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails", "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r43", "r263" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Other unallocated items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r514" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r514" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]", "terseLabel": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r98" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r98" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r98", "r99", "r102" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r67", "r70", "r76", "r102", "r107", "r120", "r126", "r127", "r128", "r129", "r132", "r133", "r143", "r175", "r180", "r183", "r186", "r189", "r207", "r524", "r607", "r626" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r479" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedges" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]", "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r118", "r119", "r122", "r123", "r134", "r135", "r136", "r214", "r215", "r305", "r306", "r307", "r308", "r426", "r444", "r445", "r446", "r595", "r596", "r597", "r644", "r645", "r646", "r647", "r649" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "verboseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r117", "r120", "r121", "r122", "r124", "r125", "r128", "r150", "r210", "r211", "r212", "r213", "r216", "r217", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r440", "r441", "r442", "r443", "r592", "r593", "r594", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r480" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r65", "r73" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r175", "r180", "r183", "r186", "r189" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Total operating profit", "totalLabel": "Operating profit" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r545", "r554" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r543" ], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r543" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r543" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r544", "r548" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r542" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r551", "r554" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r550", "r554" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseWeightedAverageDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r189" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r472" ], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Options Held [Member]", "terseLabel": "Options Held" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetImpairmentCharges": { "auth_ref": [ "r101", "r241" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 3.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.", "label": "Other Asset Impairment Charges", "terseLabel": "Fixed asset impairments" } } }, "localname": "OtherAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r60", "r62", "r464", "r468" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Defined benefit pension and other postretirement plan adjustments, net of tax of $0.1, $0.7, $1.2, and $0.7, respectively" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "auth_ref": [ "r464", "r465", "r468" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "negatedLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r464", "r465", "r468" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r62" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net (loss) gain on derivatives, net of tax of $0.2, $1.5, $0.4 and $0.7, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r63" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Net gain (loss) on derivatives, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITEDParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r55", "r62", "r483", "r487", "r506" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Cash flow hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax": { "auth_ref": [ "r490" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from discontinuance of cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Reclassification for Discontinuance, before Tax", "negatedTerseLabel": "Cash flow hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeReclassificationForDiscontinuanceBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r493" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Fair value and net investment hedges, amount of gain (loss) recognized in OCI" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r494" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedTerseLabel": "Fair value and net investment hedges, amount of (gain) loss reclassified from accumulated OCI into income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r68", "r71", "r464", "r465", "r468" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other Employee-related Liabilities, Current", "terseLabel": "Accrued salaries, wages and benefits" } } }, "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r631" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income", "terseLabel": "Other expense (income)" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r310", "r431" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "verboseLabel": "Other Expense (Income)" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r40" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other nonoperating (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 7.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedTerseLabel": "Other items" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r312", "r313", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r365", "r368", "r372", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395", "r396" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other retirement benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r101", "r244", "r250", "r256" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other charges" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "auth_ref": [ "r96" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedTerseLabel": "Contingent consideration payments in excess of acquisition-date liability" } } }, "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r87", "r90", "r112" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares purchased under share repurchase programs" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r97", "r246" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash payments" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r95" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r93" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividend payments" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r88", "r461" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "negatedTerseLabel": "Acquisition of business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangibles" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "terseLabel": "Purchase of investment in affiliated companies in cash" } } }, "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r338", "r340", "r346", "r364", "r366", "r367", "r368", "r369", "r370", "r387", "r389", "r390", "r391", "r403" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "verboseLabel": "Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r13", "r313", "r314", "r337", "r387" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "verboseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r15", "r313", "r314", "r337", "r387" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Pension and other postretirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r311", "r313", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r365", "r368", "r372", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r398", "r399", "r400", "r401" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension benefits" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Unit (PSUs)" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PositionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by position taken for a security.", "label": "Position [Axis]", "terseLabel": "Position [Axis]" } } }, "localname": "PositionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PositionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates position taken for a security.", "label": "Position [Domain]", "terseLabel": "Position [Domain]" } } }, "localname": "PositionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, 3.0\u00a0million shares authorized; 0 shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r91", "r418" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Employee stock purchase plan contributions" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r92" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Borrowings under revolving credit agreements" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r91", "r418" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock-based compensation awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r238" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r240", "r621" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Line Items]" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r65", "r73" ], "calculation": { "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified out from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Reclassification out of Accumulated Other Comprehensive Loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "auth_ref": [ "r180", "r183" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r180", "r183" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Schedule of Segment Information" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Repayments under revolving credit agreements" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r94" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r432", "r662" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r245", "r247", "r254", "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Restructuring and related cost, cumulative cost incurred" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r245", "r247", "r254", "r257" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Restructuring and related cost, expected cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r245", "r247", "r254", "r257" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 1.0, "parentTag": "wst_OtherIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Total restructuring and related charges", "totalLabel": "Total restructuring and related charges" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r101", "r244", "r250", "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges", "verboseLabel": "Restructuring and related charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring and related charges:" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r246", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance, September 30, 2020", "periodStartLabel": "Balance, December 31, 2019" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "auth_ref": [ "r244", "r251" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.", "label": "Restructuring Reserve, Settled without Cash", "terseLabel": "Non-cash restructuring charges" } } }, "localname": "RestructuringReserveSettledWithoutCash2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r277", "r427", "r619", "r644", "r649" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)", "verboseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r114", "r115", "r116", "r121", "r131", "r133", "r213", "r423", "r424", "r425", "r442", "r443", "r640", "r642" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r368", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r392", "r396", "r401" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r368", "r373", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r392", "r396", "r401" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r311", "r312", "r313", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r365", "r368", "r372", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r311", "r312", "r313", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r365", "r368", "r372", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansNarrativeDetails", "http://www.westpharma.com/role/BenefitPlansScheduleofComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r166", "r167", "r179", "r184", "r185", "r192", "r193", "r196", "r293", "r294", "r591" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r297", "r309" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r549", "r554" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r160", "r196" ], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r65", "r535", "r536" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Obligations, Net of Current Maturities" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r482", "r491", "r500" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r473", "r475", "r476", "r480", "r481", "r485", "r491", "r502", "r503" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of Foreign Currency Contracts" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Basic to Diluted Net Income Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r1", "r107", "r206", "r207", "r524" ], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]", "terseLabel": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r511", "r512" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r28", "r29", "r30" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r248", "r249", "r253" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r246", "r255" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Restructuring Reserve" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r407", "r417" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r46", "r105", "r155", "r156", "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r162", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r189", "r196", "r632" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r162", "r164", "r165", "r175", "r178", "r183", "r187", "r188", "r189", "r190", "r192", "r195", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]" } } }, "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r101", "r244", "r250", "r256" ], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringAndRelatedCostIncurredCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and post-employment benefits", "verboseLabel": "Severance related costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails", "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Stock volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r415" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for issuance under the 2016 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r409" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Stock options, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r404", "r408" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Stock options, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r412", "r428" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicates the sale of a borrowed security or written option.", "label": "Short [Member]", "terseLabel": "Short" } } }, "localname": "ShortMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsForeignExchangeRateRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r546", "r554" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r162", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r189", "r196", "r231", "r243", "r247", "r257", "r632" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r114", "r115", "r116", "r121", "r131", "r133", "r154", "r213", "r270", "r277", "r423", "r424", "r425", "r442", "r443", "r530", "r531", "r532", "r533", "r534", "r536", "r640", "r641", "r642" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r270", "r277" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock -based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r48", "r270", "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Purchase of investment in affiliated companies" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r16", "r17", "r277", "r406", "r411" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Activity related to stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Stock repurchase program, shares authorized (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r107", "r200", "r207", "r524" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossComponentsofAccumulatedOtherComprehensiveIncomeDetails", "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r277", "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount": { "auth_ref": [ "r572" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before counterparty netting, of cash proceeds received in transfers of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales, Cash Proceeds Received for Assets Derecognized, Amount", "terseLabel": "Sales of certain accounts receivable" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesCashProceedsReceivedForAssetsDerecognizedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/RevenueSupplyChainFinancingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementsAssetsandLiabilitiesRecordedatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Forward treasury locks" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/AccumulatedOtherComprehensiveLossOtherComprehensiveLossReclassificationsDetails", "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Stock repurchase program, average price per share (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r278" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r278" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r17", "r270", "r277" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Share purchased under share repurchase program (in shares)", "verboseLabel": "Stock repurchase program, shares purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r278", "r279" ], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost (1.4\u00a0million and 1.2 million shares)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r270", "r277", "r278" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Shares purchased under share repurchase program", "terseLabel": "Stock purchase program, cost of shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NetIncomePerShareDetails", "http://www.westpharma.com/role/ShareholdersEquityChangeinShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r120", "r121", "r122", "r124", "r210", "r211", "r212", "r213", "r216", "r217", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r440", "r441", "r442", "r443", "r592", "r593", "r594", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649" ], "lang": { "en-US": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/NewAccountingStandardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r35" ], "calculation": { "http://www.westpharma.com/role/DebtLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Less: unamortized debt issuance costs" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r547", "r554" ], "calculation": { "http://www.westpharma.com/role/LeasesLeaseCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r138", "r146" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r137", "r146" ], "calculation": { "http://www.westpharma.com/role/NetIncomePerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/NetIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "verboseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "xbrltype": "stringItemType" }, "wst_A2018RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Restructuring Plan [Member]", "label": "2018 Restructuring Plan [Member]", "terseLabel": "2018 Restructuring Plan" } } }, "localname": "A2018RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_A2020RestructuringPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2020 Restructuring Plan", "label": "2020 Restructuring Plan [Member]", "terseLabel": "2020 Restructuring Plan" } } }, "localname": "A2020RestructuringPlanMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "domainItemType" }, "wst_BiologicsCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Biologics Customers [Member]", "label": "Biologics Customers [Member]", "terseLabel": "Biologics" } } }, "localname": "BiologicsCustomersMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_BusinessCombinationContingentConsiderationMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration, Measurement Input", "label": "Business Combination, Contingent Consideration, Measurement Input", "terseLabel": "Business combination, contingent consideration, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationMeasurementInput", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "wst_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/LeasesLeaseCashFlowandSupplementalInformationDetails" ], "xbrltype": "stringItemType" }, "wst_ContractManufacturedCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract-Manufactured Customers [Member]", "label": "Contract-Manufactured Customers [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedCustomersMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractManufacturedProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract Manufactured Products [Member]", "label": "Contract Manufactured Products [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "ContractManufacturedProductsMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ContractWithCustomerAssetIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset, Increase (Decrease)", "label": "Contract With Customer, Asset, Increase (Decrease)", "terseLabel": "Change in contract assets - increase (decrease)" } } }, "localname": "ContractWithCustomerAssetIncreaseDecrease", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ContractWithCustomerAssetRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Asset", "label": "Contract With Customer, Asset [Roll Forward]", "terseLabel": "Contract With Customer, Asset [Roll Forward]" } } }, "localname": "ContractWithCustomerAssetRollForward", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_ContractWithCustomerLiabilityRecognitionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability, Recognition Period", "label": "Contract With Customer, Liability, Recognition Period", "terseLabel": "Contract with customer liability recognized" } } }, "localname": "ContractWithCustomerLiabilityRecognitionPeriod", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "wst_ContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contract With Customer, Liability", "label": "Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ContractWithCustomerLiabilityRollForward", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueContractsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "wst_DaikyoSeikoLtdDaikyoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Daikyo Seiko, Ltd. (Daikyo) [Member]", "label": "Daikyo Seiko, Ltd. (Daikyo) [Member]", "terseLabel": "Daikyo Seiko, Ltd. (Daikyo)" } } }, "localname": "DaikyoSeikoLtdDaikyoMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "domainItemType" }, "wst_DeliveryDevicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Delivery Devices [Member]", "label": "Delivery Devices [Member]", "terseLabel": "Delivery Devices" } } }, "localname": "DeliveryDevicesMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_DeliverySystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Delivery Systems [Member]", "terseLabel": "Contract-Manufactured Products" } } }, "localname": "DeliverySystemsMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_DevelopmentAndLicensingIncome": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": 4.0, "parentTag": "wst_OtherIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of consideration recognized during the period under a development, licensing and supply agreement entered into with a customer.", "label": "Development And Licensing Income", "negatedTerseLabel": "Development and licensing income", "terseLabel": "Development and licensing income" } } }, "localname": "DevelopmentAndLicensingIncome", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "wst_DevelopmentAndLicensingIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development and licensing income [Table]", "label": "Development and licensing income [Table]", "terseLabel": "Development and licensing income [Table]" } } }, "localname": "DevelopmentAndLicensingIncomeTable", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "wst_DevelopmentandlicensingincomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Development and licensing income [Table]", "label": "Development and licensing income [Line Items]", "terseLabel": "Development and licensing income [Line Items]" } } }, "localname": "DevelopmentandlicensingincomeLineItems", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails" ], "xbrltype": "stringItemType" }, "wst_ForeignCurrencyDenominatedDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign currency-denominated debt designated as a hedge of our net investments in foreign operations.", "label": "Foreign Currency, Denominated Debt [Member]", "terseLabel": "Foreign currency-denominated debt" } } }, "localname": "ForeignCurrencyDenominatedDebtMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "wst_GenericsCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Generics Customers [Member]", "label": "Generics Customers [Member]", "terseLabel": "Generics" } } }, "localname": "GenericsCustomersMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_HighValueComponentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "High-Value Components [Member]", "label": "High-Value Components [Member]", "terseLabel": "High-Value Components" } } }, "localname": "HighValueComponentsMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": { "order": 8.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "wst_NetSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Net sales member", "label": "Net Sales [Member]", "terseLabel": "Net sales" } } }, "localname": "NetSalesMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DerivativeFinancialInstrumentsEffectsofDerivativeInstrumentsonOCIandEarningsDetails" ], "xbrltype": "domainItemType" }, "wst_OtherFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Other Financial Instruments [Abstract]", "terseLabel": "Other Financial Instruments [Abstract]" } } }, "localname": "OtherFinancialInstrumentsAbstract", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementOtherFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "wst_OtherIncomeExpense": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of other income and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Income (Expense)", "negatedLabel": "Other expense (income) (Note 15)", "negatedTotalLabel": "Total other expense (income)" } } }, "localname": "OtherIncomeExpense", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.westpharma.com/role/OtherExpenseIncomeOtherExpenseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "wst_PackagingSystemsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Packaging Systems [Member]", "terseLabel": "Proprietary Products" } } }, "localname": "PackagingSystemsMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/SegmentInformationDetails" ], "xbrltype": "domainItemType" }, "wst_PensionSettlementCharge": { "auth_ref": [], "calculation": { "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense as a result of an irrevocable action that relieves the employer (or the plan) of primary responsibility for a benefit obligation and eliminates significant risks related to the obligation and the assets used to effect the settlement. Examples of transactions that constitute a settlement include, but are not limited to, lump-sum cash payments to plan participants in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contracts to cover vested benefits.", "label": "Pension Settlement Charge", "terseLabel": "Pension settlement charge" } } }, "localname": "PensionSettlementCharge", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "xbrltype": "monetaryItemType" }, "wst_PharmaCustomersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharma Customers [Member]", "label": "Pharma Customers [Member]", "terseLabel": "Pharma" } } }, "localname": "PharmaCustomersMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_ProbabilitiesOfSuccessfulExecutionOfAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Probabilities of Successful Execution of Agreement", "label": "Probabilities of Successful Execution of Agreement [Member]", "terseLabel": "Probabilities of Successful Execution of Agreement" } } }, "localname": "ProbabilitiesOfSuccessfulExecutionOfAgreementMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_ProbabilitiesOfSuccessfulFDAApprovalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Probabilities of Successful FDA Approval", "label": "Probabilities of Successful FDA Approval [Member]", "terseLabel": "Probabilities of Successful FDA Approval" } } }, "localname": "ProbabilitiesOfSuccessfulFDAApprovalMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_ProvisionForProductReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Provision for Product Returns", "label": "Provision for Product Returns", "terseLabel": "Provision for product returns" } } }, "localname": "ProvisionForProductReturns", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueVoluntaryRecallDetails" ], "xbrltype": "monetaryItemType" }, "wst_PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchases and Royalty Payments from Equity Method Investees", "label": "Purchases and Royalty Payments from Equity Method Investees", "terseLabel": "Purchases and royalty payments made to affiliates" } } }, "localname": "PurchasesAndRoyaltyPaymentsFromEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_PvsPayoutMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Maximum.", "label": "PVS Payout Maximum", "verboseLabel": "PSU payout, maximum" } } }, "localname": "PvsPayoutMaximum", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_PvsPayoutMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percent of an employee's targeted award to be paid out, Minimum.", "label": "PVS Payout Minimum", "verboseLabel": "PSU payout, minimum" } } }, "localname": "PvsPayoutMinimum", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "wst_RestructuringAndRelatedActivitiesPeriodOfImplementation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring And Related Activities, Period Of Implementation", "label": "Restructuring And Related Activities, Period Of Implementation", "terseLabel": "Restructuring and related activities, period of implementation" } } }, "localname": "RestructuringAndRelatedActivitiesPeriodOfImplementation", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeRestructuringandRelatedChargesDetails" ], "xbrltype": "durationItemType" }, "wst_Revolvingcreditfacilitydue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolving credit facility, due 2024 [Member]", "label": "Revolving credit facility, due 2024 [Member]", "terseLabel": "Revolving credit facility, Due 2024" } } }, "localname": "Revolvingcreditfacilitydue2024Member", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "wst_SalesProjectionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales Projections", "label": "Sales Projections [Member]", "terseLabel": "Sales Projections" } } }, "localname": "SalesProjectionsMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/FairValueMeasurementLevel3FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "wst_SalesToEquityMethodInvestees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sales to Equity Method Investees", "label": "Sales to Equity Method Investees", "terseLabel": "Sales to affiliates" } } }, "localname": "SalesToEquityMethodInvestees", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/AffiliatedCompaniesDetails" ], "xbrltype": "monetaryItemType" }, "wst_ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Other Income and Expense, by Component [Table Text Block]", "label": "Schedule Of Other Income And Expense, By Component [Table Text Block]", "terseLabel": "Schedule of Other Expense (Income)" } } }, "localname": "ScheduleOfOtherIncomeAndExpenseByComponentTableTextBlock", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeTables" ], "xbrltype": "textBlockItemType" }, "wst_SeniorBNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior B Notes Due 2024 [Member]", "label": "Senior B Notes Due 2024 [Member]", "terseLabel": "Series B notes, due July 5, 2024 (3.82%)" } } }, "localname": "SeniorBNotesDue2024Member", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorCNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior C Notes Due 2027 [Member]", "label": "Senior C Notes Due 2027 [Member]", "terseLabel": "Series C notes, due July 5, 2027 (4.02%)" } } }, "localname": "SeniorCNotesDue2027Member", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SeniorNotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior A Notes Due 2022 [Member]", "label": "Senior A Notes Due 2022 [Member]", "terseLabel": "Series A notes, due July 5, 2022 (3.67%)" } } }, "localname": "SeniorNotesDue2022Member", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "wst_SmartDoseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SmartDose [Member]", "label": "SmartDose [Member]", "terseLabel": "SmartDose" } } }, "localname": "SmartDoseMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/OtherExpenseIncomeDevelopmentandLicensingIncomeDetails", "http://www.westpharma.com/role/RevenueContractsandLiabilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "wst_StandardPackagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Standard Packaging [Member]", "label": "Standard Packaging [Member]", "terseLabel": "Standard Packaging" } } }, "localname": "StandardPackagingMember", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/RevenueRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "wst_TermLoanDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Due 2024", "label": "Term Loan Due 2024 [Member]", "terseLabel": "Term Loan, due December 31, 2024 (1.10%)", "verboseLabel": "Term Loan Due 2024" } } }, "localname": "TermLoanDue2024Member", "nsuri": "http://www.westpharma.com/20200930", "presentation": [ "http://www.westpharma.com/role/DebtCreditAgreementDetails", "http://www.westpharma.com/role/DebtLongtermDebtDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r403": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121636179&loc=d3e34841-113949" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498357-110258" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r555": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=120604989&loc=d3e56071-112765" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.4)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04.12(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r663": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r664": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r665": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r666": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r667": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r668": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(ee)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" } }, "version": "2.1" } ZIP 92 0000105770-20-000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000105770-20-000057-xbrl.zip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�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

5[$-PNWO,AB6N%^-)W.-;8)O@Y,$6M>H#4ZD->E=L,!R\%T$%C"Q)IZK%JADD[1G7O$(JPH@F:8#WV6S-W,'% MK3AWN9#ZD04SOX(3KD8RT(V:E!F\$]6I@EO:<6'-8>I+ M)PU\IQ5,RP8)'4"US(_8B.HTJ1$]:F_<2O1'XX7S63B9#+-"D;^5(OGXJC;E MLU9E1"3L3>K"'Y$/]R1$')L.NTB\ 0UN+)++E'NR-!_#]-TOE^,__H'Y A?& MY;(..>W!7CA?R\E)6B=58&3(T;)9K)8)!!F930RZ'7$>WT_H0;O;;9G>5=/@ MQ/8&7(+YVXB\I6%%2*S84ML=0&&>G"AE]ZBQY"-PQ MRTLAT=2.Q3X8YDU0"H7,F)I4M-T-YID1J6_%-#B_O8%V7KAU4E3'UH//GD,K[XUJV?S=M?NQAI%(.R(X M3@32(6)9B3Q2(NL21*$/7EOO8@S6<QS#X9>W'W%TA?5J;UD= MO99P>DQXZ#63IW_6RG*U&=-TBO1??@M_#C($Z\E58BK6JKTA%!:D*DQH<%+J ME)QKLJ[O@?7X*_RI^+E^>=M6L2VZ<(RG)*&_C\?Y2^, G+X97^:!DLY#%N1? MH;>L]HACH4;9>(A*.%4LVB8S=3ND;Y=9/:FI10A4'?=BJ ,)AKQP:%9Y+G0"'40(5N=5+N[^P6&;YURXQ"%-'!GUP]H'KVOT2/_AD6=CE>3 MX7ARO_Q!/-P-BB.BT"K'$.=,CE30(L<;9^LH!+D9!FGL4E9\_W@?KML M.X)Z&P0);4"=9E0*WXYOE$X6@V!+,2HC2S0[2"XH MF1>T6D?N;"PE<]/&!M\7\'<6-E7Q.C5M#TE3U_%&2[=U.+JJK>,^7#<0FB[" MXQ>_1QXK3G\=CL:3X>S3TJH@C^3V4Q8GKK_B[-WXQD7>=)!=<1""8("U0'XJ MB45?>TZ$5!2(H%RGC/T][,"CC?';G0 /E4CK<\;U,V=H"-?V]/6D'VAC T\\ M,F.JVP4QD/C(P"[(K42;!6"3:FU;\'SK7#Q,0>N\\8?RAO:!+_P>I'K4+Q!H M;)H^""PL>*-9B2):I8Q+NDDL]BT4WRY']E?&.C-"W_E<746QB!%VB49=6_I% M%9'<^1091(W,^"+)Z/4QRR;[ZD&HCQ7F_U#X=CP5/Y24@"_L1R\-!B"OD4DR_)C6A4:M MLV'%F S))"U4FV;!=Z$ZOE'>GP)7^T;U)OT&P0]O)_-*>)^>C]/ORZ8!N38' MB(X5B+)6J_4LZGK&$&P!$5,@4"WXL [EC$APH)P;+ K[6ER+#C2>>.D(=HQ0 M5TK-:Q%4#+9*)$"MJG6]B#KIYS.INQ/ M20VB*C?GN74!];V@RJ[:ZU1!8Q_1'ZV@"@H,QBC:_Y-(3/-@&1!:DJ*B!9C6 M6RG=5\Z'@PJJ]$^'723^ JJH.?!UW#6%!E%]6T+:C2J=0"@G..%\95J84GJV1XD0M!I_SR#0_I)47\/G"K6=XI)*]+C(('K7CQ M%K/7/")9GJ!4&=R-\W#1[=WI9>NC&HFQ0R\7=&!%L"I&R[67& 1HKF(2-GKP M&C<(\_#F+>O/?#R_QAJ.UG^R?SF$?=[22!$[#F^5\" P:N,,>/?BV)X=SY=#> M)KNHIL495)V$TV?3Z17F@;/9!2B>1:/)$#'U,XN"!2=L+8_#/;;I:G(#Q,.O MJKZ3QE9/D_85=P/O<%.)=&ZRR,FPJ+ACVCDR#VN+BQBY4D%YGE*3;(:OL:W- M030X3/0-KI]OA\8'(8PKI"K):X^=$@(+.D3X>ABT71DWCITOF3]3-+(U6_%T71^ #\P\[Z*"EB6F?B: M0;$@B;1$XF@ =%!M"CSL#O6\>=18=:U:)A#(A$TRBM A&,I-K MJP4C-*V[-K'DN D&,(%H4O?Y#DSGS9^^E-$@+?X6M/GZN416*Y8L,I('O%9_ MS:XPD6(]0)6*>;^X(^(A^.PT-KE#ZP+N&V).'^IID"7^9/AQF'&4:Y?@]^.% M,.J=SD 9*Y+3@09N>:W.Y1CMP9&5Y%2&"-9CFWR4+8#.FRJ]J*%!,OBA/=6B M]9H7(Q@*4[M1&6"QGE#%'&L-_ #NZ-\@XAVS&5VB -_=:)E'$@G/9( MKD"='TH2EEHPNX AD!R+34T.R;DQLA5.XKT9CU(QXJM3>L4KQV2 Y =95S. MJEC)FX1Q= %W#D?\O2NAQ>%N>H?YZA*O!_[SI[D8%N&0,I.+#U8S!!>93EDR M0,49 ;5%68X"F]P&W8'I6)4A^B=#7X)^*!4<[@Z12QZ0ULS$>*PNFA:%!1YH M[R*K&T'%$-N4.WJ00(-:'##-EKVPY'6"@VV MFC]D"&GGZJF>8D5Z3F.-6L0F%%A#\E#"/7?2T';3YL]6O+LD2. R%@22G,@B+P%44')OH_DY4Y\"#_L3>8 VX M=5*[[*;F @3I!3,@:_G.VD@]D3ODK8RHM7*HVU^TG(_^#Q5QDP(&,ZCQYT]A M,AJ.+I;-.TU2+GLGB'R\U/4ILE@KN H179;9UUR;%HK?#.<<=-^#H$_:KU + M[TUUC3CZ&NG$:>PUUH5\[50*<=6U*5WY@%.H&VP03=318S3(=#(;/%Y )$1/ M2\$T6\02O"R/\OC#7.#S(F529U3!L9ABK>//%2.7&ID7A2<=BL^=2KG1^VY0 MA;Y:I4E70.=RVM!$ 3WN*UWP?2XA<#_"'4X?>J'**8X@VJAT![X[= = MD)+W)!0F9 2K]JDGZRFHXAE ;=*) #IVJ?WVX!FSY9#BH1!F%S4?=&9YDO$9BK,LC%V"2[W)'VLQ^=+*.UE7)WV9P.T4!Y+_S>0T%VX7*.@2,60GRSH/.J81NV_.S2F.]?A>>*9E2,H7BTJUJ>W5:$#'/S$Y,J\WYG&>FAFMTH'W&=?+ MN4DVG0]B^FRTL-4&5B5!@O0L2 :@XK,%DGL S4"(: M, $9C2O4"@B.D0]OF''DK]-P,Y0FK1>./,[O4^8!\:A%^OR^P_T\@D?3Z=7[ MQ=AK=YY?)HC+#JFO::0# UY:06:A=,+5HZU$FVG*3,7"HPK&%-VN,DO+D7V? M&B?E2HOT_HH^WC_ V&6 M9EKHJG_%B?OQ: $XY,6@B$DP731M8H](G-6"ZXQ MD2W9[B2BR9"^3?J?GAT-R@ST.K&7(_OGN-Z 7-9TQ3JU0\F6H];,*B-IB%8P M[R*-4Y2< CE6O%$9C/9C^S9GP@/B2X.*"DV&N$RYFP\P\6B-,;2Y(9("9"W9 M75 QP;G2\W1_:!)6VGQDWZ?#2;G2H#;$W@-)HG%+4YN:D!4@2F-/)*UD@)_^PYL2. _P^-1X"50Q8<-PR%C#*2"R7DP[*S^I; ]SGV57"OQWH@?TQG@U/'<;U3#>PAU M@X8/[_MS.?\=S)N%4JWCT10'W"54O):]0$XK32;3V'M:;F3@6:?L//=-#I6[ MP?MF*-10:QO(=?@=X9<\E+TO1A=9*P34:T3+E!&#E8_-@;/?#&6"2.AU"# %)JLE%\/>>^I'/3@N=M= MOPTX^PHG\^2>45JT.5B60;#"<<@&R+O.A TB>6$B&*:"(5LG:I2Q20G3+7@> MH!?37-GC_C75(-3]-4YGDV&])9KGW_Q&>IF^?O/;LBJ"P02*].;_5CW2&V[]>>]9+)M![22N.:5BZJ@ MEYA(426$K%(R0FO!C5!:#;9A.T1$>S^L7>E'#SL M%0U:"=(9HVP0J,E1C5B/U< :541!QP>'OOS 'A,;VCR/%D5^7M%+)C@;3A:' M0JM$>TL#_?GR5N5CYY(M6=7&@XY,2XWTF3:)&1VD#TG2"MVDBU>?@SBX:<<: MECCNKW'DVG.)L.E.'&(6:&+@:F \\,N#)D62>%1D29 M;).0E5U ?F=:_[ILD 6XCO71^]K YM]SY^]E>466S>3&JOMX@GDX&V199. B M$6HL3%=!!55J RZ2C=3.*WFDU:T+W.]<;*G?!DEV&U"GV15,AG#Y=Q+_O(UN M(1R1I@[C$5)MY"&8!Q$9N;$%HY2T@C>):.B [3O?>M-<@Z2U=8BO,8TO1L-_ M8R9G;@GSR16^';_!V6QQQSP5@P1D7W*LI*B]=%719!U$ST1(*CGCZ1M-S@GW M!?R=AFUUW""Q;!WWYN.%0=0Y%%,C@_@\ 2[0 IV1P*+C(3@3I6F23=\5X'?N M]:O#!AE;>PGLR7!: W*NR&]:1'?8^:&QSJI\&IS#JJZVO-+KA:1FUM W::R*L^E':\>%,G02)D:L3?""_.:DF@<['9<0]X4S'),0N F\2FS07 MR6)%O+6,7L);H*B8L:JVE MYCO0FP_CT70\>5[_;'C=R $Y@BSD(R0U;PV7:;F56I&W4(0P$$"J)F<$]R+[ M;N;VH[0VG=VV [R>:%T@'L_XW8CQ(=C!!VMW%^XS,(5DH$ MI9D7M46RBYD%%Q0KUI*9YIV4:4,YF^E2 5-,?[D8?_SI^HD+3EQ_L4J'+V\] MM0G3@S+&!TFR@=7[RWB"PXNY5;XTPZ6$E%1B!4@).B9/Y(7$O+/!*)=YHUR- M-23GH^Y^A'V*V/@7,)G,NSWU$YJ\]KC>XX[O!KP:2V\LS\4'A29K\C"AH-7* M)N=R-,K$P9U/?D 1P[2EN)"$92H9HI&/@OF8#$LN6JE]KJ5G'\S=SM$BACO> M)&-)W!A9N[,K(.&YS'R0M'D;^I1[KJ)M4L#V&XT6V(6KO44+[*+CHX0@[^// M%LW)1LC(:(\I3"L?F??),EY2AFPB5[G):=.W>X/;+U=;Z_R!W^#ZXG00*)@+ MM>6DQ\0"#8_5BX88E7,"FY3 /,<;W)UHT>T&=Q?U'/.>K@NN;_X&=R?E=;VP MVT?R1[W!M:!R,H&VX6AGLG$91 #1M]%H'BR <+X.[<1XN MNKWK &Q]5",Q=J@)$!&\5%8[32*T2@5.RZ)27!C.E2I^@S /KPRP_LSU[^Q_ MU+;+TQL)ON-P5G112N$9A8ZA)"UY &$-#RC0>F64WD3L[2_JH0+-59I=38:C MBQK]3=8Y?0\G'_&F7QA!1N/9O&2P3K6-IK"*94(./L@B=!-/O NX@^N.8:V" M/5IDF4W%H/B"BEP*IF*(M5&HKK?HA0EIP:/7JL0F8UW!<8H]M&D\PEM+BY@D["X MS7#.D 8]R+V!L3U?7]?&/ATH&05*;VJ-.U>[%VGFM0LL0.WH6.7@F]C86_"< M(1_ZD'R3@*,;B.9COJQUL2LVVG^O)I/%YX/@-9)AZA@:#>0$V,) &\U$S&"2 MST+P)NM%1WQG2)@6FFF0*WY]^_VX AJE3V]IZYM"FIN=X^GT9RST\[?PYT ) MISW(S!ROA?H]=PS02Y84IU40N$5LDKW;$=\9$JB%9AKD@\\7QBV[)0T^""4B M[9'5=B*/N.Z61'",105R)DQHDLUQ!Z8S)$I?&N@Q(;OV^GA"AO3E^,.\S.4H M/Q^F>E UNEBXA8.DA-;&$S#KZ[+'/:LC);,Z02T%&(U>B:[>V$WESI>/Q^_C<#2/S7H\'LT(7V7CF)#2>]9*HA)-Z=-GM:K*U6CV MLFSYD^=#B/-6G6(0LK(9M&2Y8"4T>6+!V\@,?2\XRXTK3>)>CS2^,Z+L0V;& M^@0XN&GE]NUZ&0#S9E,C8"PP:S1J[O[_ M]JZMMZTGAJ):,:$"Z0/0(TR0JY M9Z7>+LL$RD2R7ITCE,13*$P'MMYP9Z-+]73D5Z38!J+;<*PW^I3WOEW0CF.# M)SH<4^&!6 MBW)SE:82$BUK4FJ011)^KR-X](DF1M&B9LS*37E$C0\+5VA.W\&KL>IWG1,> MI((N[*XU4$NBRA!8?6E_&W&=BO4W6G//V<((L1_1*EC"I(2TX+BJA4F*!,3: MJH3IE)0CS*G_Y4)O:WB6\7J@29ATD>#JFWB/T>+\=WITXM^1)#7M2 M)\[4 =-<[XYB@P_1IA""4J%H7YA21J.5J5C#U0;^U+"''H%+E:0I3EA1R_X$ M\FBB!8J#+ AOHRN8$\-.Q4_Z<:GJ^[?%EWL7;Z9?R7#R_*[2Z"_E8[78ZF(O MCADG#AF7* /PVGQ-,=3TJDL$R9)E1G$?>!JPN!WX^#,-P/+X#&4T(&* MM2,.6'4HJ/_G$VQAE*, 5J?P:1@A/,Y&M$E=W4HP%=D3EUUT]N% M?HSS(3/D]]E/]#$G_U')*+,"0K6H<1S)(Q *-#.6&Z&D.<(R_"S,'\N>QNKI MA"PPJ5-M1Z@A%4X+J"'9H+49"B,/,R@TR71I-/RR66"=[.A@S71@@:V3GE&Q MX$MB8'VI"4FV!B&*PAL3I:L>C34_,+U\C$&,D70']M86VE#Q%*@XHT#2?$ ) M9FKQ&P5!4BR#]Z.7C[*'%I+OP.IZA&@YX=]F%Q<_SZYKT^J)3SJC+0Y$L;JN7N3W M!/*F@[,R:564*?U/?I_B>H4&TE(3'=A/F^!-? C916[!:/2@N%* (2$P(9DQ M+HNH^[N;2S G-HFQ&AM@#7N)NW=HN]K0R*L5])LF::M?ZTA9P?A1O0T@4/$W2$._16_+EY-&@#ZR)OEJWI$=/?0ET MK+U4.ALKVH:NU'<02T+ $!A[T*V&:[H]W>)Y6M4(#:SK<(3X.FHS%^;)0R\0 MG>! L3N#6IP:HJUMG(3U0@UIN7P>6MQ"AVJOQ'VDUEAYGTA2E[>72R NJ%B" M<80^D>.2(@=7*VH)F[GUO#AT0QR70>I[].3C.:NC9#]K(;B&U_8+(/C7 R"& M.8=*2]!:DH_-K04?M*ZM9PI#[ZR-0Z*081I\^.07J,&#!7<,WNEB<>$LHI]S"&?:3=GJ4N MV#:.M2\E640&+MC:YM!I0IAH4Z./@\K),[66/;>-I;[U&>?#4M]+";,.$FSH MSCW+GD^,D3.B$V1;I$ S51!9K9)0;7#^7ZC51+ATN&6D9[303+ M=V0(L)YNX%9D9^ (CM7CK*<2.JPMVP%*)VIRCH4W*=+>WQ0?0V?5%]KF?4XZ$&=DA[WG^1Z M\\:28^(H9: PP!CA S)AM;>"^80*-^0\#GIFDS*$-/S%:OCI8OA_?K]N-D)$ M*Y6%>J)9CSC)ET[9 ;G227!RDYQT Z*'84_K5U:Q8/914>RN?6U=:J4!QUV! M0N$]PWC5.65>RDO^%%%?<19X>,PUKT[AKCS;^F-_]^?SN_(4C7WRO> M30)Y\ PQ09(EU6Y"&2JY!A@&JVU,Q;DN21H[4;T:XVBO@\;'7#LM=UF7Q@FC M&863.>1ZL,?J_:LPD%3FRAH>;1F2M?S\DWHSATZ]$.POSE-3A5;F^QG)?R-G M;KGEWCGSNO8?8QYLJ4D%JC# 4 *]ZK5'H5".W/D>"\<&+,<^/.FAZ5E;B7<( M=#Z2:5U/+^_2ZA?'0I]G-^\NZ@_2;%>1^@",/8]+AH \SC:K+<(3%VXK:.4TYB,?MHH;$O\N42KV]^ MHEUM&=(+J[*PB4/1-1]>APBU9QB($JPKTO,2Y0#'8VW8XQ^$M)?[K(W0&O.D M?KV>I=MX\\OUEWS]E3;$._9>XLZ&6MC6\\K4)RCD.Y%CE9+V&@5:W8PNM0G M*_(-FLBX(8/F 9[:Z'J):+XTZ"&@6M..MZ(Y/@EYO**>:KV1E!L37+>#RS+* MF)0&*6HKXG3=J&X7*1M0R XJ! MHH4,/$N%MK+@>L?.O(^4CG5#L=J2_CJH]>_#GVYRE[ 5 MSMH% :(PY!#EY$I07D@L-F6!Y"*56BC93+8@&R&>PR]G-@S26EA#+E6XTB8J M+4U$H\CAH"B"@@81 V>A2G"R&^>^HGL_N[R%5F]/G- U=T M#ZEN&*2),)\#M][[')EF)7K!I50A.X_2)&=,;9!JFSJ[RW%_RW_.KF\6.>=Q1HO'10TG;_+E MS[/[QC+DP93I3>U ]#-Y-LL?_'U6.UW-+J:IDOGN+SBLX]&Y6%-Z/#DURE#\ M6?M3>ZF=#&BV0CG^"=0Y6^.2&I(W*NI3X_9JO;G.=_Z9[WP]_Q8O; M5$FV\WFF/ZFV"E/6,Y]#!EI@!"AG-#A5'"1+KJTO07O3J0;6WEC?S.\82NYP M"[/6@JP*:6(\FJ +0C0Y@9*:@:>MK59XH4A71R-%%Y;B!BQO=M5"21TR)!?W M%_FN!G;MHZ/A1=T]CC=[&:N<#HD4 M'Z^^$I@[5[C:;VUPR)*QM6P8Q%R31Z0K$+1.$$7)%#W[2)_WL9W1+(I9Q(&G?]>A^)0/_[VE M;W_*-_^>I?MW:3[!F#T+WH QC/9I-+3V95A5 IZ&-;JQ_7K["QX2"HT*3*J<-V9R;7GH03L>>$R!>Q[['&:?N-'( M.9K.&.4\M96#V]NOX) ,\O2/J_>U2\Y5_/8[09MC7-PDYH]% M=4<0+8P";F<,2$LOBQ)>@-.E=OA1R@;FF.6=ZI2,A7ZL M#G:*!'5ORYY(=] MN2'\=:!_W,Y)CO/Y:H(+[F/ER) HR0TUF78 X0QXQ1U8KDMV,7JNNMR@[D1U MJH([Q[:0]=VYF:8Z7% ML:QXEP/ ]$PE>X3F-#EC#;7UQ$L;*^KN^NFD/^*\3_X!RU[7[[- MZZZ[*@OH!<,8!.C,'"AD%FKQ2."1?HD@LM=K7L]&)OGFT4_F0Q\B[EE3634N MH?A3OIA2E/?M,2 =T4G,&H*1M"]Y$P%1)>#))B,B:AWU .5M'/REZFZ\I!IG MZ]R[$R2]A<.[6%2*#%GZ9 &-T+6CM0;448+0CA1DZ&O7K W(9@@_F$/62!>- MT_F>(EK:_Q!,K;/YMH$Y?C)?"T7MU/L(*7=?'Y;84M*.UXX+/I::L1HC!&XC ML)"9U=D9VHQ>IN9WY/(=2_'["+X&8%ME+6-WC="TATHRXM;Z>5AT(>+Z>7T:C'K);CHH^0Q M1$B%]E2E:FGW@A%$R1AE\5J)+DTR=J)Z!<;03NH=UH3WL^L_9V2K^?/L:FFL MJT8NJ*SWBH'(M3^H$N0+ZT!+8&+9HL!HDN]A#EL1O0)3:"/M#N3?3UB+E^#% MVNGZ:MTJ@4D*9C3($#FH0.A<]D@QJ5?:*6VT[')-L1O6*S"(AG+?2O/=DDR^ M_+C^%7">__ZW_P-02P,$% @ >8!747/D.)8G^/]\"FR-[4ZFF5#) R3!FNE>4US9 M:HN,B(E05DUOVIH;3HF3+J>:=(^C/_T"/-SI%QV@@Q1[S:HB)1<)O/>#XX<' MX!W_X__^_K0$7T519OGJG_[B_]7["Q KEO-L]?!/?_G]_AW$?_F___F__)?_ M\7] ^+]>?7X/WN1L\R16:_"Z$&0M./B6K1_!/[@H_P2RR)_ /_+BS^PK@?"? MJY=>Y\\_BNSA<0T"+_ ._UK\+4@)#ED80D33""(D0XA](J"?!DD8)8*P(+UY M^%N8!IX(:0I)S#!$0KU 8TF@# -./21\$GE5H\ML]>??]#^4E (HY59E]>L_ M_>5QO7[^VR^_?/OV[:_?:;'\:UX\_!)X7OA+^_1?FL>_'SW_+:R>]M,T_:7Z MZ_;1,COUH&K6_^5__?;^"WL43P1FJW)-5DQW4&9_*ZL/W^>,K"O,+\H%SCZA M?X/M8U!_!/T AOY?OY?\+__\7P"HX2CRI?@L)-#__?WSW=DNTU_T$[^LQ(,> MV4^BR'+^94V*]7M"Q5))7[6V_O$L_NDO9?;TO!3M9X^%D*>;71;%7JM:RE1+ MZ<=:RO]ZKK-?KA#?D;SK8UD="%>I^\&5C'V8?G F[KWB!S&^P)UNKA:Y_D*] M7?&IOKO;KJX6?7R)77TM\C593O"UV'73$7FI/WBO?FJZT0WUD&G53T/='5'% M][58<5&SY5[3(./_]!?UTV)3P@="GA=?'DDA7BFBY:_SIV>Q*BO^OBT*LGH0 M>DE\]6/WR"?R0W]T^XT4_.V_;[+UCSNU"!35TEE^7#^*XOZ1K#X^ZR;*7U43 MZ_)N57^1%F$:!C%..(R#(("(! A2PB0,XH#$*(IC3-ABO9TK"[&"OW]IU:ID M?QG!_V(Q$NLSC%*(,M\4;+<6/RU/+;!J;=6K,?YE19Y$^4R:%Y3VVFRI ?GG M2CIEH?R4K4"I%2Q__A^_[$":T8@O_]..XW+<(:ST@=JZX:"K-.AH#>@/T'VN MT1Q4JM^ 6GG0T1Y4ZH.UTA\T -R &@*@OBHU"&>_*3G;TW:I[;B\.!RVG+W8 ML.WQ;35DDI2TPKP1Z1=MBO\BENNR_03J3Z#G-[;C?YU<]E^.9N-MT0)-"G;A MJ]@\\0O+E97]O(9[WTJ]*WG9$5GG+SN1ZV^J NDO("^X*-0^[P3@1_17-?XA M7^7/HE 2KA[NU,;P2;S]KD46BU#$810(#U*?2X@\',%4T 1R(24.!,.2R$77 MX+A(.\?V?KQ]U5.2U%\)70I[E;/FW7Y66@MLV56T:3Z;5,42AC%CEGY/B-4_67] MXXM8KY=5(^4B3CR11H)!'LH8HD!B2"+L0Q1S*E!** VCQ=&>\^+$&D_B =1V M;DONQ74U!K2K8U_4&;+4% ME;HW8*OP#>BH[(Z!QQ\6E^P]HK23,O_XJ!^N&A/T.&S%4<;V4[:N6KI=*=-[ MI9! Q9=_2D$40^3*-O"!B M<8067T5!<],%Q$X &[+IBC$>YW3D!V2E=^0=#>P6"0>)*G*6*4Q-CD5+FGC[D= #=B@G(K)V"5 MH&9 M7"/C9,>YV-!]?M4[Y1$.6R/=L! M1+$U4%ULEM7'9 6RHA!?%=]JNYNPZJ1Z_4C6ZJ%E)KXJ+E<[:B">GI?Y#U& MG_*B^N!9]?.S;N&YR)Y(\4.W^9PK7&H+"$CU' %4K(3,5$]TF3W4I^!ZK5 M M/V4KM24L09D]K#*9,:+$+++RSU+W6SEIK/.JHX-7]4>D5+.C!)NR?DI(*=BZ M^LMNUOP5O/U.])5>J85<%V15ULJ5M7:*2,MUMMZL57/=R9:MV'+#U0:%;M: MJ.5KE:^!%K<6Z08L-T_/L-P\ 4;*1_#<;#>U'!H2]4&QSECVW)[,B^]J^BK6 MK !1(JH=4.5:4KU1"":RKTKL9\$4"*J'!K!Z27U67X-'95BJ_A5BV7?FY.L MB :BM\N>R:/#K/C[HMI6_/BR5NOD;^*)BF+A^2C&2$@82ZG6-H803/V(09^$ M7B@B%J5Q:G-C>J*/N:UMK8B@DM'.^#X%H9F%?24P(R]H^YB /VH!'1K*/>J[ MM(9/=3.IR=NCYZ%=V_?HL G^12WD]2W81M&U*,LOXJ&VF[]GY4*$J:1I$L.( M1VI7[C$&<1S'T*-<8B35U+>;ZKV]S6W2M[*!/[1TY[_8 W U=$%PA=;8?@.& M0-E?YIL X/0&OK?#::_-370_NNLV>FD84S0&AMI/5S=5G_)R78AU5A\YOFI, MME/'22CA,D4BABG1%T1^0-0VF'E08"\6+/%9&"9V1WM#19G?(5\C+/BD/K4\ MU!L\'F;D,P7&(_/2YZV\H!5XI#.]:\%RR6c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�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end